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Abbreviations 
7-AAD 7-Aminoactinomycin D 
aEEG amplitude-integrated electroencephalogram 
AMPA/KA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/ kainate 
ANOVA analysis of variance 
BSA bovine serum albumin 
CD  cluster of differentiation 
CFSE carboxyfluorescein succinimidyl ester  
CI confidence interval 
DAMPs danger-associated molecular patterns 
DAPI 4',6-diamidino-2-phenylindole 
DCs dendritic cells 
DMSO dimethylsulfoxide  
DNA deoxyribonucleic acid 
DTI diffusion tensor imaging 
ECG electrocardiogram 
EEG electroencephalogram 
EPCs endothelial progenitor cells 
FA fractional anisotropy 
FCS  fetal calf serum 
FDR false discovery rate 
FHR  feta heart rate 
FIRS fetal inflammatory response syndrome 
FISH fluorescent in situ hybridization 
FITC fluorescein isothiocyanate 
FOV field of view 
FSC forward scatter 
GA  gestational age 
G-CSF granulocyte-colony stimulating factor 
H2O2 hydrogen peroxide 
HELLP  hemolysis, elevated liver enzymes, low platelets 
HI hypoxia-ischemia  
HIE hypoxic-ischemic encephalopathy 
HSCs hematopoietic stem cells 
IBA-1 ionized calcium binding adaptor molecule 1 
IBI interburst interval 
IL  interleukin 
IMDM Iscove’s modified Dulbecco’s medium 
IQR  interquartile range 
IR immunoreactivity 
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IUGR intrauterine growth retardation 
LF low frequency 
LMA lower margin amplitude  
log natural logarithm 
MABP mean arterial blood pressure 
MBP myelin basic protein 
MDSC myeloid suppressor cells 
MPAQ Maastricht-programmable acquisition system 
MPO myeloperoxidase 
MRI magnetic resonance imaging 
MSCs mesenchymal stem cells 
NEC necrotizing enterocolitis  
NICU neonatal intensive care unit  
NiDAB nickel sulfate-diaminobenzidine 
NK cells natural killer cells 
NMDA n-methyl-d-aspartate 
NPCs neural progenitor cells 
OL  oligodendrocyte 
PAMPs pathogen-associated molecular patterns 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PE r-phycoerythrin 
PerCP peridinin chlorophyll protein 
PHA phytohemagglutinin 
PPROM preterm premature rupture of membranes 
pre-OL pre-oligodendrocytes 
PVE periventricular echogenicity 
PVL periventricular leukomalacia 
PVWM periventricular white matter 
RNA ribonucleic acid 
RNS reactive nitrogen species 
ROS reactive oxygen species 
RT  room temperature 
SAL saline 
SBP  systolic blood pressure 
SCF stem cell factor 
SCWM subcortical white matter 
SD standard deviation 
SSC sideward scatter 
TBS  tris buffered saline 
TLR toll like receptor 
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Treg regulatory T cell 
Tris tris(hydroxymethyl)aminomethane 
UCO umbilical cord occlusion 
UMA upper margin amplitude 
VSI virtual slide imaging 
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Preterm birth 
The magnitude of the problem 
Preterm birth, defined as birth before 37 weeks of gestation, is the leading cause of 
perinatal morbidity and mortality in developed countries [1]. Prematurity is the 10th 
leading causes of death worldwide (Figure 1) [2]. Most deaths due to prematurity occur 
in low and lower-middle income countries [2]. In developed countries most preterm 
infants survive due to advancing clinical support, but preterm babies are at high risk of 
neurodevelopmental [3, 4], respiratory [5] and gastro-intestinal [6, 7] complications [8]. 
 The second Peristat study, which reported perinatal data of 25 European countries 
in 2004, showed that in the Netherlands 7,4% of all live born infants were born before 
37 weeks of gestation and 1,1% were born before 32 weeks of gestation [9-11]. These 
numbers were in accordance with the European average [10]. In 2004 approximately 
182.000 infants were born in the Netherlands, meaning that a total of 13.500 preterm 
infants were born before 37 weeks of gestation and 2000 infants were born before 32 
weeks of gestation. In the U.S. the number of preterm birth is higher; 12-13% of all live 
born infants in the U.S. are born prematurely [1]. Worldwide the number of preterm 
births is gradually increasing due to an increasing number of medically indicated pre-
term births and artificially conceived multiple pregnancies, which by itself is an im-
portant risk factor for preterm birth [1]. In contrast, in the Netherlands preterm birth 
rate has decreased from 8,0% in 2000 to 7.4% in 2007 [12]. This trend is largely ex-
plained by a reduction in multiple pregnancies [12].  
 Survival after preterm birth has sharply increased in the last decades [8]. This posi-
tive trend can be largely contributed to reduction of early pulmonary complications, 
which has been established by widespread use of antepartum corticosteroids, postpar-
tum surfactant administration and the development of improved ventilation strategies 
[5, 8]. Unfortunately, preterm birth is still associated with mortality and long-term 
morbidity, despite the mentioned improvements in perinatal care [8]. Obviously, mor-
tality and morbidity are inversely related with gestational age. Survival rate at 24 weeks 
is less than 10%, at 26 weeks survival rate increases to 45% and preterms born at 28 
weeks of gestation have a chance to survive of 70% [9]. Congenital malformation, as-
phyxia, sepsis and necrotizing enterocolitis (NEC) are the most important causes of 
death associated with preterm birth [8, 9, 13]. Among survivors preterm birth is associ-
ated with long term morbidity and disability, which have a tremendous impact on pa-
tients and their families [8].  
 Given the magnitude of the problem of preterm birth, obviously such a large scale 
health care challenge also forms a tremendous economic burden on society. Recently, 
mean health care costs of initial hospitalization were calculated to be around € 55.000 
for preterm birth compared to € 1.500 for term birth [14]. This would indicate that 
annual costs of preterm birth are around 700 million Euros in the Netherlands. In this 
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estimation, the long term costs of increased morbidity are not taken into account. Pre-
term birth is thus a significant cause for mortality and morbidity on a societal scale [15]. 
 
 
Figure 1. The 10 leading causes of death in the world in 2011. 
Prematurity is the 10th cause of death worldwide (data WHO, 
2011). 
Causes of preterm birth 
The most important causes leading to preterm birth can be roughly divided in two ma-
jor groups; fetal hypoxia-ischemia and intrauterine infection. Fetal hypoxia-ischemia 
can result from placental insufficiency caused by pre-eclampsia or HELLP (hemolysis, 
elevated liver enzymes, low platelets) syndrome, compromised umbilical cord flow 
caused by umbilical cord prolapse or compression or disturbed placental perfusion 
caused by abruptio placentae (placenta detachment) or twin-to-twin perfusion syn-
drome. These conditions result in compromised delivery of oxygen and nutrients to the 
fetus leading to intrauterine growth retardation (IUGR), chronic fetal compromise or 
acute fetal distress [1]. In this category preterm birth is usually the result from cesarean 
section on fetal and/or maternal indication [1].  
 Intrauterine infection is a frequent cause of preterm birth and can present as clini-
cal chorioamnionitis with general maternal symptoms (fever, leukocytosis and raised C-
reactive protein) and local symptoms (uterine tenderness and vaginal discharge) [1, 13]. 
Intrauterine infection, however, frequently occurs clinically silent and is diagnosed after 
birth as histological chorioamnionitis [1, 13]. Chorioamnionitis initiates an inflammatory 
cascade characterized by secretion of pro-inflammatory cytokines, prostaglandins and 
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extracellular matrix degrading proteins [16]. Prostaglandins can activate preterm uter-
ine contractions, which often results in spontaneous preterm delivery [16]. Extracellular 
matrix degrading proteins damage the membranes leading to preterm premature rup-
ture of membranes (PPROM), which may advance to spontaneous preterm delivery or 
overt clinical symptoms of infection and subsequent medically indicated cesarean sec-
tion [1, 16, 17].  
The immune system 
In this thesis the interplay between the hypoxic-ischemic brain and the developing 
peripheral immune system plays a prominent role. Therefore the function and devel-
opment of the immune system in the perinatal period will be introduced here. The 
basics of the innate and the adaptive immune system will be introduced based on ref-
erences: [18-21]. 
The innate immune system 
The immune system is classically divided into the innate immune system and the adap-
tive immune system. The innate immune system is the first response mechanism in the 
face of danger. The most important effector cells of the innate immune system are NK 
cells, monocytes, tissue macrophages and granulocytes (e.g. neutrophils) [18-21]. Path-
ogen-associated molecular patterns (PAMPs) expressed by invading microorganisms are 
recognized by pattern recognition receptors (PPRs), such as Toll-like receptors (TLRs), 
which are expressed on the effector cells of the innate immune system, as well as on 
dendritic cells (DC). TLR signaling in DC and macrophages leads to activation of these 
cells. Activated DC and macrophages phagocytize invading microorganisms and initiate 
an inflammatory response characterized by secretion of pro-inflammatory cytokines. 
These cytokines activate expression of adhesion molecules on the vascular endothelium 
around the site of inflammation. The adhesion molecules facilitate diapedesis of neu-
trophils into the tissue. Neutrophils transmigrate towards the site of inflammation 
attracted by the concentration gradient of chemokines (chemotaxis). At the site of 
inflammation, neutrophils start cleaning up debris and micro-organisms by phagocyto-
sis, thus further controlling tissue damage. Natural killer (NK) cells form another cell 
type of the innate immune system, which are predominantly involved in the recogni-
tion and killing of tumor cells and cells infected by viruses. The complement system 
consists of many proteins that enhance phagocytosis by opsonization. In addition, com-
plement proteins are able to directly kill micro-organisms by lysis and act as chemo 
attractants to attract granulocytes. Dendritic cells form the bridge between the innate 
and adaptive immune system, by presenting antigen originating from the site of in-
flammation to T-lymphocytes, which reside in the peripheral lymphoid organs. 
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The adaptive immune system 
The adaptive immune system’s effector cells are T and B lymphocytes. The response of 
the adaptive immune system is relatively slow (days to weeks), but very accurately 
targeted against a specific antigen (e.g. PAMPs associated with microorganisms). The 
specificity of the response is established after proliferation and differentiation of lym-
phocytes recognizing one antigen. Lymphocytes can be divided into B-lymphocytes and 
T-lymphocytes based on their antigen receptor. 
The antigen receptors of B-lymphocytes consist of membrane-bound antibodies (im-
munoglobulins) which are capable of recognizing a variety of antigens (i.e. protein, 
lipid, carbohydrate, DNA). Upon recognition of a specific antigen, B-lymphocytes are 
activated and differentiate into immunoglobulin producing plasma cells that secrete 
large amounts of immunoglobulins with the same specificity for the antigen which was 
originally recognized. The immunoglobulins bind to their antigen (for example on a 
microorganism) thereby enhancing phagocytosis by granulocytes (opsonization). This 
type of B-lymphocyte immunity is called humoral (humoris; Latin for liquid) immunity, 
since the protective effect is mainly established by the immunoglobulins present in the 
serum. Humoral immunity is particularly involved in the recognition of extracellular 
micro-organisms. 
 Protection against intracellular pathogens (e.g. viruses) requires a different strate-
gy, since antibodies do not penetrate the cell membrane. T-lymphocytes recognize 
their antigen with the T-cell receptor (TCR). However, the TCR does not directly recog-
nize the intracellular antigen. Instead the TCR binds to small peptide fragments of anti-
gen proteins which are presented on the cell membrane by the major histocompatibil-
ity complex (MHC), in humans called human leukocyte antigen (HLA). The HLA I mole-
cule presents cytoplasmic peptides (e.g. derived from viruses) and can only be recog-
nized by CD8 expressing cytotoxic T-lymphocytes. HLA II molecules present peptides 
derived from phagocytized proteins and can only be recognized by CD4 expressing 
helper T-lymphocytes. HLA I is expressed on all somatic cells except for erythrocytes 
and the gametes. HLA II is exclusively expressed by immune cells with antigen present-
ing function, such as dendritic cells, B-lymphocytes, macrophages and monocytes. Up-
on activation T-lymphocytes produce IL-2, which stimulates further proliferation of T-
lymphocytes and differentiation into helper T-lymphocytes and cytotoxic T-
lymphocytes.  
 Cytotoxic T-lymphocytes are capable of killing tumor cells or cells infected with 
viruses by secreting apoptosis-inducing proteins. Helper T-lymphocytes play a central 
role in orchestrating the immune response by the secretion of regulatory cytokines. 
Based on their cytokine profile, helper T-lymphocytes cells are further divided into Th1, 
Th2, Th17 and Treg cells. Th1 cells mainly produce IFN-γ, IL-2 and TNF-α. Th1 cells are 
predominantly involved in activation of macrophages by IFN-γ, stimulation of inflamma-
tory processes by TNF-α and differentiation of cytotoxic T-lymphocytes. Th2 cells main-
ly produce IL-4, IL-5 and IL-13. IL-4 and IL-5 are important for humoral immunity by 
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supporting plasma cells. During an inflammatory response to an antigen both Th1 and 
Th2 cytokines are produced. In the face of infection however, the balance is often dis-
turbed (temporarily) towards a Th1 response. Persistent disturbance of the balance 
towards Th2 is seen in allergy. The Th1/Th2 balance is maintained by regulatory T-
lymphocytes (Tregs), which play a pivotal role in determining the intensity and length of 
the inflammatory response. Th17 cells are a recently established suppopulation of Th 
cells, which mainly secrete IL-17 and IL-22 and are important for clearance of fungi and 
extracellular bacteria by attracting neutrophils and macrophages to the site of infec-
tion. 
Danger-associated molecular patterns 
Classically the immune system is activated after recognition of PAMPs by TLR signaling. 
This response is aimed at recognizing and neutralizing exogenous threats. Ratzinger and 
Seong first described the possibility of endogenous danger-associated molecular pat-
terns (DAMPs) eliciting an immune response in a similar fashion [22]. Evidence has 
shown that endogenous molecules (i.e. self-antigens, such as intracellular proteins, 
DNA, RNA, nucleotides, heat shock proteins and extracellular matrix proteins) which are 
released during cell injury indeed activate APCs through TLR signaling. In other words, 
an inflammatory response is evoked without the presence of microorganisms. Hence 
this type of response is referred to as sterile inflammation. This concept adequately 
explains the marked activation of the immune system as observed after clinical and 
experimental stroke [23-31]. In this scenario local cerebral hypoxia-ischemia causes cell 
death and tissue injury, which elicits an immune response after the release of self-
antigens (DAMPs) that are hidden to the immune system under normal conditions [26, 
27].  
Peripheral immune organs 
During human fetal development, hematopoiesis starts at gestational week 3 when the 
first hematopoietic myeloid cells develop in the yolk sac [32]. Around gestational week 
12 these hematopoietic cells migrate to the liver and spleen [32]. Until shortly before 
term birth, the liver is the predominant site of myeloid and lymphoid hematopoiesis 
[32]. Around gestational week, 16 hematopoietic cells start migrating to the bone mar-
row, which becomes the chief site of hematopoiesis at term birth [32]. Therefore, in 
preterm infants hematopoietic foci can still be seen in the liver and to a lesser extent in 
the spleen, lymph nodes and thymus [32]. At term birth and later in life all immune cells 
originate in the bone marrow. Here, pluripotent hematopoietic stem cells differentiate 
into lymphoid stem cells and myeloid stem cells. Lymphoid stem cells further differen-
tiate into B-lymphocytes, NK cells and prothymocytes. The latter migrate to the thymus 
where they differentiate into T-lymphocytes. Myeloid stem cells further differentiate 
into granulocytes, monocytes/ macrophages, erythrocytes and thrombocytes. 
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The neonatal immune system – immature or competent? 
The fetal and neonatal immune system has long been perceived as defenseless and 
naïve. In the last two decennia however, mounting evidence has demonstrated that the 
developing immune system may be more competent as previously thought. Moreover, 
it has become more evident that the fetal and neonatal immune system is very well 
adapted to its task. The fetal immune system faces a challenge which is unique in life; 
avoiding an auto-immune response between mother and fetus, protecting the fetus 
from invading pathogens, and facilitating the transition of intra-uterine sterility to ex-
tra-uterine colonization by microorganisms [33]. The fetus has adapted to these chal-
lenges in various ways; evidence shows that the fetal immune system is markedly 
skewed towards production of Th2 polarizing cytokines, protecting the fetus against a 
harmful pro-inflammatory Th1 polarizing response, which is associated with allo-
immune reactions and premature labor and preterm delivery [33]. Th2 polarization 
could be disadvantageous in the face of an infection and therefore the fetal environ-
ment (i.e. uterus, placenta, skin and amniotic fluid) is equipped with a range of anti-
microbial substances, which protect the fetus against intra-uterine invasion of patho-
gens [33]. The (IL-6 mediated) acute phase response observed immediately after birth 
in addition plays a pivotal role in the clearance of invading pathogens during birth or 
initial colonization of the skin and the gut [33].  
 The fetal cellular immune system is immature in the sense that the number of 
immune cells gradually rises during gestation up to the first weeks to months in postna-
tal life [33, 34]. Considering the innate immune system, the concentration of comple-
ment in the neonatal serum is much lower when compared to adult levels [33]. A rela-
tive lack of complement limits effective opsonization and instruction of the adaptive 
immune system [33]. Neonates, and especially preterm infants, have lower numbers of 
quiescent neutrophils, which in addition show functional impairment of adhesion, mi-
gration and microbicidal mechanisms when compared to adult neutrophils [33]. These 
functional defects may be enhanced by the tendency of APCs to predominantly pro-
duce IL-6, which inhibits neutrophil migration to sites of inflammation [33]. Fetal and 
neonatal monocytes and APCs express lower levels of MHC II molecules, which impairs 
their antigen-presenting function. Although TLR expression on monocytes in preterm 
infants is not substantially lower compared with adults, the functional consequence of 
TLR signaling in monocytes derived from preterm infants is reduced [33]. 
 The adaptive immune system has long thought to be functionally immature [34]. 
This dogma changed in the mid 90’s when multiple research groups showed that under 
certain circumstances the developing immune system is capable of mounting an adult-
level T cell response despite reduced numbers of T-lymphocytes and their functional 
immaturity [34]. As mentioned previously, the neonatal T-cell response is biased to the 
Th2-cell lineage, but evidence has shown that adult-level Th1 responses can be 
achieved in neonates depending on antigen load, distribution of fetal versus adult pre-
cursor cell derived T-lymphocytes and the local environment [34]. Similarly neonatal 
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cytotoxic T-lymphocytes can develop mature function under specific circumstances 
[34]. On the other hand, neonatal B-lymphocyte antibody responses are impaired in 
terms of peak levels, time of onset, affinity and heterogeneity [34]. These impairments 
in fetal and neonatal humoral immunity are covered by maternal immunoglobulins 
which cross the placenta. Neonatal DC function however, as for neonatal T-
lymphocytes, can reach adult levels depending on the appropriate environmental sig-
nals [34].  
 In conclusion, the fetal and neonatal immune system can be considered as being ‘un-
der construction’ and will become more effective when time passes and maturation 
occurs. Still, the developing immune system has been very well adapted to the chal-
lenges it faces in the intra-uterine environment and during transition to the outside life. 
The fetus has found a way to deal with the exposure to a great number of exogenous 
and endogenous antigens during growth and development. In order to do so the fetal 
immune system is biased to an anti-inflammatory non-responsive state under normal 
conditions [33, 34] while supported by numerous microbicidal substances [33]. At the 
same time the fetal and neonatal immune system has the flexibility to mount an effec-
tive pro-inflammatory response when faced with high levels of danger [34] such as 
invasion of pathogens or tissue injury and cell death after hypoxia-ischemia. 
Hypoxic-ischemic encephalopathy 
Brain injury, or encephalopathy, is the biggest contributor to mortality and morbidity in 
preterm infants [8, 35]. The magnitude of the problem of encephalopathy in preterm 
infants is illustrated by the fact that 25-50% of preterm infants suffer from cognitive, 
socialization, attentional and/or behavioral disorders [8, 35, 36]. Spastic motor deficits 
(i.e. cerebral palsy), which creates disability with a tremendous burden for patients and 
their environment, occur in 5-10% of preterm infants [3, 8, 35, 37, 38].  
Causes of hypoxic-ischemic encephalopathy 
Encephalopathy of prematurity is caused by fetal, perinatal or postnatal cerebral hy-
poxia-ischemia and is therefore often referred to as hypoxic-ischemic encephalopathy 
(HIE) [35]. As discussed above, fetal hypoxia-ischemia with subsequent chronic fetal 
compromise or acute fetal distress can be caused by placental insufficiency or infection, 
which is often an indication for preterm delivery by cesarean section [1]. Perinatal hy-
poxia-ischemia here refers to hypoxic-ischemic insults that occur during delivery, usual-
ly referred to as perinatal asphyxia. Although perinatal asphyxia more frequently occurs 
in term infants (due to larger size of the baby with inherent risk of difficult passage 
through the birth canal), perinatal hypoxic-ischemic events do occur in preterm infants, 
but are frequently the result of pre-existing fetal compromise [39]. In addition, preterm 
infants are especially prone to postnatal cerebral hypoxia-ischemia due to the imma-
ture cerebral vasculature and cerebrovascular regulatory system which impede ade-
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quate adaptation to fluctuation in cerebral perfusion [36, 39]. Postnatal cerebral hypox-
ia-ischemia due to diminished cerebral perfusion can be additionally caused by infec-
tion, systemic hypotension, hypocapnia (hyperventilation) or steal of cerebral perfusion 
by a persistent ductus Botalli [39]. Furthermore, apneas that disturb oxygenation and 
cause subsequent cerebral hypoxia frequently occur in preterm infants [39]. The imma-
ture cerebral vasculature of the preterm brain is more prone to bleeding leading to 
germinal matrix hemorrhage and intraventricular hemorrhage, which is often associat-
ed with secondary periventricular hemorrhagic infarction and local cerebral ischemia 
[35].  
Normal myelination of the preterm brain 
During fetal development the immature brain starts to produce myelin, which serves as 
electric insulation of neurons thereby enhancing neuronal conductivity. Myelinated 
brain regions appear white in a fresh cut brain and are therefore referred to as white 
matter. Myelin is produced by oligodendrocytes. During gestation, oligodendrocytes 
develop from oligodendrocyte progenitors towards mature myelinating oligo-
dendrocytes [40]. Each developmental stage of oligodendrocyte maturation is charac-
terized by specific cellular morphology and antigen expression (Figure 2) [40], allowing 
histopathological estimation of normal and disturbed development according to gesta-
tional age [41-46].  
 
 
Figure 2. Phenotype and antigen (O4 and MBP) expression during different developmental stages of 
oligodendrocyte maturation. MBP = myelin basic protein. (adapted from Zhang et al., Nature Reviews 
Neuroscience 2001 [40]) 
White matter injury 
White matter injury is the clinical and histopathological hallmark of HIE in preterm 
infants [35, 36, 39]. However, recent work has shown that grey matter (i.e. neuronal/ 
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axonal networks) is also importantly affected in the hypoxic-ischemic preterm brain 
[35, 47-52]. Damage to subplate neurons after hypoxia-ischemia has been shown to 
play an important role in the etiology of neuronal injury in the preterm brain [53-56]. 
These subplate neurons are crucial for development and maturation of thalamocortical 
connectivity [53, 56]. Therefore, injury to these regulatory neurons results in axonal 
and neuronal dysfunction [35, 54]. White matter injury in the preterm brain is mainly 
characterized by periventricular leukomalacia (PVL), which occurs in 50% of preterm 
infants [35, 39]. PVL is clinically diagnosed by routine ultrasound and is subdivided in 
non-cystic PVL (PVL grade 1) with diffuse periventricular echogenicity (PVE) persisting 
more than one week after birth and focal cystic PVL (PVL grade 2-4) with development 
of small (PVL grade 2) up to extensive (PVL grade 4) periventricular cysts. Focal cyst 
formation occurs when periventricular hypoxia-ischemia results in irreversible cell 
death forming necrotic lesions, which resolve over a period of several weeks into fluid–
filled cavities [35, 36]. Diffuse non-cystic PVL is caused by injury to immature oligoden-
drocytes and astrogliosis after hypoxia-ischemia and is discussed in more detail below 
[35, 36] Timing of detection of PVL provides an indication of when the hypoxic-ischemic 
insult occurred. For example, cyst formation on ultrasound in the first week of life, 
suggests that cerebral hypoxia-ischemia already occurred during fetal life [39]. Germi-
nal matrix hemorrhage or intraventricular hemorrhage with secondary venous 
periventricular hemorrhagic infarction occurs in 5% of preterm infants, with increasing 
incidence up to 20-30% in extreme preterm infants [35]. 
Seizures  
Besides abnormalities on ultrasound, preterm infants with HIE may show early clinical 
symptoms ranging from hyperexcitability to hypotonia, stupor and absent primitive 
reflexes [39]. HIE in preterm infants often presents with clinical and electrophysiologi-
cal seizures [39], which have been associated with adverse neurodevelopmental out-
come [57-59]. Electroencephalogram (EEG) and camera registration are routinely used 
to detect seizure activity in preterm infants in the Neonatal Intensive Care Unit (NICU). 
However, continuous recording of a full EEG with 16 or 32 leads is troublesome in pre-
term infants, since the application of the electrodes and interpretation of the signals 
require expertise. Therefore, most NICU’s are equipped with amplitude-integrated EEG 
(aEEG), which is recorded using only 4 leads. The amplitudes of the EEG signal are dis-
played in a time-compressed fashion, allowing easy detection of electrophysiological 
seizures. Electrographic seizure activity is usually seen in the aEEG as an abrupt rise in 
the lower margin amplitude (LMA) and a simultaneous rise in the upper margin ampli-
tude (UMA), often followed by a short period of decreased amplitude [60]. The raw EEG 
simultaneously shows gradual build-up and decline in amplitude of repetitive sharp-
waves [61]. Experimental evidence shows that EEG is a valuable tool to detect brain 
injury caused by cerebral inflammation [62]. 
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Pathophysiology of HIE 
Diffuse non-cystic PVL is predominantly caused by damage to oligodendrocytes. Oli-
godendrocyte progenitors are particularly vulnerable to hypoxic-ischemia and media-
tors of inflammation [36, 42]. Damage to oligodendrocyte progenitors causes degener-
ation and arrested maturation of these cells, which precludes differentiation into ma-
ture myelinating cells leading to hypomyelination of the developing brain [43, 46, 63]. 
Oligodendrocyte progenitors are the predominant oligodendrocyte lineage between 23 
and 32 weeks of gestation in the preterm brain [42]. The abundant presence of vulner-
able oligodendrocyte progenitors in the developing brain explains why the preterm 
brain is particularly prone to white matter injury when exposed to hypoxia-ischemia or 
inflammation [36]. The concept of oligodendrocyte progenitors as the key target of 
hypoxic-ischemic injury is underlined by data showing that the localization of white 
matter injury in the preterm brain coincides with the distribution of oligodendrocytes 
progenitors [45]. The principal mechanisms underlying oligodendrocyte injury after 
cerebral hypoxia-ischemia are (1) glutamate excitotoxicity, (2) free radical attack and 
(3) activation of microglia (Figure 3) [41, 64-70].  
 Glutamate excitotoxicity occurs when cerebral hypoxia-ischemia compromises 
delivery of oxygen and nutrients to the preterm brain leading to energy failure [36, 39, 
71]. Depletion of energy sources causes failure of the sodium/potassium pump and 
subsequent failure, or even reversed function, of sodium-dependent glutamate trans-
porters leading to increased extracellular glutamate concentrations [36]. High concen-
trations of extracellular glutamate activate N-methyl-D-aspartate (NMDA) and α-
Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/ kainate (AMPA/KA) receptors 
which are abundantly expressed in the preterm brain on oligodendrocyte progenitor 
cell processes and cell somata, respectively. Glutamate-mediated activation of NDMA 
and AMPA/KA receptors leads to Ca2+ influx with subsequent activation of proteolytic 
enzymes, apoptotic pathways and generation of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) [36, 49]. Excessive activation of AMPA/KA receptors on 
the somata of oligodendrocyte progenitors leads to cell death, whereas activation of 
NMDA receptors on the processes of oligodendrocytes progenitors may lead to loss of 
processes on viable cells with subsequent failure to differentiate into mature myelinat-
ing oligodendrocytes [36, 46, 63]. 
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Figure 3. Schematic overview of the pathophysiology of hypoxic-ischemic encephalopathy in the preterm 
brain. Global hypoxia-ischemia in the preterm brain causes energy depletion and failure of glutamate 
transporters with subsequent glutamate excitotoxicity. Microglia are activated by excessive extracellular 
glutamate and TLR-mediated recognition of DAMPs. Upon activation, microglia produce ROS/RNS (1), 
enhance glutamate excitotoxicity (2) and release pro-inflammatory cytokines (3). Pre-oligodendrocytes are 
prone to injury by excessive ROS/RNS production, since antioxidant systems in the preterm brain are 
immature. Furthermore, pre-oligodendrocytes are injured by glutamate-mediated activation of AMPA and 
NMDA receptors on the somata and cell processes and oxytosis. Excessive microglial activation induces 
cerebral inflammation, characterized by expression of adhesion molecules on the cerebral vasculature and 
prolonged release of pro-inflammatory cytokines. The state of inflammation causes dysfunction of the blood-
brain barrier and further enhances activation of microglia. Release of pro-inflammatory cytokines and TLR-
mediated recognition of DAMPs form an additional injurious hit to pre-oligodendrocytes. The multiple 
injurious triggers to pre-oligodendrocytes cause immediate cell death or arrested maturation leading to 
hypomyelination of the brain. Hypomyelination and ischemic injury to neurons and axons causes dysfunction 
of the preterm brain, characterized by suppressed electrophysiological brain activity and clinical and 
electrophysiological seizure activity. DAMP = danger associated molecular pattern, pre-OL = pre-
oligodendrocytes, AMPA rec. = α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor, NMDA rec. = 
N-methyl-D-aspartate receptor, ROS/RNS = reactive oxygen species and reactive nitrogen species, TLR = Toll-
like receptor. 
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Cerebral hypoxia-ischemia and subsequent reperfusion causes oxidative stress, which is 
characterized by excessive formation of detrimental ROS and RNS [36, 39]. Experi-
mental data have shown that oligodendrocyte progenitors are particularly vulnerable 
to oxidative stress, whereas mature oligodendrocytes are more resistant to this type of 
injury [66, 69]. The vulnerability of oligodendrocyte progenitors to free radical attack is 
explained by deficiency of free radical scavenging enzymes, making the preterm brain 
prone to oxidative stress after a hypoxic-ischemic event [66, 69].  
 Microglia play a key role in the pathophysiology of HIE in the preterm brain [36, 
72]. Microglia are the innate immune cells of the brain, which are involved in the sur-
veillance of the brain detecting possible threats such as infection and injury [72-75]. 
Under normal conditions microglia are in their resting state with long thin processes 
sensing their environment for signs of danger [72]. Following hypoxia-ischemia, activa-
tion of microglia can occur through detection of excessive extracellular glutamate by 
the glutamate receptor on the microglial membrane or by recognition DAMPs (intracel-
lular proteins, DNA, RNA, nucleotides, heat shock proteins and extracellular matrix 
protein such as hyaluronic acid), which are released after neuronal injury and detected 
by Toll-like receptors (TLR) expressed on the microglial membrane [72, 76]. Activated 
microglia initiate a cerebral inflammatory response characterized by enhanced gluta-
mate excitotoxicity, production of ROS, release of pro-inflammatory cytokines (i.g. IL-1β 
and TNFα) and expression of adhesion molecules [36, 74-76]. The cerebral inflammato-
ry response initiated by microglia triggers the peripheral innate and adaptive immune 
system as indicated by brain invasion of neutrophils and T-cell activation [31]. The in-
flammatory response mediated by microglia is aimed at fighting off pathogens, clearing 
debris and repairing injury [74]. However, prolonged and excessive activation of micro-
glia, which may occur in the event of severe cerebral hypoxia-ischemia, initiates an 
exaggerated cerebral inflammatory response causing more harm than benefit for the 
brain [72-75, 77, 78]. Remarkably, microglia are abundantly present in the cerebral 
white matter during the period that coincides with high vulnerability for white matter 
injury in the preterm brain [79]. Taken together, this implies that the preterm brain is 
prone to injury following hypoxia-ischemia due to multiple factors; the presence of 
highly vulnerable oligodendrocyte progenitors, deficient antioxidant capacity and the 
abundant presence of microglia which may trigger injurious cerebral inflammation. 
New cellular treatment strategies for HIE in preterm infants 
Despite the high prevalence of neurological sequelae, therapeutic options to improve 
the neurodevelopmental outcome in preterm infants after HIE are unavailable. In mild 
cases of HIE in term infants whole body cooling therapy has been shown to improve 
neurodevelopmental outcome [80-82]. Cooling therapy is an independent risk factor for 
adverse neurological outcomes in preterm infants and therefore is not standard clinical 
care for this vulnerable patient group [80-82]. In the last decade, stem cell therapy has 
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emerged as a putative treatment for neonatal ischemic brain damage [83-91]. The ap-
proach of regenerative medicine in treating the injured brain may be especially suitable 
for preterm infants considering the growth-promoting preterm environment, which 
may maximize regenerative effects of stem cells. Here, mesenchymal stem cells (MSCs) 
and hematopoietic stem cells (HSCs) will be described as candidates for cell-based ther-
apy in perinatal medicine.  
 MSCs possess self-renewal capacity and pluripotency defined by their ability to 
differentiate into osteoblasts, chondrocytes, adipocytes and muscle cells of mesoder-
mal lineage [92-95]. MSCs have great therapeutic potential in the field of neonatal 
regenerative medicine due to their immunomodulatory and neuroprotective properties 
[88, 89, 94]. MSCs can be harvested from various tissues such as bone-marrow [92, 93, 
96-98], adipose tissue [97, 99] and perinatal tissues such as placenta [100], umbilical 
cord blood [101-106] and umbilical cord stroma (Wharton jelly) [104, 107, 108]. There-
fore, mesenchymal stromal cells (instead of mesenchymal stem cells) may be a more 
accurate description of MSCs [109].  
 The immunomodulatory effects of MSCs consist of modulation of both innate and 
adaptive immunity [94, 95]. Innate immunomodulation by MSCs entails inhibition of 
monocyte maturation into dendritic cells (DCs) and impairing antigen presentation by 
DCs preventing clonal expansion of T-cells [94, 95, 110]. MSCs further modulate innate 
immunity by inhibiting activation and proliferation of natural killer (NK) cells and damp-
ening the respiratory burst of neutrophils [94, 95, 110]. MSCs have the ability to sup-
press the antigen specific proliferation of T-cells, which keeps these effector cells in a 
quiescent state [94, 95, 110]. Furthermore, MSCs modulate the adaptive immune sys-
tem by promoting a shift of helper T cells from a pro-inflammatory to an anti-
inflammatory state, by downregulating cytotoxicity of cytotoxic T cells and by inhibiting 
proliferation of B-cells [94, 95, 110-113]. MSCs have been shown to induce proliferation 
of regulatory T cells, which are involved in maintaining immune homeostasis [94, 95, 
110, 113]. In short, MSCs modulate innate and adaptive immunity towards an anti-
inflammatory state [94, 95, 110]. Because of their anti-inflammatory properties, MSCs 
have been studied as therapeutic intervention in many diseases, such as graft versus 
host disease [114], autoimmune encephalomyelitis [115] and bronchopulmonary dys-
plasia [116-118], in which inflammation or a pathogenic immune response play a key 
role in pathophysiology. Although the exact mechanisms remain largely unknown, gen-
eral consensus is that MSC-mediated immunomodulation is predominantly caused by 
the paracrine effect of soluble factors secreted by MSCs [94, 95, 110].  
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Figure 4. Potential neuroprotective effects of mesenchymal stem cells (MSCs). MSCs secrete soluble factors 
which promote proliferation and maturation of neural precursor cells and oligodendrocytes. MSCs release 
anti-inflammatory factors that inhibit proliferation of microglia and astrocytes. Neurotrophic factors excreted 
by MSCs may rescue neurons in the ischemic brain from going into apoptosis (Adapted from Ucelli, Nature 
Reviews Immunology 2008 [94]). 
 
The neuroprotective properties of MSCs have been attributed to several mechanisms 
(Figure 4) [85, 94, 119, 120]. MSCs have been shown to stimulate proliferation of en-
dogenous neural progenitor cells (NPCs) and promote differentiation of NPCs towards 
neurons [88, 94, 119, 121, 122] and the oligodendrocyte lineage [88, 94, 119, 123, 124]. 
By replenishing the oligodendrocyte population, MSCs promote remyelination of the 
ischemic brain [88, 94, 119, 122]. Furthermore, secretion of neurotrophic factors by 
MSCs may rescue newly formed neurons and oligodendrocytes from apoptosis in the 
ischemic environment [88, 94, 119]. Importantly, MSCs have been shown to induce a 
switch of microglia from a pro-inflammatory M1 state towards a regenerative M2 state, 
thereby reducing pro-inflammatory cytokine release in the brain [88, 119, 125]. Moreo-
ver, MSCs inhibit proliferation of reactive astrocytes [88, 94, 119]. In vitro studies have 
demonstrated that MSCs are able to transdifferentiate into neurons [126-128], but this 
has not been reliably reproduced in vivo [94, 119]. In most reports only a minor fraction 
of transplanted MSCs are recovered in the brain [129, 130], therefore the contribution 
of neural transdifferentiation to neural repair is most likely negligible [88, 94, 119]. 
Thus, MSCs most likely exert their neuroprotective effect by secreting soluble factors 
with anti-inflammatory, anti-apoptotic and neurotrophic effects [88, 93-95, 110, 119].  
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Hematopoietic stem cells (HSCs) form a second interesting stem cell population with 
therapeutic potential in perinatal medicine. HSCs are defined by their capacity to self-
renew and to differentiate into cells of all blood lineages [93, 131-134]. HSCs are 
dormant stem cells that can be activated by inflammatory stimuli and act as part of the 
inflammatory response by giving rise to immune cells [132]. Hence, transplanted HSCs 
can replace or regenerate the diseased blood system, including the immune system [93, 
131-134]. HSCs can be readily isolated from bone marrow and peripheral blood and 
umbilical cord blood also offer a rich source of HSCs [135]. Granulocyte-colony stimulat-
ing factor (G-CSF) is routinely used in the clinical setting to mobilize HSCs into the pe-
ripheral blood resulting in easy isolation of enough HSCs for clinical applications [133, 
136, 137]. 
 HSCs may not only give rise to cells of the blood and immune system. Microglia and 
perivascular cells (astrocytes) have been reported to originate from HSCs as well [138-
141]. HSC differentiation into microglia probably reflects HSC-derived myeloid cells 
(monocytes) becoming microglia once invading the brain [139, 140]. Furthermore, mo-
bilized HSCs were shown to migrate towards the brain [142] and adapt a neuronal phe-
notype [143, 144]. Neuronal differentiation from mobilized HSCs, however, may reflect 
simultaneous mobilization of neural progenitor cells (NPCs) [143-145] or transdifferen-
tiation of concomitantly mobilized MSCs into a neural phenotype [127, 141, 146]. 
Moreover, HSCs have been shown to differentiate into endothelial progenitor cells 
(EPCs) [147]. EPCs are involved in neovascularization [147-151] and may therefore be of 
high therapeutic value to re-establish adequate cerebral perfusion after ischemic brain 
injury. 
Translational animal model 
The aim of this thesis is to explore the neuroprotective potential of cell-based therapy 
in the hypoxic-ischemic preterm brain. Effectiveness, safety and feasibility of such an 
innovative therapeutic strategy should first be tested in an animal model before clinical 
application. It is essential that the animal model is chosen with care, since there are 
many examples in literature of therapeutic interventions that showed promising results 
in animal models but failed in the human situation [152-155]. The discordance between 
human and animal studies is often attributed to failure of the animal model to accu-
rately mimic the human disease [152-155]. The optimal translational animal model 
should therefore adequately mimic the biology of the human situation and the etiology 
of the human disease [152-155].  
 In this thesis, neuroprotective potential of cell-based therapy in the hypoxic-
ischemic preterm brain was studied in fetal sheep, since the developmental biology of 
the ovine fetus closely resembles the human situation of prematurity [156-160]. Devel-
opment and maturation of several key organs follow the same time course in sheep as 
in humans [159]. For example, the alveolarization of the lung [12], myelination of the 
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brain [13] and formation of the intestinal crypts and villus [14] occur before birth in 
humans and sheep. This is in contrast with widely used rodent models, in which these 
aspects of organ development follow a different time course and predominantly occur 
after birth (Figure 5).  
 
 
Figure 5. Important hallmarks of fetal organ development. Maturation of the fetal 
lung, brain and gut follow a similar time course in humans and sheep, this in 
contrast to rodents.  
 
Moreover, sheep brain anatomy is closely similar to human brain anatomy. Sheep, like 
humans, are gyrencephalic (a brain with gyri and sulci) whereas rodents are lis-
senchephalic (a smooth-surfaced brain) [160]. Furthermore, vascular anatomy as well 
as white to grey matter ratio are similar in humans and sheep [160]. The oligodendro-
cyte is the key cellular target in the hypoxic-ischemic preterm brain [36, 39]. Important-
ly, oligodendrocyte maturation in fetal sheep follows a similar time course as in human 
development (Figure 6) [158]. As in humans, sheep oligodendrocyte density is highest 
in periventricular white matter, and therefore this region is most vulnerable to HI-injury 
[36, 45]. 
 As previously described, the etiology of HIE in the preterm brain can be roughly 
divided in two groups, namely fetal hypoxia-ischemia and infection. In our studies, we 
focused on hypoxia-ischemia as the cause of preterm brain injury. In the human situa-
tion, fetal hypoxia-ischemia is generally caused by chronic or acute compromise of 
blood flow to the fetus, which induces systemic hypoxia-ischemia involving all organs. 
To adequately mimic the acute clinical scenario, we induced systemic hypoxia-ischemia 
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in the fetal sheep by transient umbilical cord occlusion in utero. In contrast, in the 
commonly used Rice-Vannucci model rat pups are postnatally exposed to focal cerebral 
ischemia by unilateral permanent occlusion of the middle cerebral artery followed by a 
period of generalized hypoxia [161, 162]. Although this model has definitely contribut-
ed to our knowledge of the mechanisms involved in hypoxic-ischemic brain injury [162], 
the developmental biology of the animal and the etiology of injury may not optimally 
mimic the human situation in which the preterm brain is exposed to systemic hypoxia-
ischemia. 
 
 
Figure 6. Timing of appearance of oligodendrocyte lineage in human and sheep. 
Oligodendrocyte maturation follows a similar time course in human and in sheep 
brain. Solid lines indicate the period in which the oligodendrocyte lineages 
predominate. During the period of pre-oligodendrocytes predominance the 
preterm brain is highly prone to periventricular white matter injury (adapted from 
Back et al. J Child Neurol 2006 [158]). In our studies hypoxia-ischemia was induced 
by transient umbilical cord occlusion at 106 days of gestation, which roughly 
corresponds to a human preterm brain between 30-34 weeks. OL = 
oligodendrocyte, HI = hypoxia-ischemia. 
 
In the fetal sheep model transient umbilical cord occlusion is performed after in utero 
instrumentation of the fetus, as described below. The instrumented fetal sheep model 
allows delivering insults in utero while physiological outcome can be monitored in utero 
and the insult can be delivered at an equivalent developmental stage that coincides 
with the window of vulnerability in human preterm infants [42, 45, 158]. In our studies 
of the preterm brain, we included sheep fetuses at 100 days (term is 145 days) of gesta-
tion, which in terms of neurodevelopment and oligodendrocyte maturation is equiva-
lent to a late preterm human newborn of 30 to 34 weeks [156]. Previous studies have 
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shown that the pattern of white matter injury closely resembles the hypoxic-ischemic 
injury seen in human preterm infants [158, 160, 163-166]. 
The instrumented fetal sheep model 
In all studies described in this thesis fetal instrumentations was performed as follows 
(Figure 7) [167-170]. Fetuses of time-mated Texel ewes were instrumented around 101 
± 1 (mean ± SD) days of gestation. Before surgery, ewes received intravenous prophy-
lactic antibiotics. After intubation and induction of anesthesia, general anesthesia was 
maintained with 1-2% isoflurane guided by depth of sedation and supplemented by 
intravenous analgesia. Vital parameters and depth of sedation were continuously moni-
tored by certified personnel. A catheter was placed in the maternal long saphenous 
vein to provide access for a peri-operative saline drip and post-operative blood sam-
pling and administration of the prophylactic antibiotics during four days.  
 
 
Figure 7. Fetal instrumentation. Electroencephalogram (EEG) electrodes are placed on the head. 
Electrocardiogram (ECG) electrodes are placed on the chest. An inflatable vascular occluder is placed around 
the umbilical cord. An arterial catheter is placed for blood pressure measurements and sampling of blood and 
blood gases. A venous catheter is placed for the administration of stem cells, G-CSF or other interventions. An 
amniotic catheter is placed to measure pressure inside the uterus. This pressure was subtracted from the 
fetal arterial pressure to obtain the real arterial pressure in the fetus. 
 
After laparotomy, the uterus was opened and fetuses were catheterized with umbilical 
vessel catheters placed in the femoral artery and the brachial or femoral vein. Three 
custom-made electrocardiogram (ECG) shielded with silver plates were sewn on the 
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chest according to Einthoven for fetal heart rate recordings. Two pairs of custom-made 
electroencephalogram (EEG) shielded electrodes with silver tips were placed bilaterally 
on the dura over the parasagittal parietal cortex, with a sub-cutaneous silver reference 
electrode placed in the neck. Both sham animals and animals assigned to global hypox-
ia-ischemia were instrumented with an inflatable vascular occluder placed around the 
umbilical cord. A catheter for amniotic pressure recording was placed in the amniotic 
sac. Before closure of the uterus antibiotics were administered into the amniotic sac to 
prevent infection related to surgery. All fetal catheters and leads were exteriorized 
through a trocar hole in the flank of the ewe. After surgery, ewes were housed in a 
confined space to allow handling and continuous perfusion of the catheters. Surgical 
wounds were inspected daily and treated with antibiotic spray to prevent infection. 
Animals had ad libitum access to water and food. The welfare of the animals was moni-
tored daily by certified personnel.  
Experimental design 
In all studies described in this thesis, the experimental design was as follows [167-170]. 
After surgery, the ewe and her fetus were allowed to recover for four days. This recov-
ery period was to minimize effects of surgery and anesthesia on the experiment. In all 
studies, fetuses were randomly allocated to the sham (no umbilical cord occlusion, with 
or without treatment) and global hypoxia-ischemia (umbilical cord occlusion with or 
without treatment) study groups. In the global hypoxia-ischemia groups, the occluder 
was rapidly inflated with sterile saline and complete occlusion was confirmed with a 
sudden drop in heart rate and subsequent arterial blood gas analysis indicating acidem-
ia, hypoxia and hypercapnia. Such an insult has been previously shown to result in 
global hypoxic-ischemia and subsequent cerebral hypoperfusion [156, 163]. After 
(sham) umbilical cord occlusion a reperfusion period of 7 days followed. At the end of 
the experiment (experimental day 7), the animals were sacrificed and all tissues includ-
ing brain were collected. 
Fetal monitoring 
In utero instrumentation of the ovine fetus allows for continuous monitoring of elec-
trophysiological brain activity by EEG, electrophysiological cardiac function by ECG, 
hemodynamics by heart rate and blood pressure measurement and blood gas analyses 
(Figure 8). In the model, physiological changes of these parameters can be accurately 
measured during umbilical cord occlusion.  
 In all studies described in this thesis data were acquired as follows [167-170]. 
Blood pressure, amniotic pressure EEG and ECG data were acquired and digitized by a 
custom-made MPAQ unit (Maastricht-Programmable AcQuisition system, Maastricht 
Instruments BV, Maastricht, the Netherlands) with IDEEQ software (Maastricht Instru-
ments BV). Heart rate (beats per minute) was extracted from the ECG by R-top identifi-
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cation. Fetal mean arterial blood pressure (mmHg) was calculated by online subtraction 
of the amniotic fluid pressure from the femoral artery pressure. In this thesis, we used 
two different approaches to analyze electrophysiological brain function. In the first 
approach, burst activity was determined and length of interburst intervals was used as 
a surrogate for functional brain suppression. Burst activity was defined as an epoch 
with an amplitude > 30 µV and a duration > 1 s in both channels. Interburst intervals 
(IBI) were defined as epochs with an amplitude < 30 µV and a duration > 3 s in both 
channels. In the second approach the raw EEG signals were converted into amplitude-
integrated EEG (aEEG) traces, using a Matlab® (R2011b; The Mathworks Inc., Natick, 
MA, USA) algorithm similar to the clinical EEG NicoletOneTM device (Viasys Healthcare, 
Conshohocken, PA, USA) [171]. The (a)EEG traces were used to detect electrographic 
seizure activity. 
 
 
Figure 8. Continuous monitoring of fetal vital parameters. Upper panel: electrocardiogram (ECG), Einthoven’s 
derivation I and II (yellow). Middle panel: electroencephalogram (EEG), left (green) and right (purple). Lower 
panel: blood pressure, fetal arterial blood pressure (P art; red), amniotic pressure (P amnion, blue) and fetal 
blood pressure corrected for amniotic pressure (P corrected, pink). 
Imaging the preterm brain 
In all studies, the effect of systemic hypoxia-ischemia and the cell-based interventions 
were assessed by immunohistochemistry of the preterm brain [167-170]. These ana-
lyses primarily focused on the cells playing a predominant role in the pathophysiology 
of white matter injury in the brain. First of all, activation and proliferation of microglia 
was assessed as a measure of cerebral inflammation. White matter injury was assessed 
by analyzing density of oligodendrocyte and myelin binding protein. Furthermore, 
white matter injury was assessed by measuring fractional anisotropy (FA) with diffusion 
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tensor imaging (DTI) [169], which is a reliable method to assess white matter organiza-
tion [172-174]. 
Research questions and hypotheses 
From the adult field of local cerebral ischemia (i.e. stroke) it became evident that the 
cross-talk between brain and the immune system is essential in health and disease 
(Figure 9) [175]. Clinical and experimental evidence showed that transient or perma-
nent local cerebral ischemia not only caused acute infarction and neurodegeneration, 
but in addition induced massive activation of the peripheral immune system as charac-
terized by the production of pro-inflammatory cytokines in peripheral lymphoid organs 
and rapid mobilization of immune effector cells from the spleen [23, 27]. Mobilized 
effector cells (i.e. T-cells, monocytes, NK-cells) were shown to invade the affected 
brain, where these inflammatory cells aggravated cerebral inflammation and injury 
[27]. The rapid mobilization of the peripheral immune system in the acute phase result-
ed in splenic atrophy and was followed by a period of immunosuppression, making 
patients more susceptible to opportunistic infections [23, 25-29, 31, 176]. Several stud-
ies showed in adult rodent models of local cerebral ischemia that stem cell therapy (i.e. 
mesenchymal stem cells, hematopoietic stem cells or cord blood cells) reduced infarc-
tion volume and the protective mechanism was particularly attributed to modulation of 
the cerebral and peripheral inflammatory response [177-184]. Similarly, stem cell ther-
apy (i.e. mesenchymal stem cells, hematopoietic stem cells or cord blood cells) reduced 
infarction volume after local cerebral ischemia in experimental models of newborn 
rodents by modulating inflammation and promoting regeneration [121, 122, 130, 185-
194].  
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Figure 9. Outline of findings leading to the basic research questions of this thesis. 
The previous findings have formed the basis on which the mechanistic and therapeutic 
research questions of this thesis have been formulated (Figure 9). All previously de-
scribed studies assessed brain injury and involvement of the peripheral immune system 
after local hypoxia-ischemia. As stated before, the clinical scenario in hypoxic-ischemic 
encephalopathy in preterm infants predominantly involves global hypoxia-ischemia 
involving all organs and not solely the brain. Therefore the mechanistic research ques-
tions were: 
 
1. Does experimental global hypoxia-ischemia induce a similar pattern of injury 
as seen in preterm infants?  
2. Does global hypoxia-ischemia induce inflammation in the preterm brain?  
3. Does global hypoxia-ischemia activate and mobilize the immature peripheral 
immune system?  
 
To answer these mechanistic research questions we have established a translational 
animal model of global hypoxia-ischemia in preterm sheep in which the developmental 
biology and the etiology of the disease closely resemble the human situation. The ther-
apeutic research question was directly derived from the mechanistic ones: 
 
Can stem cell therapy prevent cerebral inflammation, activation of the peripheral im-
mune system and white matter injury in the preterm brain after global hypoxia-
ischemia? 
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We hypothesized that preterm infants would be excellent candidates for stem cell 
therapy since (1) their immature immune system would be likely to tolerate allogeneic 
stem cells, (2) stem cells would support regeneration after injury in the growth-directed 
preterm environment and (3) the immature blood-brain barrier in the preterm brain 
would make it more likely for stem cells to reach the site of injury. These general hy-
potheses lead to the following outline of the thesis: 
Chapter 2. Immature cerebrovascular regulatory system 
In chapter 2, we validated the translational instrumented sheep model by assessing 
longitudinal function of the baroreceptor reflex in fetal sheep after umbilical cord oc-
clusion. This primitive reflex is part of an essential cerebrovascular regulatory system, 
which ensures rapid adaptation to fluctuation in systemic blood pressure thereby main-
taining adequate cerebral perfusion [39]. Preterm infants are especially prone to cere-
bral ischemia and blood pressure fluctuation due to their immature cerebral vascula-
ture and cerebrovascular auto-regulatory system [39]. Therefore, we hypothesized that 
adequate baroreflex function would be persistently disturbed by transient umbilical 
cord occlusion in fetal sheep. 
Chapter 3. Cerebral inflammation and recruitment of the peripheral immune system 
In chapter 3, we studied the pattern of injury in further detail by assessing cerebral 
inflammation, white matter injury and electrophysiological brain activity after global 
hypoxia-ischemia in fetal sheep. We hypothesized that global hypoxia-ischemia by tran-
sient umbilical cord occlusion would induce a cerebral and peripheral inflammatory 
response similar to the one seen after local cerebral ischemia. In addition, we hypothe-
sized that cerebral inflammation would result in white matter injury and suppression of 
brain function.  
Chapter 4. Exogenous stem cells 
In chapter 4, we studied the neuroprotective potential of exogenous administration of 
MSCs after global hypoxia-ischemia in fetal sheep. We chose to study MSCs for their 
potent anti-inflammatory and regenerative capacities [13–16]. MSCs were infused in-
travenously, to test effectiveness of MSC therapy using a clinically feasible administra-
tion route. We hypothesized that intravenously administered human bone-marrow 
derived MSCs would be neuroprotective and dampen the cerebral and peripheral in-
flammatory response in a translational animal model of hypoxic-ischemic preterm brain 
injury. 
Chapter 5. Endogenous stem cells 
In chapter 5, we studied the neuroprotective potential of mobilization of endogenous 
HSCs by granulocyte-colony stimulating factor (G-CSF) after global hypoxia-ischemia in 
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fetal sheep. We hypothesized that systemic G-CSF treatment would be neuroprotective 
in a translational animal model of hypoxic-ischemic preterm brain injury.  
Chapter 6. General discussion 
The overall results of this thesis and future implications are discussed in chapter 6. 
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Abstract 
The understanding of hypoxemia-induced changes in baroreflex function is limited and 
may be studied in a fetal sheep experiment before, during, and after standardized hy-
poxic conditions. 
 Preterm fetal lambs were instrumented at 102 days gestation (term: 146 days). At 
106 days intra-uterine hypoxic-ischemia was induced by 25-min of umbilical cord occlu-
sion (UCO). Baroreflex related fluctuations were calculated at 30-min intervals during 
the first week after UCO by transfer function (cross-spectral) analysis between systolic 
blood pressure and R-R interval fluctuations, estimated in the low frequency (LF, 0.04-
0.15 Hz) band. LF transfer gain (baroreflex sensitivity) and delay (s) reflect the barore-
flex function. 
 Baseline showed no differences in LF transfer gain and delay between controls and 
UCO. In controls, LF gain showed postnatal increase. In contrast, LF gain gradually de-
creased in the UCO group, resulting in significantly lower values 4-7 days after UCO. In 
the UCO group, LF delay increased and differed significantly from controls.  
 Our results show that intra-uterine hypoxic-ischemia results in reduced baroreflex 
sensitivity over a period of 7 days, indicating limited efficacy to buffer blood pressure 
changes by adapting heart rate. Cardiovascular dysregulation may augment already 
present cerebral damage after systemic hypoxic-ischemia in the reperfusion period. 
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Introduction 
Preterm infants have a higher incidence of neurological morbidity and mortality com-
pared to term infants [1]. Neurological sequelae in preterm infants may be the conse-
quence of hypoxic-ischemia during fetal and early postnatal life [2]. Hemodynamic 
factors during hypoxic-ischemia and the post-hypoxic-ischemia reperfusion phase con-
tribute considerably to these neurological disorders [3]. To ensure adequate blood flow 
to organs throughout the body, including the brain, blood pressure is controlled by 
baro- and chemoreflex mechanisms. Under normoxaemia, the baroreflex stabilizes 
perfusion pressure in the face of disturbances of circulatory homeostasis by adapting 
heart rate, myocardial contraction and vascular resistance. A poorly developed barore-
flex function could contribute to blood pressure instabilities, which may lead to im-
paired cerebral perfusion or hemorrhage [4]. A better understanding of the dynamics 
underlying the control mechanisms regulating blood pressure may be useful to improve 
diagnosis of these disorders. 
 Low-frequency (LF) fluctuations in arterial blood pressure with a wave length of 
approximate 10 s (also called Mayer waves) have historically been attributed to barore-
flex activity [5]. The oscillations are assumed to be caused by a feedback control and 
mediated through the sympathetic and parasympathetic innervations of the baroreflex 
[6]. Assessment of the baroreflex function (i.e. heart rate mediated blood pressure 
control) can be obtained through quantification of baroreceptor sensitivity. Barorecep-
tor sensitivity (ms/mmHg) may simply be defined as the change in heart rate (or R-R 
interval) in response to changes in arterial blood pressure, and may be estimated from 
LF cross spectral analysis of spontaneous fluctuations in R-R intervals and blood pres-
sure [7-10]. 
 Our understanding of the cardiovascular response of the human preterm infant is 
limited [11, 12] and knowledge of fetal baroreflex is mostly based on animal (sheep) 
models [13, 14]. There is, however, conflicting evidence on the fetal and postnatal de-
velopment of baroreceptor reflex function. While some studies show increasing barore-
flex sensitivity with age, other studies show no significant maturational change [15-18]. 
The cardiovascular system responds to hypoxic-ischemia by changing heart rate and 
redistributing cardiac output to preserve the limited energy resources and maintain 
adequate supply to the brain. Current knowledge about how the preterm fetus, ham-
pered by an immature blood pressure regulation, responds to hypoxia is limited. Exper-
iments have shown that the immature sheep fetus can survive prolonged periods of 
hypoxic-ischemia, but resulting hypotension and hypoperfusion may contribute to cer-
ebral injury as seen in human preterm fetuses [13, 19, 20]. These studies mainly focus 
on cerebrovascular and fetal heart rate response following hypoxic-ischemia for 72 h. 
Heart rate mediated blood pressure control has not been examined for longer than 
several days after the initial period of hypoxic-ischemia. 
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The aim of this study was (a) to quantify baroreflex mediated heart rate response (bar-
oreflex sensitivity) by transfer function analysis between low-frequency R-R and systolic 
blood pressure fluctuations in an instrumented preterm fetal sheep model and (b) to 
evaluate longitudinal changes of baroreflex mediated heart rate response during the 
first week following umbilical cord occlusion (UCO) induced hypoxic-ischemia. 
Materials & methods 
Animals 
Texel ewes were date-mated and the fetuses were randomized for UCO or control. The 
study group consisted of 14 fetal sheep (9 controls and 5 UCO). Fetal instrumentation 
was performed at 0.7 GA (102 days, term 146 days). The study was conducted at Maas-
tricht University Medical Center, Maastricht, The Netherlands, and was approved by 
the local Animal Ethics Research Committee. 
Experimental preparations 
The pregnant ewes were deprived of food, but not water, 24 h before surgery. They 
were anesthetized using 1-2% isoflurane, guided by depth of sedation. After a lower 
midline incision, the fetus was carefully extracted through a small incision of the uterus. 
The fetus was instrumented with a 3.5 French Argyle umbilical vessel catheter (Tyco 
Health Care Group, Mansfield, MA) in the femoral artery. The arterial catheter was 
utilized for continuous monitoring of fetal arterial pressure. A vascular occluder 
(OC16HD, in vivo Metric, Healdsburg, CA ) was placed around the umbilical cord. Three 
custom-made silver electrodes with fixed leads (Cooner, Chatsworth, CA) were inserted 
in the subdermis and fixed with sutures. These electrodes were used for electrocardiog-
raphy and formed an Einthoven triangle. The fetus was then repositioned in the uterus. 
A catheter was inserted into the amniotic sac to monitor the amniotic fluid pressure. 
Before closure the amniotic cavity was filled with warm sterile saline (NaCl 0.9%). All 
fetal catheters and electrode leads were exteriorized through the flank of the ewe. The 
lower midline incision was securely sutured. After surgery, the ewe was allowed to 
recover and housed in a confined space to allow continuous perfusion of catheters with 
heparinized saline. Post-surgery ewes received five days of intravenous amoxicillin 
(1000 mg) / clavulanic-acid (200 mg). During the complete course of the experiment (11 
days) the animals had ad libitum access to water and food.  
Experimental design 
Experiments were conducted at 102 (operation) to 113 (sacrifice) days of gestation. 
After a recovery period of four days (GA, 106 days) the umbilical cord of the fetuses in 
the UCO group was occluded by rapidly inflating the occluder with sterile saline of a 
defined volume known to completely inflate the occluder. Verification of the occlusion 
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was obtained by observation of a sudden drop in heart rate. The occlusion was discon-
tinued after 25 min, or earlier when mean arterial blood pressure dropped below 8 
mmHg or asystole occurred. At the end of the occlusion, the lambs always suffered 
from severe bradycardia (heart rate < 90 bpm, normal approximately 180 bpm) or even 
complete cardiac arrest. If there was no increase in heart rate within 20 s after the end 
of occlusion, resuscitation was started using an injection of adrenalin (0.1 mg/kg). Arte-
rial blood gas analysis (pO2, pCO2, pH) was performed before, during and after umbili-
cal cord occlusion to monitor the metabolic state during hypoxic-ischemia and recov-
ery. Fetuses were studied for 7 days post-occlusion. At the end of the experiment, both 
ewe and fetus were euthanized by administration of pentobarbital (200 mg/kg). 
 
Table 1. Baseline values and long-term monitoring of blood gas, cardiovascular and transfer function
parameters. Blood gas analyses, cardiovascular parameters and transfer function parameters during the 
baseline period and on the seventh day (T=144-168 h) after UCO, respectively. Time domain and transfer 
function measures were determined from 30-min segments during 24 hours before and 144-168 h after 
occlusion, respectively. Values are expressed as mean ± SEM or median (IQR). * p<0.01, † p<0.05 (comparison
between UCO and control at corresponding time). Assessment of change between baseline and following days
within group is performed by multilevel analysis (see Table 2). 
 Control group  UCO 
 Baseline T=144-168 h Baseline T=144-168 h 
Blood gas analysis     
pH 7.41 ± 0.04 7.38 ± 0.05 7.41 ± 0.03 7.40 ± 0.07 
Arterial pCO2 (mmHg) 42 ± 6 31 ± 10 41 ± 9 41 ± 10 
Arterial pO2 (mmHg) 17 ± 2 17 ± 3 15 ± 4 19 ± 6 
R-R interval series     
R-R interval (ms) 328 (315-341) 345 (327-363) 332 (322-341) 347 (332-357) 
SD-RR (ms) 21 (15-25) 21 (18-27) 21 (17-24) 11 (9-16) * 
Total power (ms2) 184 (54-451) 271 (149-463) 258 (46-406) 13 (2-71) * 
LF power (ms2) 138 (44-144) 214 (144-335) 116 (37-359) 13 (1-62) * 
SBP series     
SBP (mmHg) 46 (43-48) 49 (45-50) 47 (39-55) 52 (45-57) 
SD-SBP (mmHg) 1.8 (1.7-2.1) 2.2 (2.0-2.3) 1.8 (1.7-1.9) 1.9 (1.7-2.4) 
Total power (10-2 mmHg2) 1.7 (1.2-2.7) 3.2 (2.1-4.1) 1.7 (1.0-2.0) 1.3 (0.7-2.2) † 
LF power (10-2 mmHg2) 1.5 (1.1-2.5) 2.4 (1.9-3.5) 1.6 (0.9-1.8) 1.3 (0.6-2.2) † 
SD-RR/SD-SBP (ms/mmHg) 10.4 (8.6-11.9)  10.5 (8.7-12.0) 12.2 (8.6-13.2) 6.2 (3.4-8.0) * 
Transfer function     
Frequency (Hz) 0.09 (0.09-0.10) 0.09 (0.09-0.11) 0.09 (0.09-0.11) 0.09 (0.08-0.09) 
Coherence 0.62 (0.61-0.65) 0.65 (0.63-0.68) 0.64 (0.63-0.67) † 0.63 (0.61-0.65) 
Gain (ms/mmHg) 6.2 (5.6-8.4) 7.7 (6.7-10.6) 7.8 (5.6-11.4) 4.8 (3.1-6.7) * 
Delay (s) 5.5 (3.3-6.8) 4.3 (3.2-5.9) 4.0 (3.3-5.6) 6.6 (3.7-7.6) † 
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Data acquisition 
Blood pressure, amniotic pressure and ECG data were acquired and digitized by an 
MPAQ unit (Maastricht-Programmable AcQuisition system, Maastricht Instruments BV, 
Maastricht, The Netherlands). Analog filtering was applied to the ECG data, with a 1-
200 Hz band-pass filter. Arterial blood pressure and amniotic pressure data were not 
filtered. All data were sampled at 1000 Hz. Finally, data were stored on a hard drive for 
off-line analysis.  
Data analysis 
Data were processed off-line using MATLAB R2009a (The MathWorks, Inc., Natick, MA). 
Recordings were divided into 30-min segments for analysis. ECG data were filtered 
using a 50 Hz infinite impulse response notch filter and 20-80 Hz 4th-order Butterworth 
band-pass filter, empirically found to be optimal for the R-peak detection algorithm 
used. Fetal blood pressure signals were filtered using a 50 Hz infinite impulse response 
notch filter and 2-16 Hz 4th-order Butterworth band-pass filter to facilitate detection by 
the waveform analysis algorithm. Fetal blood pressure was corrected for offset by sub-
traction of the low-pass filtered amniotic fluid pressure. 
 In each 30-min segment, R-peaks of the QRS-complex and systolic blood pressure 
were detected by adaptive filtering of the ECG and blood pressure waveforms, respec-
tively. Segments containing artifacts were excluded (<5% of the data). The unevenly 
time-spaced R-R interval and SBP series were convolved with a boxcar function and 
subsequently resampled at 4 Hz using nearest-neighbor interpolation to obtain equidis-
tant sample points [21]. 
Spectral analysis and transfer-function analysis 
Spectral analysis offers the opportunity to decompose spontaneously occurring fluctua-
tions in SBP and R-R interval time series into a power spectrum, and to relate the char-
acter of the fluctuations to physiological processes. Transfer function analysis (cross-
spectral analysis) between SBP and R-R interval series in the low-frequency band (0.04-
0.15 Hz) is a useful estimate of baroreflex sensitivity [7, 22, 23]. This methodology was 
adapted for preterm infants and we refer to previous papers for further details [11, 21]. 
As R-R interval and blood pressure values obtained from fetal sheep are comparable 
with values found in preterm infants, the same spectral analysis methodology was fol-
lowed. Each 30-min segment of R-R interval and SBP series was divided into nine 192-s 
segments. In the 192-s segments total spectral power (0.04-2 Hz) and LF (0.04-0.15 Hz) 
spectral power were calculated from the auto spectra of R-R interval and SBP series. 
From the cross spectra of R-R interval and SBP series, the coherence, transfer gain and 
transfer phase were calculated for the LF band. As the reliability of transfer function 
depends on coherence between the signals, transfer function parameters were only 
assessed if coherence > 0.50. In 41% of all 192-s segments coherence was > 0.50 and 
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these segments were included for transfer function analysis. Baroreflex sensitivity was 
calculated as the LF transfer gain and assessed at the frequency with the highest coher-
ence within the LF band. Baroreflex delay was calculated by dividing the transfer phase 
at the corresponding frequency bin by 2π-times this frequency. Time domain cross 
correlation of the R-R interval and SBP series was used to correct for n·2π phase shifts. 
Time domain estimates of variability 
Heart rate variability was assessed for each 192-s segment by calculating the mean R-R 
interval and standard deviation (SD-RR) [23]. Likewise, blood pressure variability was 
assessed by calculating the mean SBP and standard deviation (SD-SBP). To verify results 
obtained by spectral analysis, baroreceptor sensitivity was also analyzed in the time 
domain. To obtain a time domain estimate for baroreceptor sensitivity, SD-RR was 
divided by SD-SBP [21]. 
Data processing 
Median values per 30-min segment were calculated from the underlying 192-s seg-
ments. For further analysis, 30-min segments were pooled as 6 h or 24 h values (medi-
an; IQR), depending on the mode of presentation in graph or table, respectively. The 
median was used because normality was not a priori assumed and to reduce the effect 
of outliers. Baseline values were assessed in the 24 h before UCO and median values for 
the long-term follow-up were assessed between 0-24, 24-48, 48-72, 72-96, 96-120, 
120-144 and 144-168 h after UCO. 
Statistics 
Blood gas data were expressed as mean ± SEM. Group comparisons for blood gas analy-
sis were performed using the two-sided unpaired student t-test. Time and frequency 
domain estimates were expressed as median and IQR and group comparisons were 
analyzed using the Mann-Whitney U test. As the 6-h values were normal distributed, 
the maturational effects on time domain and frequency domain spectral measures 
were evaluated using a multilevel analysis. In this analysis linear regression is estimated 
using the random effects model (SPSS 19.0.0, Inc., Chicago, IL), which extends the gen-
eralized linear model to allow for analysis of repeated 6-h values between and within 
subjects. Regression analysis results are shown with the a- and b-coefficient (a, inter-
cept; b, slope of regression line). A p-value < 0.05 was considered significant. 
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Table 2. Maturation of cardiovascular and transfer function parameters. Results of
multi-level regression analysis using a generalized linear model to correct for repeated
measurements. Regression analysis is performed according to: f(t) = a + b • x, with a the 
offset, b the slope and t the time (days) with t=0 corresponding to the time of occlusion
for the UCO group. Values are expressed as mean ± SD. * p<0.01, † p<0.05. 
 
Control; b 
(change/day) 
UCO; b 
(change/day) 
R-R interval series   
R-R interval (ms) 2.8 ± 0.6 * NS 
SD-RR (ms) 0.8 ± 0.2 * NS 
SBP series   
SBP (mmHg) 0.4 ± 0.1 * NS 
SD-SBP (mmHg) 0.04 ± 0.02 † 0.10 ± 0.02 * 
SD-RR/SD-SBP (ms/mmHg) NS - 0.7 ± 0.1 *  
Transfer function   
Frequency (Hz) NS NS 
Coherence NS NS 
LF gain (ms/mmHg) 0.4 ± 0.1 * - 0.7 ± 0.1 * 
LF delay (s) NS 0.5 ± 0.1 * 
Results  
Cardiovascular and transfer function parameters at baseline 
Baseline values for both the UCO and the control group were derived in the 24 h before 
the UCO (Table 1). Time domain estimates of variability were comparable in both 
groups. A slight but significant difference in coherence values was noted between both 
groups. The baseline values for LF transfer gain, delay and frequency were comparable 
in both groups. 
Cardiovascular and transfer function parameters at 144-168 h 
At the end of the experiment, mean R-R interval, mean systolic blood pressure (SBP) 
and SBP standard deviation (SD-SBP) showed no differences between the intervention 
group and controls (Table 1). In contrast, the R-R interval standard deviation (SD-RR) 
was significantly reduced after UCO at comparable endpoint. Spectral power analysis 
showed significant differences in LF and total power for the R-R interval and SBP series 
between UCO and controls. In the UCO group, LF and total power for the R-R interval 
showed a 15 to 20-times reduction, compared to controls. For the SBP series, LF and 
total power were reduced by a factor of 2. Transfer function analysis showed no differ-
ence in coherence or LF frequency. A slight increase in LF delay after UCO was observed 
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compared to controls. Following UCO, both time domain estimate for baroreflex sensi-
tivity (SD-RR/SD-SBP) and transfer gain were reduced by approximately 40%. 
Maturation of cardiovascular and transfer function parameters 
Figure 1 shows the changes in short-term variability of R-R interval time series (SD-RR) 
and SBP (SD-SBP) time series, respectively. After UCO the decrease in SD-RR is reflected 
by decrease from 72-168 h in SD-RR/SD-SBP, time domain estimate for baroreflex sensi-
tivity. Figure 2 shows the changes in coherence, LF transfer gain and delay. From 96 h, 
LF transfer gain is decreased versus controls. 
 In addition, the maturational effects on time and frequency domain spectral 
measures were evaluated by multilevel regression analysis for both the control and 
UCO group using pooled 6-hr values during the first week after UCO. This model cor-
rects for the repeated measurements within and between subjects. The results of the 
multilevel analysis are shown in Table 2. The control group showed a significant in-
crease in R-R interval, SD-RR, SBP and SD-SBP. The UCO group showed a significant 
increase in SD-SBP, approximately 2.5-fold the magnitude of the SD-SBP increase in the 
control group. The multilevel analysis supported the finding that baroreflex sensitivity 
increases in controls, but decreases gradually after UCO induced asphyxia. Both time 
domain estimate for baroreflex sensitivity (SD-RR/SD-SBP) and LF transfer gain de-
creased by the same amount following UCO, - 0.7 ms/mmHg/day. 
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Figure 1: Longitudinal changes in SD-RR, SD-SBP and SD-RR/SD-SBP. Legend: Plots of the longitudinal 
development of heart rate variability (SD-RR, A), blood pressure variability (SD-SBP, B) and time domain 
measure of baroreflex sensitivity (SD-RR/SD-SBP, C). The x-axis represents time in h. The black and gray 
symbols indicate the control and UCO group, respectively. The first 24 h after UCO significant differences are 
observed between UCO and control group, inherent to the experimental occlusion. After 72 h a consistent 
decrease in SD-RR and SD-RR/SD-SBP is noted. Data are shown as median and IQR for each 6-h period. * 
indicate p < 0.01; † < 0.05. 
 
Baroreflex in asphyxiated fetal sheep 
 55
 
Figure 2: Longitudinal changes in coherence, LF transfer gain and delay. Legend: Plots of the longitudinal 
development of coherence (A), transfer gain (B) and delay (C). The x-axis represents time in h. The black and 
gray symbols indicate the control and UCO group, respectively. The first 24 h after UCO significant differences 
are observed between UCO and control group, inherent to the experimental occlusion. After 96 h a consistent 
decrease in LF transfer gain is noted. Data are shown as median and IQR for each 6-h period. * indicate p < 
0.01; † < 0.05. 
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Discussion 
The present study demonstrates that intra-uterine induced hypoxic-ischemia in pre-
term fetal sheep has long-term effects on baroreflex function. During the first week 
following prolonged umbilical cord occlusion, heart rate variability decreases dramati-
cally and baroreflex sensitivity decreases gradually to show lower values than controls 
at 4-7 days after UCO. These results suggest that intra-uterine hypoxic-ischemia limits 
the baroreflex activity to buffer changes in SBP by adapting fetal R-R interval. The 
dysregulation of the baroreflex may augment already present cerebral damage after 
systemic hypoxic-ischemia in the reperfusion period. As a consequence of this cardio-
vascular instability the preterm brain may be prone to blood pressure fluctuations, 
leading to disruption of the immature vascular architecture and neonatal encephalopa-
thy [24]. 
Transfer function analysis and baroreflex function 
In the present study we focused on the baroreflex-mediated interactions between LF 
fluctuations of SBP and R-R intervals during the normoxaemic recovery state, hence 
after the immediate cardiovascular effects of acute hypoxia and hypoxic-ischemia. 
Under normoxaemic condition, baroreflex rather than chemoreflex is involved in the 
interactions between arterial blood pressure and fetal heart rate [25]. We were inter-
ested in the long-term effect of induced fetal hypoxic-ischemia on baroreflex function, 
i.e. baroreflex sensitivity and delay of the reflex arc. The evaluation of baroreflex func-
tion is useful for the assessment of fetal autonomic cardiovascular control [26]. Evalua-
tion of baroreflex function by spectral methods is based on the concept that each spon-
taneous oscillation in blood pressure elicits an oscillation at the same frequency in R-R 
interval by the effect of arterial baroreflex activity [7]. As found in other fetal sheep 
experiments, we observed an oscillation frequency associated with fetal baroreflex 
activity centered around 0.1 Hz [27]. According to the transfer function method, baro-
reflex sensitivity was calculated as the value of the transfer function modulus and 
phase (i.e. gain and delay) between SBP and R-R interval in the LF frequency, consider-
ing a coherence ≥ 0.5 [22]. The transfer function methodology has been used in several 
studies of human preterm infants [11, 21]. As the values of SBP and R-R intervals ob-
tained from the fetal sheep are comparable with values found in preterm infants, the 
same spectral analysis methodology was followed. Transfer function analysis in this 
study showed relatively high coherence values in the LF band, suggesting reliable esti-
mates of transfer gain and delay.  
Long-term effects of hypoxic-ischemia 
During longitudinal monitoring of the UCO group, the LF transfer gain gradually de-
creased over time, leading to a significantly lower LF transfer gain post-UCO compared 
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to the control group. Consistent with this finding is the time-domain observation of a 
decreased SD-RR, while SD-SBP remains unchanged. In contrast, the LF delay between 
blood pressure variations and subsequent heart rate variations increased compared to 
the control group. The gradual decrease of baroreflex sensitivity and increase in delay 
between variations in heart rate and systolic blood pressure suggest that hypoxic-
ischemia results in a deregulation of the baroreceptor reflex arc. A decreased LF trans-
fer gain and increased delay may result from changes in the dynamics of the sympa-
thetic and parasympathetic pathways and/or from changes in the balance between 
these pathways [6, 17, 18, 26]. As the parasympathetic effect on heart rate changes is 
fast compared to sympathetic effect, increased delay may indicate a greater relative 
contribution of sympathetic regulation. This is supported by the finding that normalized 
LF power (LF/total power) increased to nearly 100% following UCO, while remained 
stable in controls (approximately 75%). 
 The afferent signals from the baroreceptor output are projected on the nucleus of 
the solitary tract, which is located in the medulla region, to be processed and trans-
ferred to the blood pressure regulation effectors [28]. Previous findings in 0.6 gestation 
fetal sheep showed that suppressed fetal heart rate variability following 30 minute UCO 
was associated with severe neuronal loss in the brain stem 3 days after the insult [20]. 
This neuronal loss may affect the processing of afferent nerve signals and therefore the 
baroreflex function, thereby decreasing regulation efficacy. Although we did not study 
brain stem histology, our findings showed that deregulation of baroreflex function 
gradually increases over the course of seven days suggesting evolving neuronal loss in 
the brain stem. This finding also highlights the importance of study length. At 3 days 
after UCO, the end-point for most other longitudinal studies [19, 20], baroreflex trans-
fer function parameters of our UCO group were not significantly different from the 
control group, potentially obscuring long-term hypoxic-ischemia-induced functional 
loss. We speculate that gradual functional loss may be related to the evolvement of 
hypoxic-ischemic associated cytotoxic edema during the first week as seen by MRI stud-
ies in human infants [29]. Fetal heart rate variability (SD-RR) was already significantly 
decreased at 3 days post-UCO, and gradually decreased further during the remainder of 
the study. This observation is in agreement with Ikeda et al., who showed that de-
creased long-term fetal heart rate variability at 24-72 h of recovery after UCO showed 
to be an indicator of the severity of histological damage in the term fetal brain [30]. To 
our knowledge, our study is the first to describe this change in fetal heart rate variabil-
ity in preterm asphyxiated fetal lambs. 
Maturational effects of baroreflex activity 
Results of our study indicate that the baroreflex function matures during fetal life, as 
shown by the increase in LF transfer gain for the control group between 0.75 and 0.80 
GA. These results confirm findings by other experiments, which noted that the barore-
flex function was active from approximately 85 days of gestation (0.6 GA), and the 
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magnitude of fetal heart rate response to blood pressure changes increased towards 
term [15]. Other studies found a decrease in baroreflex sensitivity during development 
[31-33]. Several studies showed no significant maturation of the baroreflex sensitivity 
[16, 17]. There may be several explanations for these conflicting findings. First, it is 
known that the different pathways of the baroreflex feedback system mature at differ-
ent rates. In preterm sheep of 0.7 GA there is probably no significant control by the 
renal sympathetic nerve, which regulates vascular resistance [18, 34], whereas in the 
term sheep vascular resistance control is present [32]. In our study, fetal sheep were 
instrumented at 0.7 GA, and maturational changes were studied between 0.75 and 0.80 
GA. Other studies have little to no variation in GA, or their results lack the temporal 
resolution required to compare results to our findings directly [16, 17, 31, 32]. Second, 
the discrepancies may be due to methodological differences. Quantification of sponta-
neous baroreflex sensitivity by spectral methods and quantification by injection of 
drugs or aortic compression do not necessarily produce comparable results [35]. Spon-
taneous variations in blood pressure are normally in the order of several mmHg, 
whereas experiments using invasive quantification methods generally study heart rate 
responses to larger blood pressure changes. Third, heart rate response to blood pres-
sure changes is non-linear, and can be characterized by a sigmoidal input-output rela-
tion with maximum responses around the (normal) operating point and decreased 
regulation capacity at the extremes [8]. 
Pathophysiological implications 
Reduction in fetal heart rate variability is associated with fetal hypoxia and acidemia in 
human preterm [36] and term fetus [37]. However, despite the highly adverse out-
comes of moderate to severe encephalopathy around birth the predictive value of 
abnormal fetal heart rate patterns for cerebral palsy is consistently weak [38]. This 
study demonstrates an association between fetal hypoxic-ischemia and reduced baro-
reflex sensitivity. For obvious reasons, direct measurement of fetal blood pressure in 
humans is not possible. Future studies may explore the use of non-invasive (Doppler) 
estimation of fetal blood pressure and spectral-derived variability in assessing hypox-
emia-induced changes in brain stem mechanisms for cardiovascular control [39]. 
 In conclusion, this is the first study to quantify baroreflex mediated heart rate 
response in a preterm fetal sheep model by transfer function analysis of R-R interval 
and SBP fluctuations, and to show long-term effects on baroreflex function after intra-
uterine umbilical cord occlusion induced hypoxic-ischemia. Our results show that intra-
uterine hypoxic-ischemia limits baroreflex efficacy to buffer changes in SBP by adapting 
fetal R-R interval following umbilical cord occlusion. As a consequence, the preterm 
brain may be prone to blood pressure fluctuations, possibly leading to disruption of the 
immature vascular architecture and augmenting already present cerebral damage after 
systemic hypoxic-ischemia in the reperfusion period. 
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Chapter 3 
Cerebral inflammation and mobilization of 
the peripheral immune system following 
global hypoxia-ischemia in preterm sheep 
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Abstract 
Hypoxic-ischemic encephalopathy (HIE) is one of the most important causes of brain 
injury in preterm infants. Preterm HIE is predominantly caused by global hypoxic-
ischemia (HI). In contrast, focal ischemia is most common in the adult brain and known 
to result in cerebral inflammation and activation of the peripheral immune system. 
These inflammatory responses are considered to play an important role in the adverse 
outcomes following brain ischemia. In this study, we hypothesized that cerebral and 
peripheral immune activation was also involved in preterm brain injury after global HI. 
 Preterm instrumented fetal sheep were exposed to 25 minutes of umbilical cord 
occlusion (UCO) (n=8) at 0.7 gestation. Sham-treated animals (n=8) were used as a 
control group. Brain sections were stained for ionized calcium binding adaptor mole-
cule 1 (IBA-1) to investigate microglial proliferation and activation. The peripheral im-
mune system was studied by assessment of circulating white blood cell counts, cellular 
changes of the spleen and influx of peripheral immune cells (MPO-positive neutrophils) 
into the brain. Pre-oligodendrocytes (O4) and myelin basic protein (MBP) were detect-
ed to determine white matter injury. Electro-encephalography (EEG) was recorded to 
assess functional impairment by interburst interval (IBI) length analysis. 
 Global HI resulted in profound activation and proliferation of microglia in the hip-
pocampus, periventricular and subcortical white matter. In addition, non-preferential 
mobilization of white blood cells into the circulation was observed within 1 day after 
global HI and a significant influx of neutrophils into the brain was detected 7 days after 
the global HI insult. Furthermore, global HI resulted in marked involution of the spleen, 
which could not be explained by increased splenic apoptosis. In concordance with cere-
bral inflammation, global HI induced severe brain atrophy, region-specific preOL vul-
nerability, hypomyelination and persistent suppressed brain function.  
 Our data provided evidence that global HI in preterm ovine fetuses resulted in 
profound cerebral inflammation and mobilization of the peripheral innate immune 
system. These inflammatory responses were paralleled by marked injury and functional 
loss of the preterm brain. Further understanding of the interplay between preterm 
brain inflammation and activation of the peripheral immune system following global HI 
will contribute to the development of future therapeutic interventions in preterm HIE. 
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Introduction 
Hypoxic-ischemic encephalopathy (HIE) is one of the most important causes of brain 
injury in preterm infants [1]. Preterm infants suffering from HIE develop cognitive dis-
orders in 25-50% of all cases and 5-10% suffer from severe motor deficits (i.e. cerebral 
palsy) [2]. The hippocampus plays a key role in cognition and several studies suggest 
that HI-induced injury to the hippocampus may predispose to cognitive disorders later 
in life [3-7]. Motor deficits in preterm HIE are mainly attributable to injury of white 
matter in the immature brain [1]. Despite the high prevalence of neurological sequelae, 
no therapeutic interventions are available to treat HIE in preterm infants. Cooling ther-
apy, which has been shown to improve neurodevelopmental outcome in mild cases of 
HIE in term infants, is associated with adverse outcomes in preterm infants and has 
therefore not yet been established as standard clinical care for this vulnerable patient 
group [8-10]. 
 White matter injury, the clinical hallmark of preterm hypoxic-ischemic encephalo-
pathy, is caused by injury to the highly vulnerable immature oligo-dendrocytes in the 
preterm brain. HI-induced damage to immature oligodendrocytes impedes effective 
differentiation into mature myelinating oligodendrocytes leading to hypomyelination of 
the preterm brain [11-13]. Microglial activation is considered to be involved in the inju-
ry to immature oligodendrocytes [13]. Microglia are the resident innate immune cells in 
the brain and play a central role in the initiation of an inflammatory response aimed at 
resolving injury caused by HI [14-16]. Excessive activation of microglia, however, results 
in a detrimental cerebral inflammatory response with neurotoxic consequences [15, 
16].  
 In addition to cerebral inflammation, experimental data from adult rodent models 
of focal HI (i.e. stroke) suggest a role for the peripheral immune system in the etiology 
of cerebral HI. More precisely, several studies showed that acute brain injury after focal 
ischemia is followed by a massive activation of the peripheral immune system with 
rapid mobilization of immune effector cells from the spleen [17, 18]. These mobilized 
effector cells can invade the brain and aggravate the existing injury [17].  
Given the importance of cerebral inflammation and peripheral immune system activa-
tion in focal HI of the adult brain, we hypothesized that similar inflammatory responses 
are involved in the etiology of preterm brain injury following global HI.  
 To test this hypothesis, preterm instrumented sheep were exposed to 25 minutes 
of umbilical cord occlusion (UCO) at 0.7 gestation. At this time of gestation, neurode-
velopment of fetal sheep is equivalent to that of a preterm human infant of 28-32 
weeks [19-21]. During this neurodevelopmental stage of the human and ovine fetus, 
the preterm brain is highly prone to develop white matter injury following global HI [11-
13]. 
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Materials & methods 
Animal experiments  
The study was approved by the Animal Ethics Research Committee of Maastricht Uni-
versity, The Netherlands. Fetuses of time-mated Texel ewes were instrumented at 101 
± 1.1 (mean ± SD) days gestation. Before surgery, ewes received i.v. prophylactic antibi-
otics (1000 mg amoxicillin and 200 mg clavulanic acid). Anesthesia was induced by i.v. 
thiopenthal (15 mg/kg). After intubation, general anesthesia was maintained with 1-2% 
isoflurane guided by depth of sedation and supplemented by remifentanyl i.v. (0.75 
μg/kg/min) for analgesia. Vital parameters and depth of sedation were continuously 
monitored by certified personnel. A catheter was placed in the maternal long saphe-
nous vein to provide access for a peri-operative saline drip (250 mL/ hour) and post-
operative blood sampling and administration of the prophylactic antibiotics during four 
days.  
 Fetuses were catheterized with 3.5 French polyurethane umbilical vessel catheters 
(Tyco Healthcare Group, Mansfield, Massachusetts, USA) placed in the femoral artery 
and the brachial vein. Three custom-made electrocardiogram (ECG) shielded electrodes 
(Cooner wire Co., Chatsworth, CA, USA) with silver plates (5 mm) were sewn on the 
chest for fetal heart rate recordings. Two pairs of custom-made EEG shielded elec-
trodes (Cooner wire Co., Chatsworth, CA, USA) with silver tips were placed bilaterally 
on the dura over the parasagittal parietal cortex (5 mm and 15 mm anterior to point 
bregma and 10 mm lateral), with a subcutaneous silver reference electrode (10 mm) 
placed in the neck. The EEG electrodes were secured with cyanoacrylate glue and cov-
ered with fetal skin. All animals were instrumented with an inflatable vascular occluder 
(OC16HD, 16 mm, In Vivo Metric, Healdsburg, California, USA) placed around the umbil-
ical cord. A catheter for amniotic pressure recording was placed in the amniotic sac. 
Before closure of the uterus 80 mg of Gentamycin was administered into the amniotic 
sac. All fetal catheters and leads were exteriorized through a trocar hole in the flank of 
the ewe. 
 After surgery, ewes were housed in a confined space to allow handling and contin-
uous perfusion of the catheters with heparinized saline (25 IU/ mL, 0.2 mL/hr). Surgical 
wounds were inspected daily and treated with chlortetracycline spray to prevent infec-
tion. Animals had ad libitum access to water and food. The welfare of the animals was 
monitored daily by certified personnel.  
Experimental design 
Fetuses were instrumented at 101 ± 1 (mean ± SD) days of gestation (experimental day 
-4). After surgery, the ewe and her fetus were allowed to recover for four days. On 
experimental day 0, fetuses were randomly allocated to either be subjected to 25 
minutes of umbilical cord occlusion (HI group; n=8) or sham occlusion (sham group; 
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n=8). In the HI group, the occluder was rapidly inflated with sterile saline and complete 
occlusion was confirmed with a sudden drop in heart rate and subsequent arterial 
blood gas analysis indicating acidemia, hypoxia and hypercapnia (see figure 1). Such an 
insult has been previously shown to result in global hypoxic-ischemia and subsequent 
cerebral hypoperfusion [19, 22]. After (sham) umbilical cord occlusion a reperfusion 
period of 7 days followed. At the end of the experiment (experimental day 7), both ewe 
and fetus were euthanized by administration of pentobarbital (200 mg/kg). 
 
 
Figure 1. Vital parameters and blood gases of sham and hypoxic-ischemia (HI) animals during umbilical cord 
occlusion (UCO). (A) fetal mean arterial blood pressure (MABP), the small deflections (every five minutes) in 
the MABP curve are caused by arterial blood gas sampling (B) fetal heart rate (HR) in beats per minute (bpm) 
(C) blood gas; arterial pH (D) blood gas; arterial partial oxygen pressure (pO2) (E) blood gas; arterial partial 
carbon dioxide pressure (pCO2). Shaded areas (MABP and HR) and error bars (blood gases) depict standard 
deviation (SD). Min/ ‘ = minutes, d = day. 
Data acquisition 
Blood pressure, amniotic pressure EEG and ECG data were acquired and digitized by a 
custom-made MPAQ unit (Maastricht-Programmable AcQuisition system, Maastricht 
Instruments BV, Maastricht, the Netherlands) with IDEEQ software (Maastricht Instru-
ments BV, Maastricht, the Netherlands). All data were sampled at 1000 Hz and stored 
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on hard-disk for off-line analysis. Analog filtering was applied to the ECG data, with a 1 
Hz high-pass filter and a 200 Hz low-pass filter. Heart rate (beats per minute) was ex-
tracted from the ECG by R-top identification. Blood pressure and amniotic pressure 
data were not filtered. Fetal mean arterial blood pressure was calculated by online 
subtraction of the amniotic fluid pressure from the femoral artery pressure.  
 The EEG data were filtered using a 0.5-30 Hz 4th order Butterworth band-pass filter. 
EEG signal with an amplitude > 1000 µV was considered an artifact and removed from 
analysis (<1% of data). After filtering, EEG background analysis was performed using an 
amplitude- and time-threshold based algorithm [23]. Burst activity was defined as an 
epoch with an amplitude > 30 µV and a duration > 1 s in both channels. Interburst in-
tervals (IBI) were defined as epochs with an amplitude < 30 µV and a duration > 3 s in 
both channels. Segments not meeting above criteria were classified as undefined. Using 
these criteria, mean IBI length per 30 minutes and per 24 hours segments was calculat-
ed and used as a surrogate for functional brain suppression for all animals during the 
period starting two days before UCO (day -2) until the end of the experiment (day 7). 
 
 
Figure 2. Overview of regions of interest in the right hemisphere at the posterior hippocampus/ mid-thalamus 
level. (A) Regions of interest for the detection of IBA-1 immunoreactivity; 1 = hippocampus, 2 = subcortical 
white matter and 3 = periventricular white matter. (B) Regions of interest for the detection of O4-positive cell 
density; 1 = medial periventricular white matter, 2 = intermediate periventricular white matter, 3 = lateral 
periventricular white matter and 4 = subcortical white matter. Scale bar = 4 mm. The white dashed box (5) 
indicates in which region the myelin binding protein (MBP) images in figure 7 were obtained. 
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Immunohistochemistry brain 
The fetal brain was removed from the skull and weighed. The right hemisphere was 
submersion fixated in ice-cold 4% paraformaldehyde for 3 months. Brain tissue was 
embedded in gelatin and serial coronal sections (50 µm) were cut on a Leica VT 1200S 
vibrating microtome (Leica Biosystems, Nussloch, Germany). Free floating sections at 
the level of mid-thalamus and posterior hippocampus were stained with a rabbit anti-
ionized calcium binding adaptor molecule 1 (IBA-1) antibody (Wako Pure Chemical 
Industries, Osaka, Japan), a highly specific marker for microglia, to localize resting and 
activated microglia [24-26]. A mouse anti-O4 antibody (Merck Millipore, Billerica, MA, 
USA) was used to detect late oligodendrocyte progenitors and immature oligodendro-
cytes (hereafter collectively referred to as pre-oligodendrocytes; preOLs) and a rat anti-
myelin basic protein (MBP) antibody (Merck Millipore, Billerica, MA, USA) was used to 
detect myelin sheaths and myelin producing (mature) oligodendrocytes. A rabbit anti-
myeloperoxidase (MPO) antibody (DAKO A0398, DAKO, Glostrup, Denmark) was used 
to detect neutrophils.  
 Endogenous peroxidase-activity was blocked by incubation with 0,3% H2O2 in Tris 
buffered saline (TBS, pH 7.4). Free floating sections were incubated overnight (anti-IBA-
1, MBP and MPO) or during three days (anti-O4) at 4°C with the diluted primary anti-
body (1:1000 anti-IBA-1, 1:400 anti-O4, 1:2000 MBP and 1:1000 MPO) followed by 
incubation with a secondary donkey-anti-rabbit (anti-IBA-1 and MPO), donkey-anti-rat 
(MBP) or donkey-anti-mouse (anti-O4) biotin labeled antibody. The immunostaining 
was enhanced with Vectastain ABC peroxidase Elite kit (PK-6200, Vector Laboratories, 
Burlingame, CA, USA) followed by a nickel sulfate-diaminobenzidine (NiDAB) staining. 
Sections were mounted on gelatin-coated glass slides, air-dried, dehydrated in ascend-
ing ethanol concentrations and coverslipped with PerTex.  
Analysis immunohistochemistry brain 
For the analysis of IBA-1 immunoreactivity (IR), digital images of the hippocampus, 
subcortical white matter (SCWM) and periventricular white matter (PVWM) were ac-
quired at 100x magnification using an Olympus BX51 microscope (Olympus, Tokyo, 
Japan). In the regions of interest (ROIs) areal fraction of IBA-1 IR was determined with a 
standard threshold to determine positive staining using Leica Qwin Pro V 3.5.1 software 
(Leica, Rijswijk, the Nettherlands). Within the hippocampus IBA-1 IR was additionally 
analyzed in the CA1-2, CA3 and dentate gyrus (DG) sub regions. IBA-1 IR areal fraction 
in the ROIs was assessed in six consecutive coronal sections (posterior hippocampus/ 
mid-thalamus level) per animal (sham n=6; HI n=6) by an independent observer who 
was blinded to the experimental conditions.  
 Analysis of the O4 immunohistochemical staining clearly showed that within the 
periventricular white matter three sub-regions had region-specific preOL characteristics 
in sham animals that responded differently to global HI. Therefore O4 staining was 
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assessed in these three different regions of interest in the PVWM. In addition, O4 stain-
ing was assessed in the SCWM. Regions of interest are indicated in figure 2.  
 To assess O4 immunoreactivity, we adapted the method previously reported by 
Back et al. [11]. A differential count was performed, discriminating between immature 
(ring-shaped membrane staining, no processes), mature (ring-shaped membrane stain-
ing, extensively branched processes) and degenerative (fragmented membrane stain-
ing, fragmentation of processes, signs of cell death; nuclear condensation and apoptotic 
bodies) phenotype of the O4 positive cells. The sum of the differential count resulted in 
the total number of O4 positive cells. Differential counts were performed in six consec-
utive coronal sections (posterior hippocampus/ mid-thalamus level) per animal (sham 
n=3; HI n=3). The investigator who performed the differential count was blinded to the 
experimental conditions. In each region of interest, O4 positive cells were counted in 
eight randomly chosen fields of view with a 40x objective equipped with a counting grid 
(0.0625 mm2) using a Nikon Eclipse E400 microscope (Nikon, Amsterdam, the Nether-
lands). 
 Differential counts of MPO positive cells in the brain were performed to assess the 
localization of these cells in relation to the cerebral vasculature. Numbers of intravascu-
lar, perivascular and interstitial cells were counted in the hippocampus, periventricular 
white matter and subcortical white matter. Six coronal sections per animal (sham n=3; 
HI n=3) were studied at the posterior hippocampus/ mid-thalamus level. In each sec-
tion, cells were counted in eight fields of view (focused on the cerebral vasculature) per 
region of interest (hippocampus, periventricular white matter and subcortical white 
matter) with a 20x objective equipped with a counting grid (0.25 mm2) using a Nikon 
Eclipse E400 microscope (Nikon, Amsterdam, the Netherlands). 
 Since in the MPO analysis the fields of view were not randomly chosen, but fo-
cused on the cerebral vasculature, the numbers of cells were expressed as cells per 
field of view (FOV). All images of immunohistochemical staining in the brain (IBA-1, O4, 
MBP, MPO) presented here were obtained with an Olympus AX-70 microscope (Olym-
pus, Tokyo, Japan) equipped with a digital camera. 
White blood cell counts 
Automated white blood cell counts were performed in heparinized arterial blood on 
experimental day -3, 0, 1, 3, 5 and 7 using a Sysmex XE-5000 hematology analyzer 
(Sysmex, Etten-Leur, the Netherlands). 
Immunohistochemistry spleen 
Spleens were removed immediately following sacrifice and subsequently weighed. 
Tissue blocks (5 x 5 mm2) were snap frozen in liquid nitrogen. Frozen spleen sections (4 
µm) were stained for cleaved caspase-3 (Asp175, #9661S, Cell Signaling Technology, 
Boston, MA, USA) for detection of apoptosis, CD3 (DAKO A0452, DAKO Denmark) for 
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detection of T-cells and MPO (DAKO A0398, DAKO, Glostrup, Denmark) for detection of 
neutrophils. 
 Endogenous peroxidase was inactivated by incubation with 0,3% H2O2 that was 
dissolved in methanol. Antigen aspecific binding was prevented by incubating the slides 
for 30 minutes with 5% bovine serum albumin (BSA). Slides were incubated overnight at 
4°C with the diluted primary antibody (cleaved caspase-3 1:200, CD3 1:200, MPO 1:500) 
followed by incubation with the appropriate secondary biotin labeled antibody. Im-
munostaining was enhanced with Vectastain ABC peroxidase Elite kit (PK-6200, Vector 
Laboratories) followed by a NiDAB staining. Sections were counterstained with 0.1% 
Nuclear Fast Red washed, dehydrated and coverslipped.  
 The number of caspase-3 positive cells in the spleen were counted in twenty (to 
accommodate heterogenic distribution) fields of view per animal (sham n=6, HI n=6) 
with a 20x objective equipped with a counting grid (0.25 mm2) using a Nikon Eclipse 
E400 microscope (Nikon, Amsterdam, the Netherlands). The number of caspase-3 posi-
tive cells was expressed in cells/ mm2. 
 For the analysis of CD3 and MPO immunoreactivity (IR), digital images of spleen 
sections were acquired at 100x magnification using a Leica DM200 microscope 
equipped with a Leica DFC295 digital camera (Leica Microsystems, Rijswijk, the Nether-
lands) and Leica Application Suite (LAS) software (Leica LAS V 3.7, Rijswijk, the Nether-
lands). Areal fraction of CD3 and MPO IR was determined in five sections per animal 
(sham n=6, HI n=6) with a standard threshold to determine positive staining using Leica 
Qwin software (Leica Qwin Pro V 3.5.1, Rijswijk, the Netherlands).  
Flow cytometry  
At the end of the experiment (day 7), the spleen was immediately harvested after sacri-
fice. Single-cell splenocyte suspensions were obtained by dissociating freshly sampled 
spleen tissues in gentleMACS™ C-tubes (MiltEnyi, Leiden, the Netherlands) filled with 
Gibco® Iscove’s Modified Dulbecco’s Medium (IMDM) (Life Technologies, Bleiswijk, the 
Netherlands) using the gentleMACS™ Dissociator (MiltEnyi, Leiden, the Netherlands). 
Subsequently, the cell suspensions were passed through a 70 µm cell strainer (BD Bio-
sciences, Erembodegem-Aalst, Belgium). Splenocytes were stored in nitrogen in freez-
ing medium containing IMDM medium with 10% heat-inactivated fetal calf serum and 
10% dimethylsulfoxide (DMSO). 
 To study the cellular composition of the spleen 7 days after global HI, 200.000 
splenocytes per animal (sham n=8; HI n=8) were stained for detection of lymphocytes 
(mouse anti sheep CD45-biotin; AbDSerotec, Düsseldorf, Germany / streptavidin-
Horizon V450; BD Biosciences, Bleiswijk, the Netherlands), neutrophils (mouse anti-
bovine CD11b-Fluorescein isothiocyanate (-FITC); AbDSerotec, Düsseldorf, Germany), T-
helper cells (mouse anti sheep CD4-AlexaFluor® 647 (-A647); AbDSerotec, Düsseldorf, 
Germany), cytotoxic T-cells (mouse anti sheep CD8-R-phycoerythrin (-PE); AbDSerotec, 
Düsseldorf, Germany) and viability (7-Aminoactinomycin D (7-AAD); BD Biosciences, 
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Bleiswijk, the Netherlands) according to the manufacturer’s protocol. Stained cells were 
acquired on a FACS Canto II flow cytometer (BD Biosciences, Bleiswijk, the Netherlands) 
equipped with FACS Diva software (BD Biosciencs, Bleiswijk, the Netherlands). 
 The number of CD11b, CD4 and CD8 positive splenocytes were determined as a 
percentage of living CD45-positive lymphocytes. The expression of CD11b, CD4 and CD8 
on living CD45-positive lymphocytes was analyzed using the mean fluorescent intensity 
(MFI). 
Statistics 
Summary statistics of animal characteristics (gestational age at UCO, body weight) are 
shown as means with 95% Confidence Intervals (CI). For analysis of O4, MPO and acti-
vated caspase-3 parameters, cell counts in each section’s region of interest were first 
averaged per field of view (n=8 for O4 and MPO; n=20 for activated caspase-3).  
 Groups’ comparisons (sham vs. HI) with respect to all outcome parameters were 
drawn either with independent t-tests, or with random intercept models in case of 
repeated measurements per animal (e.g. different sections per brain). Variables, whose 
distributions were positively skewed, were log-transformed previous to statistical test-
ing. To facilitate interpretation, averages on the log scale were back transformed to the 
original scale (antilog) and are presented as geometric means and corresponding 95% 
CIs.  
 Average (additive) differences on log transformed data become ‘multiplicative’ on 
the original scale. Thus, the displayed geometric means for the sham and HI groups 
should be compared in relative terms, i.e. not as difference in averages (e.g. mean 
sham minus mean HI) but rather as a ratio of the sham geometric mean with respect to 
the HI geometric mean (mean sham divided by mean HI). The interpretation of the 
geometric means ratio is provided for example for areal fraction (%) IBA-1 immunore-
activity in the subcortical white matter (see Results section).  
 For analysis of the EEG parameter (i.e. IBI length), log transformation also preced-
ed parametric inferences regarding groups’ comparisons and temporal dynamics of 
mean IBI length before and after UCO (or sham). To accommodate both the interrupted 
nature of the experimental follow-up, with UCO happening on day 0 of the experiment, 
as well as the correlation among longitudinal measurements of individual fetuses, a 
piecewise mixed regression model was fitted [27]. This mixed model approach allowed 
additionally for heterogeneity of groups’ variances to be accounted for. In the model, 
Time (pre and post UCO, measured in days), group (sham vs. HI), and a dummy for pre 
and post UCO times, pre-post, were the fixed effects factors. Fetuses (subjects) were 
the random factor. The addition of random effects was meant to model individual vari-
ability relative to the group’s average. Variables selection was carried out via the top-
down procedure based on likelihood ratio (LR) tests for fixed effects and tests for the 
covariance structure. Statistical analysis was performed with PASW Statistics 18 (SPSS 
Inc., Chicago, IL, USA).  
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Results 
Animal characteristics 
Fetal body weight did not differ between the sham and HI group; sham man 1782 gram 
(1571; 1993) versus HI mean 1742 gram (1482; 2002), p=0.677. There was no significant 
difference in gestational age at the time of UCO between the sham and HI group; sham 
mean 105.6 days (104.6; 106.5) versus HI mean 105.5 days (104.7; 106.3), p=0.717. 
Fetal vital parameters 
Fetal vital parameters and blood gases during UCO are depicted in figure 1. After an 
initial compensatory rise, mean arterial blood pressure gradually declined from 40 
mmHg to 10 mmHg at the end of 25 minutes UCO (figure 1A). Mean fetal heart rate 
rapidly fell after initiation of UCO from around 200 beats per minute (bpm) at baseline 
to below 100 bpm at the end of UCO (figure 1B). All vital parameters normalized within 
30 minutes of reperfusion time.  
 Blood gas data (figure 1 C-E) indicate that average pH dropped from 7.4 at baseline 
to 6.8 at the end of UCO. Mean partial oxygen pressure decreased from 20 mmHg at 
baseline to values below 5 mmHg at the end of UCO. Mean partial carbon dioxide pres-
sure increased from baseline levels of 40 mmHg to values around 90 mmHg at the end 
of UCO. Upon reperfusion hypoxemia and hypercapnia resolved within minutes. Nor-
malization of pH values occurred after 60-90 minutes (data not shown).  
 
Figure 3. Global HI induced atrophy of the brain including the hippocampus as indicated by significant 
reduction of (A) brain weight (g/ kg BW) (A) and (B) hippocampus area (mm2). (A) Means ± 95% CI are 
depicted. (B) Geometric means ± 95% CI are depicted. *P≤0.05, # P≤0.01, ‡ P≤0.001, NS, non-significant. HI = 
hypoxic-ischemia. 
Brain atrophy  
Brain weight, corrected for body weight (BW), and hippocampal area were determined 
to study HI-induced brain atrophy. Average brain weight (gram/kg BW) was significantly 
decreased in animals exposed to HI compared with sham (figure 3A); sham mean 17.3 
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gram/kg BW (95% CI 15.2; 19.4) versus HI mean 14.6 gram/kg BW (95% CI 12.9; 16.4), 
p=0.037. 
 Atrophy of the hippocampus was assessed since there is clinical [3-5] and experi-
mental [19, 28] evidence that this brain region is affected in preterm HIE. Mean area 
(mm2) of the hippocampus was significantly reduced in animals exposed to HI com-
pared with sham (figure 3B); sham mean 6.1 mm2 (95% CI 5.0; 7.3) versus HI mean 3.0 
mm2 (95% CI 1.9; 4.2), p = 0.002. In hippocampal sub-regions the analysis of the areas 
(mm2) showed significant atrophy of the cornu ammonis (CA)1-2; sham mean 1.7 mm2 
(95% CI 1.3; 2.0) versus HI mean 0.7 mm2 (95% CI 0.4; 1.0), p=0.001 and CA3; sham 
mean 0.7 mm2 (95% CI 0.6; 0.9) versus HI mean 0.4 mm2 (95% CI 0.2; 0.6), p=0.013. 
Mean area of the dentate gyrus (DG) was not significantly affected by HI; sham mean 
1.2 mm2 (95% CI 1.0; 1.4) versus HI mean 0.7 mm2 (95% CI 0.6; 1.1), p=0.060. 
Microglial activation and proliferation 
Microglia (IBA-1) were studied to determine the local inflammatory response in the 
brain. Areal fraction (%) of IBA-1 immunoreactivity (IR) was studied in the subcortical 
white matter (SCWM), periventricular white matter (PVWM) and hippocampus (figure 
3A). IBA-1 IR was significantly increased in the SCWM of animals exposed to HI com-
pared with sham (figure 4D-F); sham geometric mean 25.6 % (95% CI 17.0; 38.4) versus 
HI geometric mean 70.0% (95% CI 46.6; 105.1), p=0.003. Thus, the ratio of the two 
geometric means, HI with respect to sham is 70.0 / 25.6 = 2.73. The corresponding 
interpretation is: the geometric mean of the areal fraction in the HI group is 2.73 higher 
(173% increase) than the geometric mean of the sham group.  
 In the PVWM the areal fraction (%) of IBA-1 IR was significantly increased in ani-
mals exposed to HI compared with sham (figure 4A-C); sham geometric mean 1.3 % 
(95% CI 0.6; 3.0) versus HI geometric mean 5.2 % (95% CI 2.9; 9.2), p = 0.013. The areal 
fraction (%) of IBA-1 IR in the hippocampus was significantly increased in animals ex-
posed to HI compared with sham (figure 4G-I); sham geometric mean 1.9 % (95% CI 1.0; 
3.6) versus HI geometric mean 22.5 % (95% CI 12.1; 41.8), p<0.001.  
 Analysis of hippocampal sub-region CA1-2 showed significantly increased IBA-1 IR 
in animals exposed to HI compared to sham (figure 5A-C); sham geometric mean 1.5 % 
(95% CI 0.7; 3.2) versus HI geometric mean 29.8 % (95% CI 14.1; 63.1), p<0.001. IBA-1 IR 
was also significantly increased in CA3 (figure 5D-F); sham geometric mean 1.4 % (95% 
CI 0.7; 3.0) versus HI geometric mean 31.4 % (95% CI 15.2; 64.8), p<0.001 and DG (fig-
ure 5G-I); sham geometric mean 1.3 % (95% CI 0.6; 3.0) versus HI geometric mean 5.2% 
(95% CI 2.9; 9.2), p<0.001.  
 Microglia in sham animals exhibited a quiescent state characterized by extensively 
branched thin processes (inserts figure 4E and H and figure 5B, E, and H). In contrast, in 
HI-exposed animals, microglia with thick cell bodies and retracted processes were ob-
served indicating an activated state (inserts figure 4 F and I and figure 5C, F and I). 
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Figure 4. In the hippocampus, periventricular white matter (PVWM) and subcortical white matter (SCWM) 
global HI resulted in profound proliferation and activation of microglia, as indicated by significantly increased 
areal fraction (%) of IBA-1 immunoreactivity (IR) and by loss of processes and amoeboid morphology, 
respectively. (A) Global HI significantly increased areal fraction (%) of IBA-1 IR in the hippocampus. (B) Sham, 
hippocampus; resting microglia, also depicting the analyzed hippocampal sub-regions (see figure 5); I = cornu 
ammonis (CA)1-2, II = CA3, III = dentate gyrus (DG) (C) HI, hippocampus; profound microglial proliferation and 
activation (scale bar = 500 μm). (D) Global HI significantly increased areal fraction (%) of IBA-1 IR in the 
PVWM. (E) Sham, PVWM; resting microglia (scale bar = 200 μm, scale bar insert = 25 μm). (F) HI, PVWM; 
proliferation and activation of microglia (scale bar = 200 μm, scale bar insert = 25 μm). (G) Global HI 
significantly increased areal fraction (%) of IBA-1 IR in the SCWM (H) Sham, SCWM; resting microglia (scale 
bar = 200 μm, scale bar insert = 25 μm). (I) HI, SCWM proliferation and activation of microglia (scale bar = 
200 μm, scale bar insert = 25 μm). (A, D, G) Geometric means ± 95% CI are depicted. *P≤0.05, # P≤0.01, ‡ 
P≤0.001, NS, non-significant. HI = hypoxic-ischemia. 
Region-specific pre-oligodendrocyte vulnerability 
Differential counts of O4-positive pre-oligodendrocytes were performed in the medial, 
intermediate and lateral PVWM and in the SCWM (figure 3B). Analysis of the O4 stain-
ing showed that in sham animals the medial and lateral PVWM were predominantly 
populated by O4-positive cells with a mature phenotype (figure 6A-B and G-H). In con-
trast, O4-positive cells in the SCWM and intermediate PVWM were predominantly of 
immature phenotype (figure 6D-E and J-K). Following global HI all regions showed an 
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increase in preOLs with degenerative morphology (figure 6A, D, G and J) which reached 
statistical significance in the regions which were populated by mature pre-OLs in sham 
conditions (medial and lateral PVWM). In the medial PVWM, the areal density of O4-
positive cells with degenerative phenotype significantly increased in animals exposed to 
HI compared to sham (figure 6A-C); sham geometric mean 4.6 cells/ mm2 (95% CI 1.9; 
11.3) versus HI geometric mean 44.2 cells/ mm2 (95% CI 17.8; 109.4), p=0.009. In the 
lateral PVWM, the areal density of O4-positive cells with degenerative morphology 
similarly increased following HI (figure 6G-I); sham geometric mean 8.3 cells/ mm2 (95% 
CI 3.6; 18.8) versus HI geometric mean 61.6 cells/ mm2 (95% CI 31.9; 119.1). 
 
 
Figure 5. Global HI induced significant proliferation and activation of microglia in the cornu ammonis (CA)1-2, 
CA3 and dentate gyrus (DG), sub-regions of the hippocampus. (A) Global HI significantly increased areal 
fraction (%) of IBA-1 immunoreactivity (IR) in CA1-2. (B) Sham, CA1-2; resting microglia (C) HI, CA1-2; 
profound microglial proliferation and activation. (D) Global HI significantly increased areal fraction (%) of 
IBA-1 IR in CA3. (E) Sham, CA3; resting microglia (F) HI, CA3; profound proliferation and activation of 
microglia. (G) Global HI significantly increased areal fraction (%) of IBA-1 IR in DG. (H) Sham DG; resting 
microglia. (I) HI, DG; proliferation and activation of microglia. Scale bar images = 200 μm, scale bar inserts = 
25 μm. (A, D, G) Geometric means ± 95% CI are depicted. *P≤0.05, # P≤0.01, ‡ P≤0.001, NS, non-significant. 
HI = hypoxic-ischemia. 
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Figure 6. Global HI induced region-specific vulnerability of O4-positive pre-oligodendrocytes (preOLs; late 
oligodendrocyte progenitors and immature oligodendrocytes). Regions of interest are depicted in figure 3. 
(A) Global HI significantly increased the density of total and degenerative preOLs in the medial 
periventricular white matter (PVWM). (B) Sham, medial PVWM; preOL with mature phenotype (black 
arrow). (C) HI, medial PVWM; preOLs with degenerative phenotype (white arrowheads). (D) Global HI 
significantly decreased density of total and immature preOLs in the intermediate PVWM. (E) Sham, 
intermediate PVWM; preOLs with immature phenotype (black arrow heads). (F) HI, intermediate PVWM; 
preOLs with degenerative phenotype (white arrow heads) and apoptotic preOL (white arrow). (G) Global HI 
significantly increased the density of degenerative preOLs in the lateral PVWM, density of total preOLs was 
unchanged. (H) Sham, lateral PVWM; preOL with mature phenotype (black arrow). (I) HI, lateral PVWM; 
preOL with degenerative (white arrow head) and apoptotic (white arrow) phenotype. (J) Global HI 
significantly reduced the density of total and immature preOLs subcortical white matter (SCWM). (K) Sham, 
SCWM; preOLs with immature phenotype (black arrow heads). (L) HI, SCWM; reduced density of preOLs with 
immature phenotype (black arrow heads) and disturbance of O4-positive myelin sheath organization. Scale 
bar all images = 50 µm. (A, D, G, J) Geometric means ± 95% CI are depicted. *P≤0.05, # P≤0.01, ‡ P≤0.001, 
NS, non-significant. HI = hypoxic-ischemia. 
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Following global HI, the total number of preOLs significantly decreased in those regions 
which were populated by immature preOLs in sham conditions (intermediate PVWM 
and SCWM). In the intermediate PVWM, the areal density of total O4-positive cells 
significantly decreased following global HI (figure 6D-F); sham geometric mean 244.2 
cells/ mm2 (95% CI 171.7; 347.2) versus HI geometric mean 143.2 cells/ mm2 (95% CI 
100.7; 203.6), p = 0.041. Loss of total preOLs in the intermediate PVWM was mainly 
attributable to loss of O4-positive cells with immature phenotype (figure 6D-F); sham 
geometric mean 191.9 cells/ mm2 (95% CI 137.7; 267.5) versus HI geometric mean 
104.3 cells/ mm2 (95% CI 74.8; 145.3), p=0.023. 
 The areal density of total O4-positive cells in the SCWM significantly decreased in 
HI-exposed animals compared to sham (figure 6J-L); sham geometric mean 218.3 cells/ 
mm2 (95% CI 169.2; 282.0) versus HI geometric mean 126.8 cells/ mm2 (95% CI 98.0; 
164.0), p = 0.014. Loss of total preOLs in the SCWM was mainly attributable to loss of 
O4-positive cells with immature phenotype (figure 6J-L); sham geometric mean 210.2 
cells/ mm2 (95% CI 133.9; 330.3) versus HI geometric mean 117.2 cells/mm2 (95% CI 
75.0; 183.1), p=0.014. Moreover, in the SCWM a clear disturbance of O4-positive mye-
lin sheath organization was observed following HI (figure 6L). Remarkably, in the medial 
PVWM the total number of preOLs significantly increased (figure 6A); sham geometric 
mean 169.4 cells/ mm2 (95% CI 134.4; 213.4) versus HI geometric mean 232.1 cells/ 
mm2 (95% CI 184.2; 292.4), p=0.038.  
 
 
Figure 7. Global HI-induced marked loss of myelin basic protein (MBP) positive myelin sheaths and myelin-
producing cells (mature oligodendrocytes) in the subcortical white matter (region of interest indicated in 
figure 3). 
MBP 
Brain sections were stained for myelin basic protein (MBP) to detect white matter inju-
ry following HI. In sham animals abundant MBP-positive myelin sheaths and myelin-
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producing cells (mature oligodendrocytes) were observed in the subcortical white mat-
ter (figure 7). Following global HI a marked reduction of both myelin sheaths and ma-
ture oligodendrocytes was observed (figure 7). In the PVWM (regions 1, 2 and 3 in fig-
ure 3) no MBP immunoreactivity was detected in both sham and HI animals (data not 
shown) indicating that these white matter regions were not myelinated at this devel-
opmental stage of the preterm brain. 
Cerebral neutrophil invasion 
Brain sections were stained for myeloperoxidase (MPO) to detect neutrophils that in-
vaded the brain following HI. Although microglia can also produce MPO, neutrophils 
and microglia can be easily distinguished by intensity of staining, localization and mor-
phology [29-31].  
 Following global HI the total number of MPO-positive cells inside or adjacent to the 
cerebral vasculature significantly increased in the hippocampus (figure 8A-C); sham 
geometric mean 2.0 cells/ field of view (FOV) (95% CI 1.7; 2.4) versus HI geometric 
mean 8.5 cells/ FOV (95% CI 2.7; 9.9), p<0.001. Similarly, the total number of MPO-
positive cells significantly increased in the PVWM (figure 8D-F); sham geometric mean 
2.1 cells/ FOV (95% CI 1.6; 2.9) versus HI geometric mean 4.5 cells/ FOV (95% CI 3.3; 
6.2), p=0.002 and in the SCWM (figure 7G-I); sham geometric mean 1.6 cells/ FOV (95% 
CI 0.7; 2.5) versus HI geometric mean 4.3 cells/ FOV (95% CI 2.7; 6.9), p<0.001. 
 All analyzed regions showed an increase of intravascular MPO-positive cells follow-
ing global HI, which reached significance in the hippocampus (figure 8A); sham geomet-
ric mean 1.0 cells/ FOV (95% CI 0.5; 2.3) versus HI geometric mean 2.1 cells/ FOV (95% 
CI 0.9; 4.6), p=0.002 and in the SCWM (figure 8G); sham geometric mean 1.0 cells/ FOV 
(95% CI 0.3; 2.9) versus HI geometric mean 1.6 cells/ FOV (95% CI 0.7; 4.0), p=0.009.  
 The number of perivascular MPO-positive cells was significantly increased in the 
hippocampus of HI-exposed animals (figure 8A-C); sham geometric mean 0.4 cells/ FOV 
(95% CI 0.3; 0.6) versus HI geometric mean 4.3 cells/ FOV (95% CI 3.1; 5.9), p<0.001. 
Likewise, the number of perivascular MPO-positive cells was significantly increased in 
the PVWM of HI-exposed animals (figure 8D-F); sham geometric mean 0.4 cells/ FOV 
(95% CI 0.3; 0.7) versus HI geometric mean 2.1 cells/ FOV (95% CI 1.5; 3.1), p<0.001 and 
in the HI-exposed SCWM (figure 8G-I); sham geometric mean 0.3 cells/ FOV (95% CI 0.2; 
0.5) versus HI geometric mean 1.8 cells/ FOV (95% CI 1.2; 2.6), p<0.001. 
 All analyzed regions showed an increase of interstitial MPO-positive cells following 
global HI, which reached significance in the hippocampus (figure 8A); sham geometric 
mean 0.4 cells/ FOV (95% CI 0.3; 0.5) versus HI geometric mean 1.6 cells/ FOV (95% CI 
1.3; 2.1), p<0.001 and in the SCWM (figure 8G); sham geometric mean 0.3 cells/ FOV 
(95% CI 0.2; 0.6) versus HI geometric mean 0.9 cells/ FOV (95% CI 0.6; 1.3), p=0.007.  
 MPO-positive cells in the brain sections studied were large round-shaped cells with 
lobular intracellular structures situated in and around the cerebral vasculature (figure 8 
B-C, E-F and H-I). These morphological features and their localization indicate that 
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these MPO-positive cells were neutrophils. MPO-positive cells lacking neutrophil mor-
phology were rarely detected (data not shown). 
 
 
Figure 8. Global HI induced significant invasion of MPO-positive cells (neutrophils) into the hippocampus, 
periventricular white matter (PVWM) and subcortical white matter (SCWM). Invading neutrophils were 
predominantly localized in the perivascular zone. (A) Global HI caused a significant increase in the total 
number of MPO-positive cells in the hippocampus, mainly attributable to a profound increase in the number 
of perivascular MPO-positive cells. (B) Sham, hippocampus; perivascular MPO-positive cell (black arrow 
head). (C) HI, hippocampus; profound increase in the number of perivascular MPO-positive cells (black arrow 
heads). (D) Global HI caused a significant increase in the total number of MPO-positive cells in the PVWM, 
attributable to a significant increase in the number of perivascular MPO-positive cells. (E) Sham, PVWM; 
perivascular (black arrow head) and interstitial (black arrow) MPO-positive cell. (F) HI, PVWM; marked 
increase in perivascular MPO-positive cells (black arrow heads). (G) Global HI caused a significant increase in 
the total number of MPO-positive cells in the SCWM, attributable to a significant increase in the number of 
intravascular, perivascular and interstitial MPO-positive cells. (H) Sham, SCWM; intravascular MPO-positive 
cells (white arrow heads). (I) HI, SCWM; intravascular (white arrow heads), perivascular (black arrow heads) 
and interstitial (black arrow) MPO-positive cells. Scale bar all images = 50 µm. (A, D, G) Geometric means ± 
95% CI are depicted. *P≤0.05, # P≤0.01, ‡ P≤0.001, NS, non-significant. HI = hypoxic-ischemia. 
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White blood cell mobilization 
One day post-UCO a significant increase in white blood cell count was observed (figure 
9); sham geometric mean 1.5 x 109 cells/L (95% 0.8; 2.2) versus HI geometric mean 3.1 
109 cells/L (95% CI 2.1; 4.5), p=0.009.  
 Furthermore, white blood cell counts showed a gradual increase in the number of 
circulating white blood cells during the study period in both sham and HI animals (fig-
ure 9). When geometric means were compared to sham day -3 (0.5 x 109 cells/ L (95% 
CI 0.3; 0.9)), white blood cell counts of sham animals significantly increased at day 0 
(1.4 x 109 cells/L (95% CI 1.0; 2.0); p=0.027), day 1 (1.5 x 109 cells/ L (95% CI 0.8; 2,2); 
p=0.024), day 3 (1.6 x 109 cells/ L (95% CI 1.1; 2.3); p=0.008), day 5 (2.3 x 109 cells/ L 
(95% CI 1.6; 3.4); p<0.001) and day 7 (2.9 x109 cells/ L (95% CI 1.7; 4.8); p<0.001). In HI 
animals geometric mean white blood cell counts were significantly elevated compared 
to HI day -3 (0.9 x 109 cells/ L (95% CI 0.5; 1.4)) at day 1 (3.1 x 109 cells/ L (95% CI 2.1; 
4.5); p<0.001) and day 7 (2.5 x 109 cells/ L (95% CI 1.3; 3.7); p=0.002). 
 
 
Figure 9. Global HI induced significant white blood cell mobilization in the first 24 hours following 
umbilical cord occlusion (UCO). White blood cell counts gradually increased during the study 
period. Geometric means ± 95% CI are depicted. *P≤0.05, # P≤0.01, ‡ P≤0.001, NS, non-significant. 
HI = hypoxic-ischemia. 
 
Flow cytometry analysis of whole blood showed that the percentage of living (7-AAD 
negative) CD45-positive lymphocytes expressing CD11b (neutrophils), CD4 (helper T-
cells) or CD8 (cytotoxic T-cells) did not differ between sham and HI groups in the circu-
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lation on day 1 (data not shown). This indicated that global HI induced non-preferential 
mobilization of immune cells 24 hours following global HI. 
Splenic involution 
Seven days after global HI, splenic weight was analyzed as an indication of activation of 
the peripheral immune system. Spleen weight, corrected for fetal BW, was significantly 
decreased in fetuses exposed to HI (figure 10A); sham geometric mean 2.5 gram/ kg 
BW (95% CI 1.7; 3.6) versus HI geometric mean 1.7 gram/ kg BW (95% CI 1.5; 1.9), 
p=0.033. Consistently, spleen size was markedly reduced following HI (figure 10B).  
To assess whether splenic involution was caused by increased apoptotic cell death, 
spleen sections were stained for activated caspase-3. The number (cells/ mm2) of acti-
vated caspase-3 positive cells in the spleen did not differ between sham and HI groups 
(figure 11A-C); sham mean 12.2 cells/ mm2 (95% CI 4.4; 20.0) versus HI mean 16.4 cells/ 
mm2 (95% CI 6.4; 26.4), p=0.391.  
 
Figure 10. Global HI resulted in splenic involution. Global HI significantly reduced (A) spleen weight (g/ kg 
BW) and (B, C) size. (B) Sham, spleen. (C) HI, spleen. (A) Geometric means ± 95% CI are depicted. *P≤0.05, # 
P≤0.01, ‡ P≤0.001, NS, non-significant. HI = hypoxic-ischemia. 
Splenic cellular composition 
Immunohistochemical staining of spleen sections for neutrophils showed that areal 
fraction (%) of MPO immunoreactivity (IR) in the spleen did not differ between sham 
and HI animals after a reperfusion time of 7 days (figure 11D-F); sham mean 5.3 % (95% 
CI 3.5; 7.1) versus HI mean 4.0 % (95% CI 2.4; 5.6), p=0.254. Immunohistochemical 
staining of spleen sections for T-cells showed that areal fraction (%) of CD3 IR in the 
spleen did not differ between sham and HI animals after a reperfusion time of 7 days 
(figure 11D-F); sham mean 3.8 % (95% CI 1.6; 6.0) versus HI mean 6.3 % (95% CI 4.2; 
8.3), p=0.100.  
 Similarly, no differences in splenic cell populations were found between sham and 
HI animals using flow cytometry on splenocytes. The percentage of living (7-AAD nega-
tive) CD45-positive splenocytes expressing CD11b (neutrophils) did not differ between 
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sham and HI groups (figure 12); sham mean 45.8 % (95% CI 28.0; 63.7) versus HI mean 
44.9 % (95% CI 27.1; 62.7), p=0.936. The percentage of living CD45-positive splenocytes 
expressing CD4 (helper T-cells) was not changed 7 days following HI (figure 12); sham 
mean 9.9 % (95% CI 7.3; 12.5) versus HI mean 9.9 % (95% CI 7.6; 12.2), p=0.996. The 
percentage of living splenocytes in the spleen expressing CD8 (cytotoxic T-cells) re-
mained also unchanged 7 days following HI (figure 11); sham mean 4.1 % (95% CI 2.4; 
5.8) versus HI mean 3.9 % (95% CI 2.4; 5.3), p=0.825. In line with these data, expression 
levels of CD11b, CD4 and CD8 on living CD45+ splenocytes, as measured with mean 
fluorescence intensity (MFI), were not changed by global HI after a reperfusion period 
of seven days (data not shown). 
 
Figure 11. (A) Splenic apoptosis was not affected by global HI as indicated by unchanged numbers (cells/ 
mm2) of activated caspase-3 positive cells in the spleen assessed seven days after umbilical cord occlusion 
(UCO). (B) Sham, spleen; activated caspase-3. (C) HI, spleen; activated caspase-3. (D) Global HI did not 
change areal fraction (%) of MPO immunoreactivity in the spleen seven days after UCO. (E) Sham, spleen; 
MPO. (F) HI, spleen; MPO. (G) Global HI did not change areal fraction (%) of CD3 immunoreactivity in the 
spleen seven days after UCO. (H) Sham, spleen; CD3. (I) HI, spleen; CD3. Scale bar activated caspase-3 images 
= 50 µm. Scale bar CD3 and MPO images = 200 µm, scale bar inserts = 50 µm. (A, D, G) Means ± 95% CI are 
depicted. *P≤0.05, # P≤0.01, ‡ P≤0.001, NS, non-significant. HI = hypoxic-ischemia. 
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Figure 12. Global HI did not affect the number of splenocytes expressing 
CD11b (neutrophils), CD4 (helper T-cells) or CD8 (cytotoxic T-cells) seven 
days after umbilical cord occlusion (UCO). (A) Means ± 95% CI are 
depicted. *P≤0.05, # P≤0.01, ‡ P≤0.001, NS, non-significant. HI = 
hypoxic-ischemia. 
EEG suppression 
The fetal EEG was continuously recorded in HI-exposed (n=8) and sham (n=8) fetuses 
during the complete study period. EEG analysis was performed from two days before 
UCO until the end of the experiment after a reperfusion period of seven days. Inter-
burst interval (IBI) length was assessed to determine suppression of brain function 
following HI. EEG suppression was indicated by prolonged IBI length. Figure 13A dis-
plays the observed IBI length values (background; grey) over time of two animals, one 
sham fetus and one HI fetus, averaged over 30 minutes. Time point ‘0’ indicates day of 
UCO. Note the distinct difference in IBI length between the HI vs. sham fetuses after 
occlusion, with more prolonged length and larger fluctuations for the former. Superim-
posed on the 30 minutes data in figure 13A are also the IBI length values averaged over 
24 hours – the same two animals (foreground; full circles). For model simplicity, the 
piecewise regression model was fitted on the 24 hours data.  
 Figure 13B displays the IBI length temporal dynamics as estimated by the final 
regression model. Its fixed and random effect parameters are displayed in Table 1. The 
predicted lines (according to the model) are superimposed on observed 24 hours values 
(all animals). Note the greater IBI length variability in the HI fetuses induced by the 
occlusion. This more variable responsiveness was captured in the model by the signifi-
cant random slope variance for in the HI group (Table 1).  
 There is a clear upwards shift (increase) in the average IBI length values (log scale) 
for the HI group compared to sham after UCO (significant interaction between pre-post 
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dummy and group variables, capturing the average change in IBI length level for the HI 
group immediately after UCO). Mean IBI length after UCO remained higher throughout 
the measured time span (one week) for the HI group. With respect to temporal chang-
es, it is noteworthy to mention that before UCO the averaged values remain stable over 
time (pre-UCO time variable did not reach statistical significance), contrary to post-UCO 
time. After UCO, IBI length seemed to change in a curve-linear pattern for both groups 
(significant quadratic and cubic post-time parameters in the model). In summary, IBI 
length was significantly increased following UCO and remained higher in the HI group 
during the seven day reperfusion time, indicating prolonged suppression of preterm 
brain function following global HI.  
 
 
Figure 13. Global HI resulted in prolonged profound suppression of preterm brain function. (A) Observed 
mean IBI length (log scale) per 24 hours of two animals, one sham and one HI, superimposed on observed 
mean IBI length per 30 minutes. (B) Values predicted by the mixed linear model are superimposed on 
observed IBI length per 24 hours of all animals. IBI = interburst interval length, log = natural logarithm, s = 
seconds, UCO = umbilical cord occlusion, 30’ = 30 minutes, 24h = 24 hours, d = day.  
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Discussion 
In this study we showed that global hypoxic-ischemia (HI) caused profound inflamma-
tion of the preterm ovine brain, which was paralleled by mobilization of the peripheral 
innate immune system. These inflammatory changes were associated with suppressed 
brain function, brain atrophy, region-specific vulnerability of pre-oligodendrocytes 
(preOLs) and hypomyelination, which are known to correlate with white matter dis-
ease, the clinical hallmark of preterm HIE [13]. 
 Microglial proliferation following global HI was demonstrated by immuno-
histochemical staining of IBA-1, a specific marker for microglia under normal and neu-
roinflammatory conditions [24-26, 32, 33]. Moreover, we showed morphological trans-
formation of IBA-1 positive microglia from ramified into amoeboid state indicating 
activation of these cells following global HI in preterm sheep [34, 35]. These microglial 
changes, as seen after global ischemia in preterm lambs, are in line with the microglial 
response after focal ischemia of the adult brain which typically occurs within 24 hours 
after the insult [36-38].  
 Mobilization of the peripheral innate immune system in our model was demon-
strated by a non-preferential recruitment of immune cells into the circulation within 24 
hours following global HI as well as a marked influx of neutrophils into the HI-exposed 
preterm hippocampus and white matter seven days after the global HI insult. This inva-
sion of neutrophils, which is an important histopathological finding in cerebral ische-
mia, was primarily localized in the perivascular zone [39-41]. The influx of neutrophils, 
which typically occurs as a second hit within 48-72 hours after cerebral ischemia, is 
considered to further aggravate acute inflammation of the brain that was initiated by 
immediate cell death and microglial activation by enhanced free radical attack [36-38].  
 A permeable blood brain barrier (BBB) is a prerequisite for the influx of neutrophils 
such as seen following global HI [41, 42]. Clinical [43] and experimental [44-46] evi-
dence showed disruption of the BBB in perinatal hypoxic-ischemia. The influx of neu-
trophils also indicates that the immature immune system is capable of responding to an 
inflammatory stimulus induced by global HI. This concept is in line with recent literature 
challenging the dogma that the preterm immune system is naive [47-49]. However, the 
fact that neutrophils were predominantly observed in the perivascular zone following 
HI, and to a lesser extent in the interstitium, indicated that the capacity of fetal neutro-
phils to transmigrate was immature [48]. 
 We postulate that the cerebral neutrophils, as seen in our model, were derived 
from the spleen, since this organ is considered to be the predominant source of invad-
ing neutrophils following focal ischemia of the brain [18, 50, 51]. This concept is further 
supported by work of Ajmo et al. who showed in a rat model of focal cerebral ischemia 
that splenectomy reduced neutrophil influx and microglial activation, ultimately dimin-
ishing ischemic brain injury [17].  
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Notably, HI-induced involution of the spleen may have clinical postnatal consequences 
since splenic involution has been associated with an increased risk of postnatal infec-
tious complications such as early onset sepsis [21, 53]. Splenectomy in our model of 
global HI is required to confirm the role of the spleen as a source of neutrophils.  
 
Table 1. Estimated fixed and random effect parameters of the piecewise (mixed)
regression model. Estimated fixed and random effect parameters of the
piecewise (mixed) regression model (Outcome variable: mean IBI length, on the
log scale. Covariance structure: diagonal). The fixed effect regression coefficients
β for the continuous time variables indicate average changes in mean IBI length
per day. For nominal variables, β represent average changes in the highlighted
category (in brackets) with respect to the reference group (omitted). *P≤0.05, #
P≤0.01, ‡ P≤0.001, NS, non-significant. 
Parameters  (95% CI) 
(fixed and random effects)    n=16 
Intercept   2.60 (2.19, 3.00) ‡ 
Group (Sham )   -7.14 (-1.39, -0.03) * 
Dummy Pre-post UCO (pre-time)   -0.63 (-0.95, -0.32) ‡ 
Group*pre-post dummy    0.65 (0.27, 1.02) ‡ 
Pre-UCO time   -0.01 (-0.20, 0.18) NS 
Post-UCO time   0.29 (0.12, 0.46) ‡ 
Post-UCO time2   -0.12 (-4.84, 1.73) ‡ 
Post-UCO time3   0.01 (0.00, 0.02) ‡ 
Residual variance   0.03 (0.02, 0.05) ‡ 
Random intercept variance - pre-UCO time   0.29 (0.12, 0.68) * 
Random slope variance – pre-UCO time   0.03 (0.01,0.10) * 
Random slope variance –post-UCO time HI   0.007 (0.002, 0.20)* 
 
The cerebral and systemic inflammatory changes observed in our study were accompa-
nied by prolonged suppression of preterm brain function. The persistent reduction in 
brain activity as observed in our study is in line with previous studies in comparable 
ovine models of global HI [22, 54]. Clinical evidence showed that persistent suppression 
of EEG activity is associated with poor outcome, indicating the severity of the HI-insult 
applied in this study [55, 56]. Furthermore, global HI induced severe brain atrophy in 
our study, which has previously been associated with neuronal injury [57, 58].  
 Our findings showed that HI-induced cerebral inflammation was paralleled by re-
gion-specific preOL vulnerability. In the subcortical white matter (SCWM), loss of mor-
phologically immature O4-positive preOLs was associated with hypomyelination, which 
is in concordance with previous results in a similar model of hypoxic-ischemic sheep 
[22, 54]. In the periventricular white matter (PVWM), we observed loss of morphologi-
cally immature preOLs as well as increased numbers of morphologically mature preOLs 
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following global HI. These findings suggested that the preOL response following global 
HI varied from degeneration to proliferation and depended on the region and the mor-
phological maturity of preOLs. This concept is supported by recent studies suggesting 
that myelination failure of the preterm brain following HI may be caused by a combina-
tion of preOL degeneration, regeneration and arrested maturation [59-61]. 
 
Table 2. Interpretation of model parameters 
Group (Sham ) Captures IBI length differences in means between SHAM 
and HI averaged over all time points 
Dummy Pre-post UCO  
(pre-time) 
Captures the (vertical) shift of mean IBI values, induced by 
the interrupted treatment (UCO) 
Group*pre-post dummy  Captures the differential shift of mean IBI length values 
immediately after UCO - significant only for the HI group  
Pre-UCO time Captures a linear increase of mean IBI length over time 
before UCO – Note: Non-significant 
Post-UCO time 
All 3 time associated parameters capture curve-linear 
changes of mean IBI lengths over time after UCO 
Post-UCO time2 
Post-UCO time3 
Residual variance Captures within subjects variability (noise) 
Random intercept variance - pre-UCO time Captures between subject variability at the outset 
Random slope variance – pre-UCO time Captures between subject variability with respect to linear IBI 
changes over time before UCO (each animal has its own 
slope) 
Random slope variance –post-UCO time HI Captures heterogeneity of between subject variability with 
respect to linear IBI changes over time after UCO – larger 
variable responsiveness for the HI group 
 
The observed white matter injury and functional impairments following global HI are 
typical findings in preterm infants with HIE underlining the translational character of 
the preterm sheep model.  
 In conclusion, this study provides evidence that cerebral inflammation and mobili-
zation of the peripheral innate immune system are paralleled by injury and functional 
loss of the preterm brain following global HI. We postulate that the spleen plays a key 
role in preterm HIE by providing immune effector cells to the circulation and subse-
quently to the injured brain. Further studies should focus on the interplay between 
preterm brain inflammation and the activation of the peripheral immune system fol-
lowing global HI. Better understanding of the involvement of cerebral and systemic 
inflammation in the course of global HI will contribute to the development of future 
therapeutic interventions in preterm HIE. 
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Abstract 
Hypoxic-ischemic encephalopathy (HIE) in preterm infants is a severe disease for which 
no curative treatment is available. Cerebral inflammation and invasion of activated 
peripheral immune cells have been shown to play a pivotal role in the etiology of white 
matter injury, which is the clinical hallmark of HIE in preterm infants. The objective of 
this study was to assess the neuroprotective and anti-inflammatory effects of intrave-
nously delivered mesenchymal stem cells (MSC) in an ovine model of HIE. In this trans-
lational animal model, global hypoxia-ischemia (HI) was induced in instrumented pre-
term sheep by transient umbilical cord occlusion, which closely mimics the clinical in-
sult. 
 Intravenous administration of 2 x 106 MSC/kg reduced microglial proliferation, 
diminished loss of oligodendrocytes and reduced demyelination, as determined by 
histology and Diffusion Tensor Imaging (DTI), in the preterm brain after global HI. These 
anti-inflammatory and neuroprotective effects of MSC were paralleled by reduced 
electrographic seizure activity in the ischemic preterm brain. Furthermore, we showed 
that MSC induced persistent peripheral T-cell tolerance in vivo and reduced invasion of 
T-cells into the preterm brain following global HI.  
 These findings show in a preclinical animal model that intravenously administered 
MSC reduced cerebral inflammation, protected against white matter injury and estab-
lished functional improvement in the preterm brain following global HI. Moreover, we 
provide evidence that induction of T-cell tolerance by MSC might play an important role 
in the neuroprotective effects of MSC in HIE. This is the first study to describe a marked 
neuroprotective effect of MSC in a translational animal model of HIE. 
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Introduction 
Preterm infants are prone to brain injury after a perinatal hypoxic-ischemic insult [1-3]. 
Hypoxic-ischemic encephalopathy (HIE) in preterm infants is predominantly character-
ized by white matter injury (i.e. periventricular leukomalacia) which is caused by dam-
age to highly vulnerable immature oligodendrocytes [1, 2, 4]. HIE in preterm infants is 
associated with cognitive disorders in 25-50% of all cases and 5-10% suffer from severe 
motor deficits (i.e. cerebral palsy) [5]. However, therapeutic options to improve the 
neurodevelopmental outcome in preterm infants after HIE are unavailable.  
 There is mounting evidence that the inflammatory response following brain ische-
mia plays a crucial role in the pathophysiology of ischemic brain injury [6, 7]. This con-
cept is predominantly based on literature showing activation of the cerebral and pe-
ripheral immune system after focal ischemia (i.e. stroke; transient or permanent occlu-
sion of cerebral perfusion) in adult [8, 9] and term neonatal [10] rodent models. Re-
cently, we have demonstrated in a translational ovine model, that global hypoxia-
ischemia (HI), which was induced by transient umbilical cord occlusion, caused cerebral 
inflammation and activation of the peripheral immune system in a similar way as ob-
served after focal ischemia [11]. More precisely, we showed in this model, which is 
representative for brain development of preterm infants, that global HI induced a pro-
found microglial response followed by a second peripheral inflammatory response 
characterized by invasion of mobilized peripheral immune cells into the ischemic pre-
term ovine brain [11]. These inflammatory changes were associated with marked injury 
to pre-oligodendrocytes and hypomyelination of the preterm brain [11], which are well 
known indicators of white matter injury in the ischemic preterm brain [1, 2, 12]. Our 
findings indicated that the immature immune system is readily mobilized after global HI 
and is involved in the etiology of white matter injury, the clinical hallmark of hypoxic-
ischemic preterm brain injury [11].  
 Since inflammation plays an important role in the etiology of neonatal brain injury, 
neuroprotective therapies should have strong anti-inflammatory and regenerative 
capacities if aimed at the repair of the hypoxic-ischemic neonatal brain. Mesenchymal 
stem cells (MSC) meet these criteria [13-16], and therefore several studies have been 
conducted to assess whether MSC therapy can protect the neonatal term brain after 
focal ischemia [17-22]. The objective of our study was to assess the neuroprotective 
and anti-inflammatory potential of MSC therapy in the preterm brain exposed to global 
hypoxic-ischemia. We hypothesized that intravenously administered human bone-
marrow derived MSC would be neuroprotective in a translational animal model of pre-
term HIE. To test this hypothesis, preterm instrumented sheep were exposed to 25 
minutes of umbilical cord occlusion at 0.7 gestation. At this time of gestation neurode-
velopment of fetal sheep is equivalent to that of a preterm infant of 30-32 weeks [23, 
24]. The neuroprotective effect of MSC treatment was studied by assessment of white 
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matter injury and electrographic seizure activity. The anti-inflammatory effect of MSC 
treatment was studied by evaluation of the peripheral T-cell response. 
Materials & methods 
Ethics Statement 
The experimental protocol and design of the study were in line with the institutional 
guidelines for animal experiments and were approved by the institutional Animal Ethics 
Research committee of Maastricht University, The Netherlands. 
Animals and surgery 
Fetuses of time-mated Texel ewes were instrumented as previously described [11]. In 
short, all fetuses were instrumented with an arterial catheter for blood pressure meas-
urements and blood sampling, a venous catheter for administration of MSC and ECG 
electrodes for heart rate monitoring. EEG electrodes were placed as previously de-
scribed [11]. The anterior and posterior placed electrodes were considered C3-C4 
channel and P3-P4 channel, respectively. An inflatable vascular occluder (OC16HD, 
16mm, In Vivo Metric, Healdsburg, CA, USA) was placed around the umbilical cord to 
induce transient global HI. All fetal catheters and leads were exteriorized through a 
trocar hole in the flank of the ewe. The welfare of the animals was monitored daily by 
certified personnel.  
Randomization and blinding 
Prior to the entire series of experiments, animals were randomized by an independent 
researcher who was not involved in the animal experiments. The randomization 
resulted in four experimental groups (Fig 1). The investigator performing the (sham) 
umbilical cord occlusions was blinded for treatment allocation. Tissue sampling and the 
analyses of brain tissue and electrophysiological data were conducted in a blinded 
fashion. 
Experimental design 
Fetuses were instrumented at 101.5 ± 1.0 (mean ± SD) days of gestation (experimental 
day -4). After surgery ewe and fetus were allowed to recover for four days. At 
gestational age 105.5 ± 1.1 (mean ± SD) (experimental day 0) fetuses were subjected to 
25 minutes of umbilical cord occlusion (Fig 2) by rapidly inflating the occluder. After 
umbilical cord occlusion a reperfusion period of 7 d followed.  
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Mesenchymal stem cells 
Human bone marrow-derived mesenchymal stem cells (Merck Millipore, Billerica MA, 
USA) isolated from a male healthy donor were expanded following the manufacturer’s 
protocol. After four passages the cells were frozen in freezing medium containing 10% 
FCS and 10% DMSO and stored in liquid nitrogen. The expanded MSC were validated for 
their differentiation potential and cell surface molecules. MSC effectively differentiated 
into osteoblasts and adipocytes (data not shown). Expression of cell surface molecules 
on infused MSC was confirmed by flow cytometry analysis. MSC expressed CD44, HLA-I, 
CD49c, CD13, CD54, CD58, CD140b, CD105, CD90, CD73 dimly expressed CD117 and 
CD49d and did not express HLA-II, CD45, CD34, CD40, CD80, CD146, CD3, CD86 and 
CD19. MSC were thawed and washed twice with PBS one hour before administration. 
MSC were infused intravenously 1 h after (sham) umbilical cord occlusion. Fetuses 
received 3.5 x 106 MSC (approximately 2.0 x 106 / kg BW) resuspended in 1 mL PBS via 
the venous line. 
 
 
Figure 1. Study design. Fetuses were instrumented at a gestational age (GA) of 102 d. After a recovery 
period of 4 d fetuses were subjected to 25 min of umbilical cord occlusion (UCO) or sham. One hour after 
UCO or sham, fetuses received either intravenous mesenchymal stem cells (2.0 million/ kg BW) (closed 
arrow) or saline 0,9% (open arrow). After a 7 d reperfusion period brain tissue was collected. Abbreviations: 
in = instrumentation, HI = hypoxia-ischemia, SAL = saline, MSC = mesenchymal stem cells. 
Data acquisition 
Physiological data was acquired as described previously [11]. After filtering, the raw 
EEG signals of the central and posterior channels were converted into amplitude-
integrated EEG (aEEG) traces, using a Matlab® (R2011b; The Mathworks Inc., Natick, 
MA, USA) algorithm similar to the clinical EEG NicoletOneTM device (Viasys Healthcare, 
Conshohocken, PA, USA) [25]. The EEG processing included an asymmetric band-pass 
filter that strongly attenuates activity below 2 Hz and above 15 Hz, semi-logarithmic 
amplitude compression and time compression [26]. The (a)EEG traces were used to 
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detect electrographic seizure activity, which in the aEEG usually is seen as an abrupt 
rise in the lower margin amplitude (LMA) and a simultaneous rise in the upper margin 
amplitude (UMA), often followed by a short period of decreased amplitude [27]. The 
raw EEG simultaneously shows gradual build-up and decline in amplitude of repetitive 
sharp-waves [28]. From 24 h before UCO to the end of the experiment, aEEG and EEG 
were displayed simultaneously. Electrographic seizure activity with a duration ≥ 10 s 
was annotated using both aEEG/EEG traces in n=6 animals per experimental group. 
Annotation was performed by a neonatologist, experienced in neonatal aEEG 
interpretation, who was blinded for treatment allocation.  
 
 
Figure 2. Reproducibility of 25 min umbilical cord occlusion (UCO). (A) Fetal mean arterial blood pressure 
(MABP) and (B) fetal heart rate (FHR) measurements indicated that all animals exposed to global HI 
experienced the same degree of hypotension and bradycardia, respectively, at the end of UCO; means (thick 
line) ± SD (shaded areas) of n=8 animals per experimental group are shown. MABP and FHR normalized 
within one hour after the end of UCO and were stable throughout the rest of the study period. All sham 
operated animals had similar MABP and FHR parameters during the entire duration of the study. For clarity 
reasons the sham-SAL and sham-MSC groups are depicted as one sham group. (C-E) Blood gas analysis 
indicated that twenty five minutes of umbilical cord occlusion induced comparable acidosis, hypoxemia and 
hypercarboxemia in all animals exposed to global HI, as demonstrated by (C) arterial pH, (D) arterial partial 
oxygen pressure (pO2) and (E) arterial partial carbon dioxide pressure (pCO2), respectively; means (lines) ± 
SD (error bars) of n=8 animals are depicted. Blood gas indices in animals exposed to global HI normalized 
within one hour after the end of UCO and stayed within the normal range throughout the rest of the study 
period. 
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MRI 
At the end of the experiment (day 7), the fetal brain was removed from the skull and 
weighed. The right hemisphere was submersion fixated in 4% paraformaldehyde (PFA) 
for 3 months and stored at 4 degrees Celsius. Forty eight hours prior to MRI imaging, 
the right hemisphere was washed with PBS and stored in PBS containing 1% 
sodiumazide at 4 degrees Celsius to wash out all PFA. After optimization, all DTI images 
were acquired using an echo planar imaging (EPI) sequence with diffusion gradients 
(b=4000 s/mm2) applied in 66 non-collinear directions and 6 B0 measurements. An 
average of 60 slices was recorded within 36 minutes using a repetition time (TR) = 500 
ms and echo time (TE) = 75 ms. Isovolumetric voxel size was 0.5 mm3. The FOV was 
30x60x60 mm and scan matrix size 60x120x60 mm. 
 DTI data was post processed using ExploreDTI software and fractional anisotropy 
(FA) maps maps were displayed [29]. White matter injury was assessed by measuring 
fractional anisotropy (FA), which has been previously shown to be unaffected by fixa-
tion [30]. Delineation of ROIs was performed by a neonatologist, experienced in DTI 
analysis, who was blinded for the treatment allocation. FA values within the delineated 
ROI in the SCWM and hippocampus were calculated with ExploreDTI [29]. 
Immunohistochemistry brain 
Following MRI imaging the right hemisphere was embedded in gelatin and serial coro-
nal sections (50 µm) were cut on a Leica VT 1200S vibrating microtome (Leica Biosys-
tems, Nussloch, Germany). Free floating sections at the level of mid-thalamus and pos-
terior hippocampus were stained with a rabbit anti-ionized calcium binding adaptor 
molecule 1 (IBA-1) antibody (Wako Pure Chemical Industries, Osaka, Japan), which is a 
highly specific marker for microglia, localizing resting and activated microglia [11]. A 
mouse anti-O4 antibody (Merck Millipore, Billerica, MA, USA) was used to detect pre-
oligodendrocytes (preOLs) (oligodendrocyte progenitors and immature oligodendro-
cytes) and a rat anti-myelin basic protein (MBP) antibody (Merck Millipore, Billerica, 
MA, USA) was used to detect myelin sheaths and myelin producing (mature) oligoden-
drocytes. Endogenous peroxidase-activity was blocked by incubation with 0,3% H2O2 in 
Tris buffered saline (TBS, pH 7.6). Free floating sections were incubated overnight (anti-
IBA-1 and MBP) or during three days (anti-O4) at 4°C with the diluted primary antibody 
(1:1000 anti-IBA-1, 1:400 anti-O4 and 1:2000 MBP) followed by incubation with a 
secondary donkey-anti-rabbit (anti-IBA-1), donkey-anti-rat (MBP) or donkey-anti-mouse 
(anti-O4) biotin labeled antibody.  
 The immunostaining was enhanced with Vectastain ABC peroxidase Elite kit (PK-
6200, Vector Laboratories, Burlingame, CA, USA) followed by a nickel sulfate-
diaminobenzidine (NiDAB) staining. Sections were mounted on gelatin-coated glass 
slides, air-dried, dehydrated in ascending ethanol concentrations and coverslipped with 
PerTex. After cutting of free floating sections, the remainder of the tissue was 
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embedded in paraffin and serial coronal sections (4 µm) were cut. Sections at the level 
of mid-thalamus and posterior hippocampus were stained with CD3 (DAKO A0452, 
DAKO Denmark) for detection of T-cells.  
 Endogenous peroxidase was inactivated by incubation with 0,3% H2O2 that was 
dissolved in PBS. Antigen retrieval was performed by boiling in citrate buffer pH 6.0. 
Antigen aspecific binding was prevented by incubating the slides for 30 minutes with 
5% bovine serum albumin (BSA). Slides were incubated overnight at 4°C with the 
diluted primary antibody (CD3 1:200) followed by incubation with the appropriate 
secondary biotin labeled antibody. Immunostaining was enhanced with Vectastain ABC 
peroxidase Elite kit (PK-6200, Vector Laboratories) followed by a NiDAB staining. 
Sections were counterstained with 0.1% Nuclear Fast Red washed, dehydrated and 
coverslipped.  
Analysis of immunohistochemistry 
For the analysis of IBA-1 immunoreactivity, digital images of the subcortical white 
matter (SCWM) (100x magnification) and hippocampus (20x magnification) were 
acquired using an Olympus AX-70 microscope (Olympus, Tokyo, Japan) equipped with a 
black and white digital camera. For the analysis of IBA-1 immunoreactivity, n=6 for 
sham-SAL, n=3 for sham-MSC, n=6 for HI-SAL and n=6 for HI-MSC animals per group 
were analyzed. In each individual animal, IBA-1 immunoreactivity was assessed in six 
consecutive coronal sections (posterior hippocampus/ mid-thalamus level). In the 
hippocampus, area fraction of IBA-1 immunoreactivity was assessed in one 20x digital 
image per section by delineating the hippocampus and determining the areal fraction 
of IBA-1 immunoreactivity expressed as a percentage of total hippocampal area with a 
standard threshold using Leica Qwin Pro V 3.5.1 software (Leica, Rijswijk, the 
Netherlands). In the SCWM, the area fraction of IBA-1 immunoreactivity was 
determined in five adjacent 100x digital images obtained in standardized locations 
within the SCWM of each section (Fig 3A). The results of five images per section were 
averaged to obtain the areal fraction of IBA-1 immunoreactivity within the SCWM for 
each section. The digital images were obtained and analyzed by an independent 
observer who was blinded to the experimental conditions.  
 For the analysis of MBP immunoreactivity, digital images of the subcortical white 
matter (SCWM) (100x magnification) were acquired using the Olympus AX-70 
microscope. For the analysis of MBP immunoreactivity, n=6 for sham-SAL, n=3 for 
sham-MSC, n=6 for HI-SAL and n=6 for HI-MSC animals per group were analyzed. In 
each individual animal, MBP immunoreactivity was assessed in six consecutive coronal 
sections (posterior hippocampus/ mid-thalamus level). In the SCWM, the MBP 
immunoreactivity was determined in five adjacent 100x digital images obtained in 
standardized locations within the SCWM of each section (Fig. 3A). Areal fraction of 
MBP-positive myelin sheaths was determined in each digital image with a standard low-
pass intensity threshold set to detect all MBP immunoreactivity and a standard high-
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pass intensity threshold set to exclude the intense staining of the MBP-positive mature 
oligodendrocytes (Fig 4B) using Leica Qwin Pro V 3.5.1 software. By excluding the 
immunoreactivity of MBP-positive mature oligodendrocytes the measurements 
accurately represented white matter only. The results of five images per section were 
averaged to obtain the areal fraction of MBP immunoreactivity within the SCWM for 
each section. The digital images were obtained and analyzed by an independent 
observer who was blinded to the experimental conditions.  
 O4 immunoreactivity in the SCWM was assessed as previously described [11]. In 
short, a differential count was performed, discriminating between immature (ring-
shaped membrane staining, no processes), mature (ring-shaped membrane staining, 
extensively branched processes) and degenerative (fragmented membrane staining, 
fragmentation of processes, signs of cell death; nuclear condensation and apoptotic 
bodies) phenotype of the O4 positive cells. The sum of the differential count resulted in 
the total number of O4 positive cells. For the analysis of O4 positive cells in the SCWM, 
n=6 for sham-SAL, n=3 for sham-MSC, n=6 for HI-SAL and n=6 for HI-MSC animals per 
group were analyzed. In each individual animal, the number of O4 positive cells was 
assessed in six consecutive coronal sections (posterior hippocampus/ mid-thalamus 
level). In each section, O4 positive cells were counted in eight randomly chosen fields of 
view in the SCWM (within the regions as indicated in Fig 3A) with a 40x objective 
equipped with a counting grid (0.0625 mm2) using a Nikon Eclipse E400 microscope 
(Nikon, Amsterdam, the Netherlands). The results of the eight differential counts were 
averaged to obtain the differential count of O4 positive cells per section. The 
investigator who performed the differential count was blinded to the experimental 
conditions. 
 For the analysis of CD3 staining in the SCWM, three coronal sections per animal 
(n=4 for sham-SAL, n=4 for sham-MSC, n=4 for HI-SAL and n=4 for HI-MSC) were studied 
at the posterior hippocampus/ mid-thalamus level. In each section, cells were counted 
in ten fields of view (focused on the cerebral vasculature) in the subcortical white 
matter with a 20x objective equipped with a counting grid (0.25 mm2) using a Nikon 
Eclipse E400 microscope (Nikon, Amsterdam, the Netherlands). The numbers of CD3-
positive cells were expressed as cells per field of view (FOV). 
Proliferation assay 
At the end of the experiment (day 7), the spleen was immediately harvested after 
sacrifice. Single-cell splenocyte suspensions were obtained by dissociating freshly 
sampled spleen tissues in gentleMACS™ C-tubes (MiltEnyi, Leiden, the Netherlands) 
filled with Gibco® Iscove’s Modified Dulbecco’s Medium (IMDM) (Life Technologies, 
Bleiswijk, the Netherlands) using the gentleMACS™ Dissociator (MiltEnyi, Leiden, the 
Netherlands). Subsequently, the cell suspensions were passed through a 70 µm cell 
strainer (BD Biosciences, Erembodegem-Aalst, Belgium). Splenocytes were stored in 
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nitrogen in freezing medium containing IMDM medium with 10% heat-inactivated FCS 
and 10% DMSO. 
 For the proliferation assay, splenocytes of all experimental groups (sham-SAL n=4, 
sham-MSC n=4, HI-SAL n=4, HI-MSC n=4) were thawed. Splenocytes were labeled with 
CFSE (Sigma-Aldrich, Zwijndrecht, The Netherlands) in a final concentration of 1 μM. 
CFSE-labeled splenocytes were plated at a concentration of 1.0 million cells/ mL in a 
round bottom 96-wells plate in DMEM (Gibco®, Life Technologies, Bleiswijk, The 
Netherlands) culture medium containing 10% FCS and 1% Penicillin Streptomycin 
solution. CFSE-labeled splenocytes were stimulated by adding Phytohemagglutinin 
(PHA) (Lectin; Sigma-Aldrich, Zwijndrecht, The Netherlands) at a final concentration of 1 
µg/ mL and human recombinant IL-2 (Proleukin®; Aldesleukin (Chiron), Novartis, Basel, 
Switzerland) at a final concentration of 500 IU/mL to the culture medium. These final 
concentrations yielded optimal proliferation of fetal sheep splenocytes in pilot 
experiments (data not shown). Stimulated splenocytes were cultured during five days in 
an incubator set at 37°C and 5% CO2. On day 5 the proliferated splenocytes were 
stained for detection of T-helper cells (mouse anti sheep CD4-AlexaFluor® 647 (CD4-
A647); AbDSerotec, Düsseldorf, Germany), cytotoxic T-cells (mouse anti sheep CD8-R-
PE (CD8-PE); AbDSerotec, Düsseldorf, Germany) and viability (7-Aminoactinomycin D 
(7-AAD); BD Biosciences, Bleiswijk, the Netherlands) according to the manufacturer’s 
protocol. Stained cells were acquired on a FACS Canto II flow cytometer (BD 
Biosciences, Bleiswijk, the Netherlands) equipped with FACS Diva software (BD 
Biosciencs, Bleiswijk, the Netherlands). Gating strategy is depicted in Fig S1A-C. The 
number of non-proliferating (high CFSE fluorescent intensity) CD4- and CD8-positive 
cells was expressed as a percentage of total viable splenocytes in the well. 
 Because of the lack of good flow cytometry antibodies cross-reacting with ovine 
lineage markers it was not possible to gate on CD3. However, it was possible to 
discriminate between ovine CD4-positive T-cells and CD8-positive T-cells (gating 
strategy; Fig S1). Cells being positive for both CD4 and CD8 are presumably monocytes 
or myeloid cells (with Fc receptor) and were not taken along in our analysis. The gate 
for the non-proliferating fraction was set based on the condition without mitogen (data 
not shown). 
Fluorescent In Situ Hybridization (FISH) 
The FISH probe for chromosomes Y (DYZ3, Sat. III) [31] was selected to identify intrave-
nously administered human male MSC in the preterm ovine brain. The probe was la-
beled by standard nick translation with biotin (Bio). The labeled probe was applied at a 
concentration of 1 ng/µl in 60% formamide, 2x SSC, 10% dextran sulphate, and a 50x 
excess of carrier DNA (salmon sperm DNA). FISH was performed on 4 µm thick formalin 
fixed and paraffin embedded tissue sections (at the posterior hippocampus/ 
midthalamus level) put on amino coated slides (superfrost plus+). In brief, sections 
were heated at 80 °C for 15 minutes to improve cellular adhesion to the slides during 
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the entire FISH procedure, dewaxed and hydrated followed by microwaving in 10 mM 
Na-Citrate pH buffer 1 x 10 min at 100 °C and 20 min at RT to cool down. Washed in 
demineralized water and rinsed in 0.01 M HCl and subsequently digested in 2.5 mg 
pepsin in 0.01 N HCl. Afterwards the slides were washed in 1 x 0.01 N HCl, 1 x PBS and 
post fixed in 1% formaldehyde in PBS for 5 min at RT. Slides were washed with PBS, 
demineralized water and dehydrated in an alcohol series. The probe was applied under 
a coverslip, simultaneously denatured at 80 °C for 10 min and hybridized overnight at 
37 °C. After hybridization, the preparations were washed for 5 min in 2 x SSC, 0.05% 
tween-20 (Janssen Chimica, Beerse, Belgium) and 0.1 X SSC 61 °C (2 × 5 min). The 
hybridized probe was detected in a triple layer detection method with FITC-conjugated 
avidin (Av-FITC, 1: 100 dilution; Vector Laboratories, CA, USA), biotinylated goat anti-
avidin (Bio-GaA, 1:100 dilution: Vector Laboratories) and Av-FITC. Finally, the slides 
were washed in PBS containing 0.05% Tween-20, dehydrated in an ascending ethanol 
series, and mounted in Vectashield (Vector Laboratories) containing DAPI (Sigma: 0.5 
µg/µl). Images were recorded with the Metasystems Image Pro System (black and 
white CCD camera; Sandhausen, Germany) mounted on top of a Leica DM-RE 
fluorescence microscope equipped with FITC and DAPI single band pass filters for single 
color analysis. Images were recorded using an automatic integration time allowing semi 
quantitative evaluation (using the full dynamic range of the camera without signal 
intensity saturation; TIF 8 bits image).  
PCR 
The distribution of MSC throughout the tissues was confirmed by PCR for human-
specific β-2 microglobulin as previously reported [32]. Genomic DNA that was used as 
template was extracted from snap frozen tissues including subcortical white matter and 
hippocampus of the left hemisphere, fetal lung (right middle lobe) and spleen using the 
Wizard Genomic Purification kit (Promega, Leiden, The Netherlands) according to the 
supplier’s recommendations. The presence of amplifiable DNA was evaluated by PCR 
for β-actin. PCR reactions were performed in a total volume of 25 µl with specific 
primers for β-actin or β-2 microglobulin using 1 µl of genomic DNA. Next, a nested PCR 
was conducted for β-2 microglobulin using 2.5 µl of the amplified product of the first 
reaction as a template. The amplified products were separated on ethidium bromide-
stained 2% agarose gels and captured using the Imagemaster® VDS equipped with a 
CCD camera (GE Healthcare Life Sciences (Pharmacia Biotech), Uppsala, Sweden). The 
amplified products were evaluated using the Big Dye termination sequencing kit (Perkin 
Elmer/Cetus, Emeryville, CA).  
 Primers for β-actin were 5’-CGGGACCTGACTGACTAC-3’ (sense) and 5’-
GAAGGAAGGCTGGAAGAG-3’ (antisense); primers used for the amplification of β-2 
microglobulin were 5’- GTGTCTGGGTTTCATCAATC-3’ (sense), 5’- 
GGCAGGCATACTCATCTTTT-3’ (antisense), 5’- TGGGTTTCATCAATCCGACAT-3’ (nested 
sense) and 5’- CTCATCTTTTTCAGTGGGGGT-3’ (nested antisense).  
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PCR were performed in a total volume of 25 µl in PCR buffer (Promega, Leiden, The 
Netherlands) in the presence of 0.2 mM dNTP (Promega, Leiden, The Netherlands), 1 M 
of each primer, 0.3 mM MgCl2, and 0.5 U of Taq polymerase (Promega, Leiden, The 
Netherlands). PCR conditions for each primer couple were as follows: β-actin; 95°C for 
30 s, 53°C for 45 s and 72°C for 30 s during 40 cycles: human-specific β-2 microglobulin; 
95°C for 30 s, 53°C for 30 s and 72°C for 20 s during 45 cycles: human-specific β-2 
microglobulin nested 95°C for 30 s, 50°C for 45 s and 72°C for 20 s during 45 cycles. 
 
Table 1. Animal characteristics.Fetuses were subjected to umbilical cord occlusion at a comparable age. Fetal
body weight did not differ between experimental groups. Global HI caused significant brain atrophy, which
was prevented by intravenous MSC administration. 
 sham-SAL (n=8) sham-MSC (n=8) HI-SAL (n=8) HI-MSC (n=8) 
 mean (95% CI) mean (95% CI) mean (95% CI) mean (95% CI) 
GA at UCO (d) 105.5 (104.9;106.1) 105.3 (104.6;106.1) 105.3 (104.7;105.9) 105.8 (105.0;106.7) 
BW (g) 1791.9 
(1602.2;1963.7) 
1783.0 
(1584.7;1981.3) 
1742.0 
(1553.8;1930.2) 
1829.7 
(1586.8;2072.6) 
brain (g) 29.9 (28.2;31.5) 29.0 (27.3;30.8) 24.7 (23.3;26.2) 27.5 (25.5;29.5) 
Statistics 
Summary statistics of animal characteristics and all outcome parameters are shown as 
means with 95% CI. Groups’ comparisons with respect to all outcome parameters 
(except seizure data) were drawn with analysis of variance (ANOVA) or with random 
intercept models in case of repeated measurements per animal (e.g. different sections 
per brain). Since these tests assume normal distribution of the data, variables, whose 
distributions were positively skewed, were log-transformed previous to statistical 
testing. To facilitate interpretation, averages on the log scale were back transformed to 
the original scale (antilog) and are presented as geometric means and corresponding 
95% CIs, as previously reported [11]. Seizure data was zero-inflated (i.e. no seizures in 
sham animals), showing pronounced skewness that could not be remedied by log trans-
formation. Hence, pair-wise groups’ comparisons of seizure data were performed with 
nonparametric Mann-Whitney tests. Seizure data are presented as medians and 
corresponding interquartile range (IQR). For assessment of correlations, the Pearson or 
Spearman correlation coefficient was calculated, as appropriate. To avoid 
overestimation of treatment effects, a False Discovery Rate (FDR) of 5% was used for 
multiple testing correction. Groups’ differences with FDR corrected P<0.05 were 
considered statistically significant. Statistical analysis was performed with IBM SPSS 
Statistics Version 20.0 (IBM Corp., Armonk, NY, USA).  
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Results 
Animal characteristics and reproducibility of umbilical cord occlusion 
Fetal body weight and gestational age at the time of UCO did not differ significantly 
between the four experimental groups (Table 1). No differences were found in MABP, 
FHR, pH, arterial partial oxygen pressure or arterial partial carbon dioxide pressure 
between the HI-SAL and HI-MSC group, indicating that the physiological response to 
UCO and the degree of acidosis, hypoxemia and hypercarboxemia was similar in all 
animals exposed to global HI (Fig 2).  
MSC reduced microglial proliferation after global HI 
Global HI resulted in a significant (sham-SAL vs. HI-SAL; P=0.002) increase of IBA-1 
immunoreactivity in the SCWM, indicating profound microglial proliferation in this 
region (Fig 3 A and C). In line, significantly (sham-SAL vs. HI-SAL; P<0.001) increased 
IBA-1 immunoreactivity was found in the hippocampus following global HI (Fig 3 B and 
D). Intravenous MSC significantly (HI-SAL vs. HI-MSC; P=0.020) reduced IBA-1 
immunoreactivity in the SCWM (Fig 3 A and C). Intravenous MSC administration 
partially reduced IBA-1 immunoreactivity in the hippocampus, but the difference did 
not reach statistical significance (HI-SAL vs. HI-MSC; P=0.218) (Fig 3 B and D).  
MSC reduced white matter injury after global HI 
The O4-positive preOLs observed in the SCWM were predominantly of immature 
phenotype (i.e. ring-shaped membrane staining, no processes) (Fig 4 A). The number of 
O4-positive cells was significantly (sham-SAL vs. HI-SAL; P<0.001) decreased after global 
HI in the SCWM (Fig 4 A and C), indicating HI-induced loss of preOLs in this region. 
Intravenous MSC administration significantly (HI-SAL vs. HI-MSC; P=0.002) increased 
the number of O4-positive preOLs with immature phenotype in the SCWM (Fig 4 A and 
C). The number of preOL was inversely related (r = -.83, P<0.001) to IBA-1 
immunoreactivity in the SCWM (Fig S2 A). 
 Global HI significantly (sham-SAL vs. HI-SAL; P<0.001) reduced MBP 
immunoreactivity in the SCWM, indicating marked demyelination in this region (Fig 4 B 
and D). Accordingly, the number of MBP-positive mature oligodendrocytes clearly 
decreased following global HI (Fig 4 B). Intravenous MSC administration significantly 
increased (HI-SAL vs. HI-MSC; P=0.007) myelination (Fig 4 B and D). In line, loss of MBP-
positive mature oligodendrocytes was prevented by MSC treatment (Fig 4 B). MBP 
immunoreactivity was inversely related (r = -.71, P=0.002) to IBA-1 immunoreactivity in 
the SCWM (Fig S2 B). 
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Figure 3. Intravenous MSC reduced proliferation of microglia after global HI. (A) Immunohistochemical IBA-1 
staining in the SCWM of the four experimental groups with squares in the first panel indicating the regions 
where immunoreactivity was assessed. Global HI induced a profound increase of IBA-1 immunoreactivity, 
which was significantly reduced by intravenous MSC treatment. (B) Immunohistochemical IBA-1 staining in 
the hippocampus of the four experimental groups. Profound proliferation of microglia was observed in the 
hippocampus following global HI. MSC partially reduced the inflammatory response of microglia in the 
hippocampus after global HI. (C-D) Graphical presentation of area fraction of IBA-1 immunoreactivity in 
SCWM and hippocampus; (C) geometric means ± 95% CI and (D) means ± 95% CI and levels of significance 
are depicted, which were calculated by the random intercept model with all repeated measures (i.e. brain 
sections) per animal (sham-SAL n=6, sham-MSC n=3, HI-SAL n=6, HI-MSC n=6). Dots show the averaged 
results of the repeated measures (i.e. brain sections) per animal. * P≤0.05, ‡ P≤0.01, # P≤0.001. IBA-1 = 
ionized calcium binding adaptor molecule 1, HI = hypoxia-ischemia, SAL = saline, MSC = mesenchymal stem 
cells, IR = immunoreactivity. (A-B) Scale bars represent 1 mm. 
 
FA values in the SCWM were significantly decreased (sham-SAL vs. HI-SAL; P=0.017) 
following global HI (Fig 5 A and B), indicating disturbed organization of white matter 
tracts. Intravenous MSC administration significantly increased (HI-SAL vs. HI-MSC; 
P=0.028) FA values in the SCWM following global HI (Fig 5 B), indicating that intrave-
nous MSC prevented disturbances in white matter tracts organization. In line with clini-
cal findings [33], DTI did not show significant changes of FA values after global HI in the 
hippocampus (data not shown).  
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Figure 4. Intravenous MSC treatment reduced loss of pre-oligodendrocytes and demyelination after global HI. 
(A) Immunohistochemical O4 staining in the subcortical white matter (SCWM) of all four experimental 
groups. The number of O4-positive cells was similar between sham operated animals treated with saline or 
MSC. Global HI induced marked loss of O4-positive cells. Intravenous MSC significantly increased the number 
of O4-positive cells after global HI. (B) Immunohistochemical MBP staining in the SCWM of all four 
experimental groups. The area fraction of MBP was similar between sham operated animals treated with 
saline or MSC. Marked hypomyelination was observed in the SCWM following global HI. Intravenous MSC 
significantly increased myelination of the preterm brain after global HI. (C-D) Graphical presentation of 
number of O4-positive cells and MBP immunoreactivity in SCWM; (C) means ± 95% CI (D) geometric means ± 
95% CI and levels of significance are depicted, which were calculated by the random intercept model with all 
repeated measures (i.e. brain sections) per animal (sham-SAL n=6, sham-MSC n=3, HI-SAL n=6, HI-MSC n=6). 
Dots show the averaged results of the repeated measures (i.e. brain sections) per animal. * P≤0.05, ‡ P≤0.01, 
# P≤0.001. PreOL = pre-oligodendrocytes, HI = hypoxia-ischemia, SAL = saline, MSC = mesenchymal stem cells, 
IR = immunoreactivity, log = natural logarithm. Scale bars: (A) 100 µm, (B) 200 µm. 
MSC reduced the electrographic seizure burden following global HI 
Global HI significantly increased (sham-SAL vs. HI-SAL p=0.008) the electrographic sei-
zure activity following UCO (Fig 5 C-D). In line with clinical [34] and experimental [35] 
data, the seizure activity peaked in the first 24 h after UCO, followed by a second small-
er peak in the period between 24 and 48 h after UCO (data not shown). 
 Intravenous MSC administration significantly reduced (HI-SAL vs. HI-MSC p=0.031) 
the number of electrographic seizures during the study period after global HI (Fig 5 D). 
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Seizure activity was very rarely detected in sham animals treated with saline or MSC 
(Fig 5 D). Neuronal injury was further demonstrated by significant (sham-SAL vs. HI-SAL; 
P<0.001) brain atrophy following global HI (Table 1), which was diminished (HI-SAL vs. 
HI-MSC; P=0.058 and sham-MSC vs. HI-MSC; P=0.381) by intravenous MSC treatment 
(Table 1).  
 
 
Figure 5. Intravenous MSC treatment prevented white matter injury and reduced electrographic seizure 
activity after global HI. (A) Regions of interest; SCWM and hippocampus in FA map. FA values in the 
hippocampus were not altered by global HI (data not shown). (B) Global HI caused a significant decrease in 
FA values in the SCWM, which was prevented by intravenous MSC administration; means ± 95% CI and levels 
of significance are depicted, which were calculated with ANOVA (sham-SAL n=8, sham-MSC n=4, HI-SAL n=8, 
HI-MSC n=8). Dots show each measurement (i.e. non-repeated measures) per animal. * P≤0.05, ‡ P≤0.01, # 
P≤0.001. FA = fractional anisotropy, SAL = saline, MSC = mesenchymal stem cells, HI = hypoxia-ischemia. (C) 
Representative image of an aEEG trace from a HI-SAL animal. The two upper traces represent aEEG traces of 
the C3-C4 and P3-P4 channel, respectively. The aEEG signal is time-compressed, showing a 120-min period. 
The amplitude is displayed semi-logarithmic, indicating a LMA of approximately 4-3 μV and UMA of 
approximately 10 μV. The arrows indicate seizure activity. The two lower traces depict the corresponding EEG 
signal (30 s) of one electrographic seizure activity indicated by the diamond. (D) Intravenous MSC 
administration significantly reduced electrographic seizure burden following global HI; medians ± IQR are 
depicted (sham-SAL n=6, sham-MSC n=6, HI-SAL n=6, HI-MSC n=6). * P≤0.05, ‡ P≤0.01, # P≤0.001. SAL = 
saline, MSC = mesenchymal stem cells, HI = hypoxia-ischemia. 
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MSC induced sustained T-cell tolerance 
The percentage of non-proliferative (i.e. reduced CFSE dilution) CD4-positive 
splenocytes derived from HI-SAL animals was not significantly altered compared to 
those splenocytes from sham-SAL animals (Fig 6 A and C), indicating that global HI did 
not alter the proliferative capacity of splenocytes.  
 Remarkably, the percentage of non-proliferative CD4-positive splenocytes derived 
from sham-MSC animals was significantly (P=0.012) increased compared to the sham-
SAL group (Fig 6 A and C). In line, the percentage of non-proliferative CD4-positive 
splenocytes derived from HI-MSC animals was significantly (P=0.020) increased 
compared to the HI-SAL group (Fig 6 A and C), indicating that intravenously 
administered MSC persistently suppressed the in vivo responsiveness of CD4-positive 
helper T cells in the spleen.  
 The proliferation capacity of CD8-positive splenocytes was not affected by global 
HI or MSC (data not shown). MSC-mediated suppression of helper T-cells in vivo was 
inversely related (Pearson r = - .60, P=0.035) to proliferation of microglia in the 
subcortical white matter (Fig S2 C). 
MSC reduced T-cell invasion after global HI 
In sham conditions, T-cells were predominantly detected in the intravascular space of 
the preterm brain (Fig 6 B). Global HI significantly increased (sham-SAL vs. HI-SAL; 
P<0.001) the number T-cells in the SCWM (Fig 6 B and D). In the hypoxic-ischemic 
preterm brain, T-cells were primarily located in the perivascular and interstitial space, 
indicating HI-induced invasion of T-cells into the preterm brain (Fig 6 B). Remarkably, 
intravenous MSC administration significantly reduced (HI-SAL vs. HI-MSC; P=0.028) the 
number of T-cells in the SCWM following global HI (Fig 6 B and D), indicating that 
intravenous MSC prevented invasion of T-cells into the preterm brain.  
Detection of MSC in the preterm brain seven days after administration 
Within the subcortical white matter of MSC treated animals, we localized 20-40 cells 
per section that stained positive for the human specific Y-chromosome probe (Fig 7 C 
and D). MSC were detected in 4 of 5 studied animals that received MSC. The presence 
of MSC in the brain was confirmed by human-specific β2-microglobulin PCR (Fig S3). 
The amplified PCR products contained the correct human β2-microglobulin sequences 
as evaluated by sequencing. In addition, MSC were detected with PCR in SCWM, 
hippocampus, lung and spleen (data not shown). 
  
Chapter 4 
108 
 
Figure 6. Intravenous MSC modulated the peripheral T-cell response after global HI. MSC persistently 
suppressed the proliferative capacity of CD4-positive splenocytes and reduced the number of invading T-cells 
into the preterm brain follow global HI and. (A) Representative flow cytometry histograms showing 
proliferation (increased CFSE dilution) of CD4-positive splenocytes (green) and CD8-positive splenocytes (blue) 
derived from the different experimental groups. Global HI did not alter the proliferative capacity of CD4-
positive splenocytes (HI-SAL versus sham-SAL). MSC significantly suppressed the proliferation of CD4-positive 
splenocytes in sham operated animals (sham-MSC versus sham-SAL) and in animals exposed to global HI (HI-
MSC versus HI-SAL). (B) Immunohistochemical CD3 (T-cell) staining in the subcortical white matter (SCWM) of 
all four experimental groups. In sham conditions, T-cells were primarily detected in the intravascular space 
(open arrows). Following global HI, a significant increase in the number of perivascular and interstitial (black 
arrows) CD3-postive cells was observed. T-cell invasion after global HI was significantly reduced by MSC. (C-
D) Graphical presentation of (C) the percentage of non-proliferative CD4-positive splenocytes and (D) number 
of CD3-positive cells in SCWM; (C) means ± 95% CI and (D) geometric means ± 95% CI and levels of 
significance are depicted, which were calculated by ANOVA for CD4 proliferation (C) and the random 
intercept model with all repeated measures (i.e. brain sections) for CD3 counts (D). Dots show each 
measurement (i.e. non-repeated measures) per animal for CD4 proliferation (C) and the averaged results of 
the repeated measures (i.e. brain sections) per animal for CD3 counts (D). * P≤0.05, ‡ P≤0.01, # P≤0.001. SAL 
= saline, MSC = mesenchymal stem cells, HI = hypoxia-ischemia, FOV = field of view. 
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Discussion 
Hypoxic-ischemic encephalopathy (HIE) in preterm infants is associated with cognitive 
and motor disorders, for which there is currently no therapeutic cure. The lack of feasi-
ble experimental models which are comparable to human neurodevelopment is one of 
the main hurdles that prevent the development of novel therapeutic strategies for 
hypoxic-ischemic injury in the preterm brain. We and others previously demonstrated 
that the fetal ovine model of global hypoxia-ischemia (HI) by umbilical cord occlusion 
(UCO) closely resembles the situation in human preterm infants in terms of neurode-
velopment and white matter injury, which is the clinical hallmark of hypoxic-ischemic 
injury in the preterm brain [1, 11, 12]. In the current study, we use this translational 
animal model to provide evidence for the therapeutic potential of intravenous admin-
istration of MSC in the preterm brain after global HI. 
 We first assessed the effects on the cerebral anti-inflammatory effects of MSC by 
studying the proliferative response of microglia, which are typically activated early after 
global HI [11, 36]. Our findings demonstrated that intravenous administration of MSC 
reduced the cerebral inflammatory response in the hypoxic-ischemic preterm brain 
after global HI. Secondly, we studied the protective effects of MSC on white matter 
injury. We showed that global HI induced a marked loss of preOLs, which was paralleled 
by hypomyelination of the preterm brain. In line with clinical evidence [37], FA values 
obtained with diffusion tensor imaging (DTI) were decreased following global HI indicat-
ing HI-induced breakdown of white matter organization. Intravenous administration of 
MSC prevented the loss of preOLs after global HI and reduced histological white matter 
injury, which was confirmed with DTI. The third step was to study neuronal injury on a 
functional level by assessing electrographic seizure burden following global HI in ampli-
tude-integrated electroencephalogram (aEEG). Our findings showed that intravenous 
MSC treatment decreased the electrographic seizure activity following global HI. Reduc-
ing seizure activity is clinically highly relevant, since several studies have shown that 
seizures in neonatal HIE are associated with adverse neurodevelopmental outcome [38-
40].  
 The preceding findings showed that intravenous MSC reduced the initial inflamma-
tory response in the preterm brain mediated by microglia and provided protection 
against evolving white matter and neuronal injury after global HI. To further assess the 
mechanism underlying the therapeutic effects of MSCs, we studied modulation of the 
peripheral T-cell response and subsequent invasion of these cells into the ischemic 
preterm brain. We and others have previously shown that the initial cerebral inflamma-
tory response after the hypoxic-ischemic insult is followed by a second peripheral in-
flammatory response characterized by mobilization and invasion of peripheral immune 
effector cells (i.e. neutrophils and T-cells) into the preterm brain [10, 11, 36, 41]. Previ-
ous in vitro studies have demonstrated that MSC suppressed helper T-cell proliferation 
and induced an anti-inflammatory, more tolerant, phenotype in these immune effector 
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cells [42-44]. These findings were confirmed and extended by our study showing that 
MSC induced persistent tolerance of T-cells in vivo. Furthermore, we showed that the 
degree of peripheral T-cell tolerance was inversely related to cerebral inflammation. 
Moreover we found that MSC reduced T-cell invasion following global HI. Based on 
these findings, we hypothesize that sequestered MSC modulated peripheral helper T-
cells to become unresponsive, making them less susceptible for activation and mobili-
zation in response to brain-derived damage signals following global HI. This suppression 
of peripheral immune cells may decrease invasion of immune effector cells into the 
brain observed after global HI, thereby reducing a second inflammatory hit to the is-
chemic preterm brain [11].  
 
 
Figure 7. MSC were detected in the fetal ovine brain. A FISH probe specific for the human Y-chromosome 
detected the presence of systemically deliverd MSC in the ovine brain. (A-D) Representative fluorescent 
images of the SCWM in the different experimental groups; (A) sham-SAL, (B) sham-MSC, (C) HI-SAL and (D) 
HI-MSC. (A-B) In saline treated animals the FISH probe did not react with any nucleus. (C-D) The FISH probe 
was detected in MSC treated animals indicating that MSC were present in the preterm brain 7 d after 
intravenous administration. Scale bars: (A-D) 50 µm, scale bars inserts: (A-D) 5 µm. 
 
The newly identified modulation of T-cell tolerance in vivo and reduction of T-cell 
invasion after intravenous MSC administration adds to the understanding of the anti-
inflammatory effects of MSC in the context of inflammation-driven organ injury. Be-
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sides the anti-inflammatory effects of MSC in our model, we speculate that the ob-
served protective effects of MSC on white matter injury are based on additional mech-
anisms. First, the MSC-mediated reduction of cerebral inflammation potentially re-
duced injury to vulnerable preOLs in the preterm brain. This concept is supported by 
studies showing microglia-mediated injury to preOLs [45] and our findings that preOL 
density and myelination in the subcortical white matter were inversely related to pro-
liferation of microglia. A second effect might be attributed to MSC-mediated regenera-
tion of lost preOLs and diminished arrested oligodendrocyte maturation. The latter 
concept is supported by in vitro data showing that MSC stimulate neural progenitor 
cells to differentiate towards the oligodendrocyte lineage [46, 47] and in vivo data 
demonstrating remyelination after intracerebral delivery of MSC in a rat model of neo-
natal hypoxic-ischemic brain injury [48]. 
 From the MSC that were administered intravenously, only a few cells (<0.01%) 
were located within the preterm ovine brain at seven days after global HI. PCR and 
sequencing confirmed the presence of MSC in the brain and also confirmed that MSC 
were present in lung and spleen seven days after intravenous administration. In con-
cordance with our findings, a study by Lee et al. showed that MSC were neuroprotec-
tive in a rat model of neonatal hypoxic-ischemic brain injury, while less than 0.01% of 
intravenously administered MSC were recovered in brain, lung and spleen tissue within 
96 h after infusion [49]. Remarkably, also intracerebral injected MSC were shown to be 
neuroprotective, although they disappeared rapidly after injection [50]. These findings 
suggest that the neuroprotective effects of MSC last longer than their presence imply-
ing that MSC-mediated modulation of inflammation and repair of injury is initiated 
early after administration. 
 Several other studies using rodent models of neonatal hypoxic-ischemic brain inju-
ry have previously shown neuroprotective effects of MSC after intracerebral injection 
[18, 20, 48], intranasal [51] and intravenous administration [17, 21]. These rodent 
models however have several limitations that make them less suitable for clinical trans-
lation [23, 24, 52]. The strength of the instrumented preterm sheep model is that it 
closely resembles human preterm neurodevelopment and second, that the global HI 
insult induced by umbilical cord occlusion accurately mimics the common clinical etiol-
ogy of HIE in preterm infants [24, 52].  
 We showed that xenotransplanted human MSC effectively modulated immune 
responses and stimulated neuronal repair in preterm sheep, without any signs of im-
munological rejection. These findings are in line with early work by Zanjani et al. show-
ing that human xenotransplanted HSC were well tolerated by the permissive environ-
ment of preimmune fetal sheep [53] and even after establishment of the fetal immune 
system [32]. The latter findings indicated that MSC have unique immunological charac-
teristics that allow them to persist in a xenogeneic environment [32].  
 The observed neuroprotective effects in our model were seen following severe 
hypoxic-ischemic brain injury suggesting that the MSC-mediated treatment effects will 
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be enhanced following milder episodes of ischemia in the preterm brain. Although the 
dosage of MSC administered in our model was consistent with completed [21, 54] and 
ongoing (ClinicalTrials.gov: NCT01501773, NCT01297413, NCT01678534) clinical trials 
of focal cerebral ischemia (i.e. stroke), dose escalation studies need to be conducted to 
determine the optimal dosing strategy in hypoxic-ischemic preterm brain injury. In 
addition, the magnitude of the treatment effect may depend on the timing of 
intervention; we infused MSC 1 h after the HI insult particularly aimed at intervening 
early with the detrimental inflammatory response following global HI. However, it is 
conceivable that repetitive dosing may especially enhance the regenerative effects of 
MSC. Furthermore, neuroprotective effects of MSC observed here may have been un-
derestimated after a reperfusion period of one week. It is plausible that additional 
MSC-mediated repair of white matter and neuronal networks takes place beyond the 
period of one week after global HI. Whether the observed structural changes and re-
duction in electrographic seizures are associated with long term improvement of cogni-
tive and motoric function needs to be addressed in future (clinical) studies [13].  
 In conclusion, we report for the first time that intravenously administered 
mesenchymal stem cells (MSC) were neuroprotective in a translational ovine model of 
preterm brain injury after global HI. We demonstrated that MSC protected the preterm 
brain against white matter injury and established functional improvement. We provide 
evidence that the neuroprotective effects of MSC may be mediated by modulation of 
the peripheral T-cell response after global HI. Further experimental research is needed 
to elucidate the anti-inflammatory and regenerative mechanisms of action of MSC and 
to evaluate the long-term therapeutic effect of MSC on motoric and cognitive function 
after global HI. Future clinical trials should focus on the optimization of timing and 
dosing of MSC therapy in preterm infants with hypoxic-ischemic brain injury. 
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Supplementary figures 
 
Figure S1. Gating strategy proliferation assay. (A-C) Dot plots illustrating gating strategy in the flow 
cytometry analysis of the proliferation assay. FSC = forward scatter, SSC = sideward scatter, 7-AAD = 7-
Aminoactinomycin D (viability stain). 
 
 
Figure S2. Correlation plots. (A) Density of immature preOLs was inversely related (Pearson r = - .83, 
P<0.001) to IBA-1 immunoreactivity in the SCWM. (B) MBP immunoreactivity was inversely related (Pearson 
r = - .71, P=0.002) to IBA-1 immunoreactivity in the SCWM. (C) The number of non-proliferating CD4-postive 
T cells harvested from the spleen was inversely related (Pearson r = - .60, P=0.035) to IBA-1 immuno-
reactivity in the subcortical white matter. 
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Figure S3. Detection of human specific β-2-microglobulin DNA sequences in preterm sheep 
brain. Genomic DNA was extracted from subcortical white matter of a MSC treated animal 
(MSC) and a saline treated animal (SAL) and analyzed by nested PCR for the presence of 
human β-2-microglobulin (B2M) DNA sequences. The presence of amplifiable DNA was 
evaluated by PCR for β-actin (actin). - = water control, + = positive control; genomic DNA 
extracted from one million human MSC.  
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Systemic G-CSF attenuates cerebral 
inflammation and hypomyelination but 
does not reduce seizure burden in preterm 
sheep exposed to global hypoxia-ischemia 
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Abstract  
Hypoxic-ischemic encephalopathy (HIE) is common in preterm infants, but currently no 
curative therapy is available. Cell-based therapy has great potential in the treatment of 
hypoxic-ischemic preterm brain injury. Granulocyte-colony stimulating factor (G-CSF) is 
known to mobilize endogenous hematopoietic stem cells (HSC) and promotes prolifera-
tion of endogenous neural stem cells. On these grounds, we hypothesized that systemic 
G-CSF would be neuroprotective in a large translational animal model of hypoxic-
ischemic injury in the preterm brain. 
 Global hypoxia-ischemia (HI) was induced by transient umbilical cord occlusion in 
instrumented preterm sheep. G-CSF treatment (100 µg/kg intravenously, during five 
consecutive days) was started one day before the global HI insult to ascertain mobiliza-
tion of endogenous stem cells within the acute phase after global HI. Mobilization of 
HSC and neutrophils was studied by flow cytometry. Brain sections were stained for 
microglia (IBA-1), myelin basic protein (MBP) and myeloperoxidase (MPO) to study 
microglial proliferation, white matter injury and neutrophil invasion respectively. Elec-
trographic seizure activity was analyzed using amplitude-integrated electroencephalo-
gram (aEEG). 
 G-CSF effectively mobilized CD34-positive HSC in the preterm sheep. In addition, G-
CSF caused marked mobilization of neutrophils, but did not influence enhanced inva-
sion of neutrophils into the preterm brain after global HI. Microglial proliferation and 
hypomyelination following global HI were reduced as a result of G-CSF treatment. G-
CSF did not cause reduction of the electrographic seizure activity after global HI. 
 In conclusion, G-CSF induced mobilization of endogenous stem cells which was 
associated with modulation of the cerebral inflammatory response and reduced white 
matter injury in an ovine model of preterm brain injury after global HI. G-CSF treatment 
did not improve neuronal function as shown by seizure analysis. Our study shows that 
G-CSF treatment has neuroprotective potential following hypoxic-ischemic injury in the 
preterm brain.  
 
  
Endogenous stem cells 
 121 
Introduction 
Hypoxic-ischemic brain injury (i.e. hypoxic-ischemic encephalopathy; HIE) in preterm 
infants is associated with cognitive and motor disorders causing life-long neurological 
disability with a tremendous impact on the patient’s life and his environment [1]. HIE in 
preterm infants is predominantly characterized by white matter injury, the clinical 
hallmark of HIE in prematurity [1-5]. Currently no therapeutic intervention is available 
for HIE in preterm infants. The regenerative potential of cell-based therapy may provide 
a good treatment option for this vulnerable patient group [6-8]. Recently, we showed in 
a translational animal model of HIE that exogenous administration of bone marrow-
derived mesenchymal stem cells (MSC) early after global hypoxia-ischemia (HI) estab-
lished functional neuroprotection and dampened the cerebral and systemic inflamma-
tory response [9]. These findings indicated that the therapeutic window of opportunity 
for modulation of the cerebral and peripheral inflammatory response and initiation of 
repair mechanisms after global HI corresponds to the first hours after the insult [9]. 
 Although exogenous administration of stem cells seems beneficial for the preterm 
ischemic brain, the alternative of pharmacologically potentiating the endogenous re-
generative capacity after injury remains appealing as biological risks, logistics and costs 
remain potential obstacles for exogenous stem cell therapy [6]. In preterm infants es-
pecially, the brain and other tissues possess high numbers of regenerative stem cells [7, 
10, 11]. Pharmacological interventions aimed at mobilizing these stem cells after injury 
form a promising prospect in the preterm environment [6]. 
 Granulocyte-colony stimulating factor (G-CSF) is a potent drug that has been 
shown to mobilize hematopoietic stem cells (HSC), which can be neuroprotective, and 
to stimulate proliferation of endogenous neural stem cells [12]. G-CSF is clinically ap-
proved in neonatal and pediatric medicine for the treatment and prevention of neutro-
penia [13-15]. The neuroprotective properties of G-CSF are currently tested in clinical 
trials with adult stroke patients [16-20]. Its protective role on the neonatal brain follow-
ing hypoxia-ischemia however remains debated [21-26]. These previous neonatal stud-
ies have tested G-CSF therapy in rodent models of neonatal hypoxic-ischemic brain 
injury. Neurodevelopment in the rodent brain however follows a different time course 
then in the human brain [27-29]. In contrast to the human (and ovine) situation, white 
matter myelination in the rodent brain occurs in the postnatal period [27-29].  
 Therefore, we hypothesized that systemic G-CSF treatment would be neuroprotec-
tive in a large translational animal model (sheep) of hypoxic-ischemic preterm brain 
injury. To test this hypothesis, instrumented fetal sheep were exposed to 25 minutes of 
umbilical cord occlusion at 0.7 gestation, which is equivalent to 30-32 gestational weeks 
of human neurodevelopment [28, 29]. G-CSF treatment (100 µg/ kg intravenously daily, 
during five consecutive days) was started one day before the global HI insult to ascer-
tain that mobilized endogenous stem cells were readily available within the therapeutic 
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window of opportunity. We studied the effect of G-CSF treatment on the cerebral and 
systemic inflammatory response, white matter injury and seizure activity.  
Materials & methods 
Study approval  
The experimental protocol and study design were in line with the institutional guides 
for animal experiments and were approved by the institutional Animal Ethics Research 
committee of Maastricht University, the Netherlands.  
Randomization and blinding 
Prior to the entire series of experiments, animals were randomized by an independent 
researcher who was not involved in the animal experiments. Randomization resulted in 
four experimental groups: (1) sham umbilical cord occlusion, saline treatment (sham-
SAL; n=8), (2) sham umbilical cord occlusion, G-CSF treatment (sham-G-CSF; n=8), (3) 
umbilical cord occlusion, saline treatment (HI-SAL; n=8) and (4) umbilical cord occlu-
sion, G-CSF treatment (HI-G-CSF; n=8) (Figure 1). The investigator performing the 
(sham) umbilical cord occlusions was blinded to treatment allocation. Tissue sampling 
and the analyses of brain tissue and electrophysiological data were conducted in a 
blinded fashion. 
Animals and surgery 
Singleton fetuses of time-mated Texel ewes were instrumented at 101.6 ± 1.0 (mean ± 
SD) days of gestation as previously described [30]. In short, all fetuses were instru-
mented with an arterial catheter for blood pressure measurements and blood sam-
pling, a venous catheter for administration of G-CSF and electrocardiogram (ECG) elec-
trodes for heart rate monitoring. Two pairs of custom-made shielded silver-tipped elec-
troencephalogram (EEG) electrodes (Cooner wire Co., Chatsworth, CA, USA) were 
placed bilaterally on the dura over the parasagittal parietal cortex (5 mm and 15 mm 
anterior to point bregma and 10 mm lateral), with a subcutaneous silver reference 
electrode (10 mm) placed in the neck. The EEG electrodes were secured with cy-
anoacrylate glue and covered with fetal skin. The anterior and posterior placed elec-
trodes were considered C3-C4 channel and P3-P4 channel, respectively. An inflatable 
vascular occluder (OC16HD, 16mm, In Vivo Metric, Healdsburg, CA, USA) was placed 
around the umbilical cord to induce transient global HI. The fetus was placed back in 
the uterus which was subsequently closed. All fetal catheters and leads were exterior-
ized through a trocar hole in the flank of the ewe. Catheters were continuously per-
fused with heparinized saline (25 IU/ mL, 0.2 mL/h). Surgical wounds were inspected 
daily and treated with chlortetracycline spray to prevent infection. Animals had ad 
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libitum access to water and food. The welfare of the animals was monitored daily by 
certified personnel.  
Experimental design 
Fetuses were instrumented at 101.6 ± 1.0 (mean ± SD) days of gestation (experimental 
day -4). After surgery, the ewe and her fetus were allowed to recover for three to four 
days. At gestational age 105.6 ± 1.0 (mean ± SD) (experimental day 0) fetuses were 
subjected to 25 minutes of umbilical cord occlusion by rapidly inflating the occluder 
with sterile saline of a defined volume known to completely inflate the occluder. Com-
plete occlusion was confirmed by a sudden drop in heart rate and subsequent arterial 
blood gas analysis indicating acidemia, hypoxemia and hypercarboxemia (Figure 2), 
which has previously been shown to induce global hypoxia-ischemia and subsequent 
cerebral hypoperfusion [31]. After umbilical cord occlusion a reperfusion period of 7 
days followed. At the end of the experiment (experimental day 7), both ewe and fetus 
were euthanized by administration of pentobarbital (200 mg/kg). 
 
Figure 1. Study design. Fetuses were instrumented at a gestational age (GA) of 102 d (experimental day -4). 
After a recovery period of 4 d, on experimental day 0 fetuses were subjected to 25 min of umbilical cord 
occlusion (UCO) or sham. One day before UCO or sham, fetuses received either intravenous G-CSF (100 µg/ 
kg BW) (grey arrow) or saline (open arrow). After a reperfusion period of 7 days brain tissue was collected. 
in = instrumentation, HI = hypoxia-ischemia, SAL = saline, G-CSF = granulocyte-colony stimulating factor. 
Granulocyte colony-stimulating factor administration 
One day before umbilical cord occlusion (experimental day -1), fetuses received 100 
µg/kg human recombinant G-CSF (Neupogen, Amgen Inc, Thousand Oaks, CA, USA) or 
saline daily through the venous catheter for five consecutive days (Figure 1).  
Chapter 5 
124 
Human recombinant G-CSF (5 µg /kg) has been previously shown to mobilize sheep 
white blood cells [32]. In a pilot study we confirmed that human recombinant G-CSF (10 
µg /kg) mobilized white blood cells in instrumented fetal sheep (data not shown).  
 G-CSF dosage in our experiments (100 µg /kg) was chosen based on a meta-
analysis by Minnerup et al., which concluded that in most adult rodent studies 50 µg 
/kg G-CSF was neuroprotective in focal cerebral ischemia (i.e. stroke) [33]. However, 
meta-regression analysis showed that higher doses were likely to have even stronger 
therapeutic effects [33]. In addition, neonatal rodent studies showed neuroprotection 
with G-CSF dosage varying between 50 µg /kg up to 200 µg /kg during five consecutive 
days [22, 23, 25, 26, 34]. Based on these findings, we performed a second pilot study 
which showed marked mobilization of ovine white blood cells and HSC after administra-
tion of 100 µg /kg human recombinant G-CSF during five consecutive days (data not 
shown). Ovine HSC were detectable 24 hours after the initial infusion of human recom-
binant G-CSF. Therefore, we started G-CSF treatment 24 hours before the global hypox-
ic-ischemic insult to ascertain mobilization of endogenous stem cells within the acute 
phase after global HI. 
EEG and ECG data acquisition 
Physiological data was acquired as described previously [30]. In short, blood pressure, 
amniotic pressure EEG and ECG data were acquired and digitized by a custom-made 
MPAQ unit (Maastricht-Programmable AcQuisition system, Maastricht Instruments BV, 
Maastricht, the Netherlands) with IDEEQ software (Maastricht Instruments BV). EEG 
data were sampled at 1000 Hz and stored on hard-disk for off-line analysis. EEG data 
were filtered using a 0.5-30 Hz 4th order Butterworth band-pass filter. EEG signal with 
an amplitude > 1000 µV was considered an artifact and removed from analysis (<1% of 
data). After filtering, the raw EEG signals of the central and posterior channels were 
converted into amplitude-integrated EEG (aEEG) traces, using an (Matlab® based) algo-
rithm similar to the clinical EEG NicoletOneTM device (Viasys Healthcare, Conshohocken, 
PA, USA), as previously described [35-37]. The aEEG processing includes an asymmetric 
band pass filter that strongly attenuates activity below 2 Hz and above 15 Hz, semi-
logarithmic amplitude compression, rectifying, smoothing and time compression. The 
bandwidth reflects variations in minimum and maximum EEG amplitude. The amplitude 
display is linear between 0 and 10 μV and logarithmic from 10 to 100 µV. The semi-
logarithmic display enhances identification of changes in low-voltage activity and avoids 
overloading of the display at high amplitudes. 
 We previously showed that seizure activity in instrumented fetal sheep can be 
easily detected on aEEG as an abrupt rise in the lower margin amplitude and a simulta-
neous rise in the upper margin amplitude often followed by a short period of decreased 
amplitude [9]. When detected on aEEG, seizure activity was confirmed on the raw EEG 
by gradual build-up and then decline in frequency and amplitude of repetitive spikes or 
sharp-wave or activity with duration of at least 10 s. 
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EEG seizure activity was annotated manually using aEEG/EEG traces and the total num-
ber and length of seizures was subsequently calculated. Annotation was performed by a 
neonatologist, experienced in aEEG interpretation, who was blinded to treatment allo-
cation. For the analysis of seizure burden, n=6 for sham-SAL, n=4 for sham-G-CSF, n=6 
for HI-SAL and n=4 for HI-G-CSF animals per group were available for analysis. 
 
 
Figure 2. Reproducibility of 25 min umbilical cord occlusion (UCO) as evidenced by comparable vital 
parameters and blood gases in animals exposed to global HI. (A) Fetal mean arterial blood pressure (MABP) 
and (B) fetal heart rate (FHR) measurements indicated that all animals exposed to global HI experienced the 
same degree of hypotension and bradycardia, respectively; means (thick line) ± SD (shaded areas) of n=8 
animals per experimental group are shown. (C-E) Blood gas analysis indicated that 25 min of umbilical cord 
occlusion induced comparable acidosis, hypoxemia and hypercarboxemia in all animals exposed to global HI, 
as demonstrated by (C) arterial pH, (D) arterial partial oxygen pressure (pO2) and (E) arterial partial carbon 
dioxide pressure (pCO2), respectively; means (lines) ± SD (error bars) of n=8 animals are depicted. HI = 
hypoxia-ischemia, SAL = saline, G-CSF = granulocyte-colony stimulating factor, min = minutes. 
Brain immunohistochemistry 
After 3 months of submersion fixation in 4% paraformaldehyde, the right cerebral hem-
isphere was embedded in gelatin and serial coronal sections (50 µm) were cut on a 
Leica VT 1200S vibrating microtome (Leica Biosystems, Nussloch, Germany). Free float-
ing sections at the level of mid-thalamus and posterior hippocampus were stained with 
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a rabbit anti-ionized calcium binding adaptor molecule 1 (IBA-1) antibody (Wako Pure 
Chemical Industries, Osaka, Japan) for microglia, a rabbit anti-myeloperoxidase (MPO) 
antibody (DAKO A0398, DAKO, Glostrup, Denmark) for neutrophils or a rat anti-myelin 
basic protein (MBP) antibody (Merck Millipore, Billerica, MA, USA) for myelin sheaths 
and myelin producing (mature) oligodendrocytes, as previously described [30].  
Analysis of immunohistochemistry 
For the analysis of IBA-1 immunoreactivity, digital images of the subcortical white mat-
ter (SCWM) (100x magnification) and hippocampus (20x magnification) were acquired 
using an Olympus AX-70 microscope (Olympus, Tokyo, Japan) equipped with a black 
and white digital camera. For the analysis of IBA-1 immunoreactivity, n=6 for sham-SAL, 
n=3 for sham-G-CSF, n=6 for HI-SAL and n=6 for HI-G-CSF animals per group were ana-
lyzed. In each individual animal, IBA-1 immunoreactivity was assessed in six consecutive 
coronal sections (posterior hippocampus/ mid-thalamus level). In the hippocampus, 
area fraction of IBA-1 immunoreactivity was assessed in one 20x digital image per sec-
tion by delineating the hippocampus and determining the areal fraction of IBA-1 immu-
noreactivity expressed as a percentage of total hippocampal area with a standard 
threshold using Leica Qwin Pro V 3.5.1 software (Leica, Rijswijk, the Netherlands). In the 
SCWM, the area fraction of IBA-1 immunoreactivity was determined in five adjacent 
100x digital images obtained in standardized locations within the SCWM of each sec-
tion. The results of five images per section were averaged to obtain the areal fraction of 
IBA-1 immunoreactivity within the SCWM for each section. The digital images were 
obtained and analyzed by an independent observer who was blinded to the experi-
mental conditions.  
 For the analysis of MBP immunoreactivity, digital images of the subcortical white 
matter (SCWM) (100x magnification) were acquired using the Olympus AX-70 micro-
scope. MBP immunoreactivity was analyzed in n=6 for sham-SAL, n=3 for sham-G-CSF, 
n=6 for HI-SAL and n=6 for HI-G-CSF animals per group. In each individual animal, MBP 
immunoreactivity was assessed in six consecutive coronal sections (posterior hippo-
campus/ mid-thalamus level). In the SCWM, the MBP immunoreactivity was deter-
mined in five adjacent 100x digital images obtained in standardized locations within the 
SCWM of each section. Using Leica Qwin Pro V 3.5.1 software, areal fraction of MBP-
positive myelin sheaths was determined in each digital image with a standard low-pass 
intensity threshold set to detect all MBP immunoreactivity and a standard high-pass 
intensity threshold set to exclude the intense staining of MBP-positive mature oli-
godendrocytes, to ensure measurements accurately represented white matter only. 
The results of five images per section were averaged to obtain the areal fraction of MBP 
immunoreactivity within the SCWM for each section. The digital images were obtained 
and analyzed by an independent observer who was blinded to the experimental condi-
tions.  
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White blood cell counts 
Automated white blood cell counts were performed in heparinized arterial blood on 
experimental day -3, 0, 1, 3, 5 and 7 using a Sysmex XE-5000 hematology analyzer 
(Sysmex, Etten-Leur, the Netherlands). 
Spleen immunohistochemistry 
Spleens were removed immediately following sacrifice and subsequently weighed. 
Tissue blocks were snap frozen in liquid nitrogen. Frozen spleen sections (4 µm) were 
stained for CD3 (DAKO A0452) for detection of T-cells and MPO (DAKO A0398) for de-
tection of neutrophils, as previously described [30]. 
 For the analysis of CD3 and MPO immunoreactivity, digital images of spleen sec-
tions were acquired at 100x magnification using a Leica DM200 microscope equipped 
with a Leica DFC295 digital camera (Leica Microsystems) and Leica Application Suite 
(LAS) software (Leica LAS V 3.7). Areal fraction of CD3 and MPO immunoreactivity was 
determined in five sections per animal (sham-SAL n=6, sham-G-CSF n=6, HI-SAL n=6, HI-
G-CSF n=6) with a standard threshold to determine positive staining using Leica Qwin 
software (Leica Qwin Pro V 3.5.1).  
Flow cytometry  
Fetal whole blood was stored in liquid nitrogen in freezing medium containing Iscove’s 
modified Dulbecco’s medium (IMDM) medium with 10% heat-inactivated fetal calf 
serum and 10% dimethylsulfoxide (DMSO). To study mobilization of hematopoietic 
stem cells, neutrophils and T-cells on experimental day 0, 1 and 3, fetal whole blood 
samples were stained for detection of lymphocytes (mouse anti sheep CD45-biotin; 
AbDSerotec, Düsseldorf, Germany / streptavidin-Horizon V450; BD Biosciences, Ble-
iswijk, the Netherlands), hematopoietic stem cells (mouse anti sheep CD34; a kind gift 
by Dr. Porada, University of Nevada, Reno, NV, USA [38], with secondary rat anti 
mouse- R-phycoerythrin (-PE); BD Biosciences), neutrophils (mouse anti-bovine CD11b-
Fluorescein isothiocyanate (-FITC); AbDSerotec), T-helper cells (mouse anti sheep CD4-
AlexaFluor® 647 (-A647); AbDSerotec), cytotoxic T-cells (mouse anti sheep CD8-R-
phycoerythrin (-PE); AbDSerotec) and a viability marker (7-Aminoactinomycin D (7-
AAD); BD Biosciences) according to the manufacturer’s protocol. Stained cells were 
acquired on a FACS Canto II flow cytometer (BD Biosciences) equipped with FACS Diva 
software (BD Biosciencs). The total number of CD34, CD11b, CD4 and CD8 positive cells 
was calculated by multiplying the percentage of living CD45-positive lymphocytes with 
the corresponding white blood cell count.  
Statistics 
Summary statistics of animal characteristics and all outcome variables are shown as 
means with 95% Confidence Interval (CI). Groups’ comparisons of all outcome parame-
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ters (except white blood cell mobilization and seizure data) were drawn with analysis of 
variance (ANOVA) or with random intercept models in case of repeated measurements 
per animal (e.g. different sections per brain). HI (sham vs. HI) and treatment (saline vs. 
G-CSF) were the fixed effects. For random intercept models, animals constituted addi-
tionally the random effect. Variables, whose distributions were positively skewed, were 
log-transformed previous to statistical testing. To facilitate interpretation, averages on 
the log scale were back transformed to the original scale (antilog) and are presented as 
geometric means and corresponding 95% CIs.  
 Mobilization (HSC and neutrophils) and seizure data, both of them measured over 
time, showed pronounced right-skewness that could not be remedied by log transfor-
mation. Hence, for these variables, pair-wise groups’ comparisons of mobilization and 
seizure data were performed with nonparametric Mann-Whitney tests, per individual 
time-point. They are presented as medians and corresponding interquartile range (IQR). 
A False Discovery Rate (FDR) of 5% was used for multiple testing correction. Groups’ 
differences with FDR corrected P<0.05 were considered statistically significant. Statisti-
cal analysis was performed with IBM SPSS Statistics Version 20.0 (IBM Corp., Armonk, 
NY, USA).  
 
Table 1. Animal characteristics (n=8 animals per experimental group). Fetuses were subjected to umbilical
cord occlusion at a comparable age. Fetal body weight did not differ between experimental groups. Global HI
caused significant atrophy of the brain and hippocampus, which was not prevented by G-CSF. * = significantly 
different compared to sham-SAL. 
 sham-SAL sham-G-CSF HI-SAL HI-G-CSF 
 mean (95% CI) mean (95% CI) mean (95% CI) mean (95% CI) 
GA at UCO (d) 105.6  
(105.2;106.1) 
105.7  
(104.9;106.4) 
105.4  
(104.8;105.9) 
105.7  
(105.0;106.4) 
BW (g) 1686.3  
(1517.8;1854.8) 
1819.7  
(1527.9;2111.5) 
1739.5  
(1524.0;1955.1) 
1764.3  
(1494.1;2034.4) 
brain (g/ kg BW) 17.6  
(16.2;18.9) 
16.2  
(14.0;18.3) 
15.0*  
(13.4;16.6) 
14.8  
(12.9;16.8) 
hippocampus (mm2) 8.7 
(8.0;9.4) 
8.5  
(7.3;9.6) 
4.9*  
(4.1;5.6) 
4.9  
(4.1;5.7) 
Results 
Animal characteristics 
To test the therapeutic potential of G-CSF, we randomized 32 preterm sheep fetuses in 
four different experimental groups (Figure 1). After instrumentation and a recovery 
period of four days, animals were subjected to 25 min of (sham) umbilical cord occlu-
sion (UCO) to induce global hypoxia-ischemia (HI). G-CSF was administered during five 
consecutive days, starting one day before UCO (Figure 1). Fetal body weight and gesta-
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tional age at did not differ significantly between the four experimental groups (Table 1). 
We assessed mean arterial blood pressure (MABP), fetal heart rate (FHR) and blood 
gases during UCO to investigate the physiological response during (sham) global HI in 
the different experimental groups. MABP (Figure 2A), FHR (Figure 2B), pH (Figure 2C), 
arterial partial oxygen pressure (Figure 2D) and arterial partial carbon dioxide pressure 
(Figure 2E) were comparable between the HI-SAL and HI-G-CSF group, indicating that 
the degree of hypotension, bradycardia, acidosis, hypoxemia and hypercarboxemia was 
similar in all animals exposed to global HI.  
 
 
Figure 3. G-CSF induced mobilization of hematopoietic stem cells (HSC) within the therapeutic window of 
opportunity. (A) G-CSF induced marked mobilization of white blood cells (all treatment groups are shown. (B) 
G-CSF significantly increased the number of HSC (CD45/CD34 double positive) on experimental day 1 and 3. 
(C) G-CSF induced significant mobilization of neutrophils (CD45/CD11b double positive). (B-C) Saline treated 
animals (sham-SAL and HI-SAL) were compared with G-CSF treated animals (sham-G-CSF and HI-G-CSF), since 
white blood cell mobilization was altered by G-CSF treatment and not global HI. (A-C) medians ± interquartile 
ranges (IQR) of n=5 animals are depicted. * P≤0.05, ‡ P≤0.01, # P≤0.001. SAL = saline, G-CSF = granulocyte-
colony stimulating factor, HI = hypoxia-ischemia. 
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G-CSF mediated stem cell mobilization 
We assessed white blood cell (WBC) counts in arterial fetal blood to study G-CSF medi-
ated mobilization of these cells. G-CSF induced marked mobilization of white blood cells 
(Figure 3A), which peaked around experimental day 3, after four doses of G-CSF.  
 We aimed to mobilize endogenous stem cells within the first hours after global HI, 
which was considered the therapeutic window of opportunity [9]. Flow cytometry anal-
ysis of fetal blood showed that G-CSF did not significantly increase numbers of 
CD45/CD34 double positive cells on experimental day 0 (SAL vs. G-CSF, P=0.091), but 
CD45/CD34 double positive cells were significantly increased on experimental day 1 
(SAL vs. G-CSF, P=0.028) and day 3 (SAL vs. G-CSF, P=0.028) (Figure 3B).  
 These findings indicated that hematopoietic stem cells (HSC) were significantly 
mobilized 48 hours after the first dose of G-CSF. Since G-CSF therapy was initiated on 
experimental day -1, HSC were mobilized within the first 24 hours following global HI, 
which has previously been reported to correspond with the therapeutic window of 
opportunity [9]. In addition, flow cytometry demonstrated that G-CSF caused a pro-
found mobilization of CD11b+ neutrophils, which reached significance 48 hours after 
the first dose of G-CSF (Figure 3C). As expected, no changes were observed in the CD4+ 
and CD8+ T-cell subpopulations after G-CSF administration (data not shown). 
 To study placental transfer of G-CSF, we assessed mobilization of white blood cells 
in blood of the ewes. The numbers of white blood cells, neutrophils and HSC, were not 
altered in the maternal blood during the study period (data not shown), indicating that 
G-CSF, which was administered intravenously to the fetus, did not cross the placenta at 
sufficient levels to induce mobilization. 
G-CSF mediated effects on the spleen 
As previously reported [30], global HI induced splenic involution in saline treated ani-
mals (sham-SAL vs. HI-SAL, P=0.034) (Figure 4A), indicating HI-induced mobilization of 
splenocytes into the circulation. G-CSF significantly increased splenic weight (sham-SAL 
vs. sham-G-CSF, P<0.001) (Figure 4A). Despite the G-CSF mediated increase in splenic 
weight, global HI still caused splenic involution in G-CSF treated animals (sham-G-CSF 
vs. HI-G-CSF, P=0.028), indicating that global HI induced efflux of splenocytes in G-CSF 
treated animals. Immunohistochemical staining of neutrophils in the spleen showed 
that the area fraction of MPO immunoreactivity was significantly increased after G-CSF 
administration (sham-SAL vs. sham-G-CSF, P<0.010) (Figure 4B and C). The increased 
number of splenic neutrophils after G-CSF treatment may represent either increased 
mobilized neutrophils, which are present in the blood-filled red pulpa, or indicate in-
creased myeloid hematopoietic activity, which can still be present in the preterm 
spleen. In line with observations in the circulation, G-CSF did not alter the number of 
splenic T-cells (data not shown). 
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Figure 4. G-CSF increased splenic weight and number of splenic neutrophils. (A) G-CSF caused a significant 
increase in splenic weight in sham animals and animals exposed to global HI. Global HI induced significant 
splenic involution in both saline and G-CSF treated animals. Geometric means ± 95% CI and levels of 
significance are depicted, which were calculated with ANOVA (sham-SAL n=8, sham-G-CSF n=8, HI-SAL n=8, 
HI-G-CSF n=8) (B-C) G-CSF significantly increased the number of neutrophils in the spleen in sham and HI 
conditions. Means ± 95% CI and levels of significance are depicted, which were calculated by the random 
intercept model with all repeated measures (i.e. spleen sections) per animal (sham-SAL n=6, sham-G-CSF n=6, 
HI-SAL n=6, HI-G-CSF n=6). * P≤0.05, ‡ P≤0.01, # P≤0.001. SAL = saline, G-CSF = granulocyte-colony 
stimulating factor, HI = hypoxia-ischemia, IR = immunoreactivity, MPO = myeloperoxidase. Scale bars: 200 
µm. 
G-CSF treatment reduced cerebral inflammation 
The cerebral inflammatory response after global HI was studied by assessing microglial 
proliferation using ionized calcium binding adaptor molecule 1 (IBA-1), which is a highly 
specific marker for resting and activated microglia in sheep [30]. We performed im-
munohistochemical IBA-1 staining in 6 coronal brain sections at the mid-thalamus/ 
posterior hippocampus level per animal. Area fraction of IBA-1 immunoreactivity was 
assessed in six animals per experimental group (n=3 in the sham-G-CSF group). The 
response of microglia following global HI was assessed in the subcortical white matter 
(SCWM) and hippocampus, which are involved in motoric [1] and cognitive function, 
respectively [39].  
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Figure 5. G-CSF reduced cerebral inflammation in the subcortical white matter (SCWM), but not in the 
hippocampus after global HI. (A) Immunohistochemical IBA-1 staining in the SCWM of the four experimental 
groups. Global HI induced a profound increase of IBA-1 immunoreactivity, which was significantly reduced by 
G-CSF. (B) Immunohistochemical IBA-1 staining in the hippocampus of the four experimental groups. Global 
HI caused profound proliferation of microglia in the hippocampus. G-CSF did not reduce the inflammatory 
response of microglia in the hippocampus after global HI. (C-D) Area fraction of IBA-1 immunoreactivity in 
SCWM and hippocampus; geometric means ± 95% CI and levels of significance are depicted, which were 
calculated by the random intercept model with all repeated measures (i.e. brain sections) per animal (sham-
SAL n=6, sham-G-CSF n=3, HI-SAL n=6, HI-G-CSF n=6). * P≤0.05, ‡ P≤0.01, # P≤0.001. IBA-1 = ionized calcium 
binding adaptor molecule 1, HI = hypoxia-ischemia, SAL = saline, G-CSF = granulocyte-colony stimulating 
factor, IR = immunoreactivity. Scale bars: 1 mm. 
 
In line with previous results [30], global HI resulted in a significant (sham-SAL vs. HI-SAL; 
P<0.001) increase of IBA-1 immunoreactivity in the SCWM, indicating profound micro-
glial proliferation in this region (Figure 5A and C). In accordance, significantly (sham-SAL 
vs. HI-SAL; P<0.001) increased IBA-1 immunoreactivity was found in the hippocampus 
following global HI (Figure 5B and D). G-CSF significantly (HI-SAL vs. HI-G-CSF; P=0.028) 
reduced IBA-1 immunoreactivity in the SCWM (Figure 5A and C). G-CSF did not reduce 
IBA-1 immunoreactivity in the hippocampus (HI-SAL vs. HI-G-CSF; P=0.578) (Figure 5B 
and D). No differences in IBA-1 immunoreactivity were observed between saline or G-
CSF treated sham operated animals in the SCWM and hippocampus. 
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Figure 6. G-CSF reduced white matter injury. (A) Immunohistochemical MBP staining in the SCWM of the four 
experimental groups. The area fraction of MBP was similar between sham operated animals treated with 
saline or G-CSF. Global HI induced marked hypomyelination in the SCWM. G-CSF slightly increased 
myelination of the preterm brain after global HI (B) MBP immunoreactivity in SCWM; geometric means ± 95% 
CI and levels of significance are depicted, which were calculated by the random intercept model with all 
repeated measures (i.e. brain sections) per animal (sham-SAL n=6, sham-G-CSF n=3, HI-SAL n=6, HI-G-CSF 
n=6). * P≤0.05, ‡ P≤0.01, # P≤0.001. MBP = myelin basic protein 1, HI = hypoxia-ischemia, SAL = saline, G-CSF 
= granulocyte-colony stimulating factor, IR = immunoreactivity. Scale bars: 200 µm. 
G-CSF reduced white matter injury 
We studied histological white matter injury by assessing myelin binding protein (MBP) 
immunoreactivity in the SCWM. We performed immunohistochemical MBP staining in 6 
coronal brain sections at the mid-thalamus/ posterior hippocampus level per animal. 
MBP immunoreactivity was assessed in six animals per experimental group (n=3 in the 
sham-G-CSF group).  
 Global HI significantly (sham-SAL vs. HI-SAL; P<0.001) reduced MBP immunoreac-
tivity in the SCWM, indicating marked demyelination in this region (Figure 6A and B). G-
CSF treatment significantly increased MBP immunoreactivity (HI-SAL vs. HI-G-CSF; 
P=0.032) No differences in MBP immunoreactivity in the SCWM were observed be-
tween sham operated animals treated with saline or G-CSF (Figure 6A and B). 
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G-CSF treatment did not reduce seizure burden following global HI 
Global HI caused high electrographical seizure activity in the first 72 hours following the 
hypoxic-ischemic insult. Analysis of the first 72 hours showed that global HI significantly 
increased seizure burden (sham-SAL vs. HI-SAL: day 0; P=0.010, day 1; P=0.028, day 2; 
P=0.012). However, G-CSF treatment did not reduce the seizure burden after global HI 
(HI-SAL vs. HI-G-CSF; day 0; P=0.955, day 1; P=0.955, day 2; P=0.164). No differences in 
electrographical seizure activity were observed between sham operated animals treat-
ed with saline or G-CSF (Figure 7).  
 Furthermore, we studied neuronal injury by assessing brain weight and size of the 
hippocampus. Global HI induced profound atrophy of the brain (sham-SAL vs. HI-SAL; 
P=0.041) and hippocampus (sham-SAL vs. HI-SAL; P<0.001). G-CSF did not prevent glob-
al HI-induced atrophy in the brain (HI-SAL vs. HI-G-CSF; P=0.981) or the hippocampus 
(HI-SAL vs. HI-G-CSF; P=0.983) (Table 1). Brain weight and hippocampal area were sig-
nificantly related (Pearson r = 0.60, P=0.002). 
 
Figure 7. G-CSF did not reduce seizure burden after global HI. Global HI induced marked electrographic 
seizure activity, which peaked in the first 72 hours after the insult. G-CSF treatment did not reduce the 
number of seizures after global HI. Medians ± interquartile ranges (IQR) and levels of significance are 
depicted, which were calculated by Mann-Whitney test (sham-SAL n=6, sham-G-CSF n=4, HI-SAL n=6, HI-G-
CSF n=4). * P≤0.05, ‡ P≤0.01, # P≤0.001. SAL = saline, G-CSF = granulocyte-colony stimulating factor, HI = 
hypoxia-ischemia. 
Neutrophil invasion in the preterm brain after global HI was not enhanced by G-CSF 
To study whether the massive G-CSF mediated mobilization of neutrophils would cause 
a proportional influx of neutrophils in the brain, we qualitatively assessed brain sec-
tions for MPO-positive neutrophils. In the sham-G-CSF group, we observed a marked 
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increase in intravascular MPO-positive cells. However, the intravascular neutrophils 
observed in sham-G-CSF animals did not extravasate (Figure 8), indicating that the BBB 
was not permeable for the abundantly available neutrophils in the non-ischemic pre-
term brain. In accordance with our previous findings, we observed an increase in peri-
vascular and interstitial neutrophils after global HI in saline treated animals (Figure 8). 
In line with previous findings [40], G-CSF treatment did not enhance neutrophil invasion 
after global HI, despite the high numbers of neutrophils present inside the cerebral 
vasculature (Figure 8).  
 
Figure 8. G-CSF did not enhance neutrophil invasion in the preterm brain after global HI. G-CSF increased the 
number of intravascular (open arrows) in animals exposed to sham and global HI. Global HI increased 
invasion of neutrophils (black arrows), which was not further enhanced by G-CSF. Scale bars: 100 µm. SAL = 
saline, G-CSF = granulocyte-colony stimulating factor, HI = hypoxia-ischemia. 
Discussion 
Preterm infants with hypoxic-ischemic encephalopathy (HIE) often experience severe 
disorders in motor and cognitive function, for which there is no effective cure [1]. Alt-
hough granulocyte-colony stimulating factor (G-CSF) showed promising results in adult 
stroke [16, 33], there is conflicting data from rodent studies on the neuroprotective 
potential of G-CSF in neonatal brain after focal HI [22, 23]. In this study, we therefore 
assessed the neuroprotective potential of G-CSF treatment in the preterm brain in a 
translational ovine model of global hypoxic-ischemic injury. We aimed at mobilizing 
bone marrow-derived stem cells with G-CSF within the acute phase after global HI and 
therefore started G-CSF treatment 24 hours before the global hypoxic-ischemic insult. 
 We showed that human recombinant G-CSF effectively mobilized ovine hemato-
poietic stem cells (HSC) within the first 24 hours after global HI. These findings con-
firmed the presence of bone-marrow derived HSC in the systemic circulation in the 
acute phase following global HI, which has previously been suggested to coincide with 
the therapeutic window of opportunity for the repair of hypoxic-ischemic preterm brain 
injury [9]. HSC, mobilized by G-CSF, have been shown to migrate to the ischemic brain 
[20]. Although differentiation of HSC into neurons most likely occurs rarely [41], HSC 
have been shown to support neuronal repair by secreting neurotrophic factors in the 
ischemic brain [42]. Furthermore, G-CSF has been reported to promote the transition of 
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bone marrow-derived neural cells into the brain [12, 43]. Interestingly, the neuropro-
tective effect of G-CSF has been shown to be potentiated by additional treatment with 
stem cell factor (SCF) [12, 34]. Since G-CSF and SCF act synergistically on mobilization 
and proliferation of bone marrow-derived stem cells [44-46], the potentiated neuro-
protective effect was most likely explained by enhanced mobilization of hematopoietic 
stem cells and neural stem cells from the bone marrow. These findings underline that 
mobilization of endogenous bone-marrow derived stem cells is a feasible strategy to 
treat hypoxic-ischemic brain injury [12, 34, 43] 
 Despite effective mobilization of fetal HSC, administration of G-CSF to the fetus did 
not mobilize HSC in maternal blood, indicating that G-CSF did not pass the placenta at 
sufficient levels to induce mobilization. These findings indicate that a reversed admin-
istration route (mother to fetus) in the case of suspected intrauterine fetal asphyxia 
would most likely be ineffective in mobilizing neuroprotective fetal HSC. 
 We showed that the cerebral inflammatory response after global HI, initiated by 
microglia, was attenuated by G-CSF treatment. Although the mechanisms of action of 
G-CSF are not fully understood, the anti-inflammatory effect of G-CSF may be attribut-
ed to several mechanisms. First of all, G-CSF has been shown to induce tolerance of T-
cells [47-50], which have previously been reported to aggravate cerebral inflammation 
after invading the ischemic brain [9, 51-53]. Furthermore, previous studies demonstrat-
ed that G-CSF treatment increased the number of regulatory T cells [48, 54, 55], mye-
loid suppressor cells [54] and tolerogenic dendritic cells [50, 56]. These anti-
inflammatory effects of G-CSF on the peripheral immune system may dampen the pe-
ripheral inflammatory response after global HI, consequently reducing the second in-
flammatory hit to the preterm brain characterized by invading immune effector cells. In 
line with this concept, we found that cerebral invasion of neutrophils after global HI 
was not enhanced by G-CSF, despite the marked G-CSF-mediated mobilization of these 
immune effector cells. 
 Furthermore, we studied white matter injury since this is the clinical hallmark of 
HIE in preterm infants. We demonstrated that G-CSF reduced hypomyelination after 
global HI, which may be secondary to the G-CSF-mediated reduction of microglial acti-
vation after global HI, since it has been previously shown that activated microglia are 
injurious to pre-oligodendrocytes [57]. A second mechanism for increased myelination 
by G-CSF may be caused by G-CSF-mediated proliferation of intrinsic neural stem cells, 
which can replenish pre-oligodendrocytes [12, 58].  
 In the current study, G-CSF did not reduce the seizure burden after global HI, indi-
cating that neuronal function was not improved by this treatment. These findings are in 
line with the work of Schlager et al. showing that systemic G-CSF did not improve long-
term motor and cognitive function in a rat model of neonatal hypoxic-ischemic brain 
injury [22]. In contrast, other experimental studies have reported that G-CSF improved 
function after cerebral ischemia [25] and protected against neuronal injury by activat-
ing the anti-apoptotic pathway [58-60] and stimulating angiogenesis [61-63].  
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G-CSF has been shown to be neuroprotective in rodents models of stroke [33, 58, 63-
68] and is currently being investigated in stroke patients [16-20]. Nevertheless, there is 
conflicting evidence on the neuroprotective potential of G-CSF in the neonatal brain 
exposed to focal hypoxia-ischemia [21-26, 69]. This discrepancy may be explained by 
distinct effects of G-CSF on the developing brain in comparison to the adult brain and 
underlines the need for an animal model that is closely similar to the human situation 
in terms of neurodevelopment and the mechanism of injury when studying G-CSF in the 
preterm brain. Despite the fact that our data showed effective mobilization of HSC in 
preterm sheep, it is conceivable that in the preterm environment expression of the G-
CSF receptor on precursor cells in the bone marrow and neural cells in the brain has not 
yet reached its mature state and therefore mobilization of HSC and neuroprotection are 
suboptimal. A limitation of the treatment protocol in our study was that G-CSF admin-
istration was started prior to injury. Although this regimen was deliberately chosen as a 
proof of principle to mobilize endogenous stem cells within the acute time period fol-
lowing global HI, it did not allow assessment of the post injury treatment effect of G-
CSF, which would be clinically more relevant. Furthermore, we based the dosage of G-
CSF on previous studies that showed neuroprotective effects of G-CSF treatment in 
focal cerebral ischemia of the adult brain. The distinct causes of injury (global versus 
focal ischemia) and the different developmental stages of the adult versus the preterm 
brain may require different dosing strategies and therefore the dosage used in our 
study may be suboptimal.  
 In conclusion, we report that G-CSF treatment resulted in mobilization of endoge-
nous stem cells, which was associated with decreased cerebral inflammation and re-
duced white matter injury after global HI. G-CSF treatment, however, did not protect 
against acute HI-induced cerebral dysfunction as shown by seizure analysis. Our study 
shows that G-CSF treatment has the potential to attenuate structural injury in the pre-
term brain following global HI. Follow-up studies need to assess whether the observed 
structural improvements of the ischemic preterm brain mediated by G-CSF result in 
improved function on the long term, despite the fact that G-CSF did not reduce the 
initial seizure burden after global HI. Before any clinical translation, these studies 
should also address the mode of action of G-CSF in a developing environment similar to 
the human situation and optimize dosing and timing of administration.  
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Hypoxic-ischemic encephalopathy (HIE) in preterm infants is associated with high mor-
bidity, for which no therapeutic cure is available. Cell-based therapy is a promosing 
candidate to treat preterm infants suffering from hypoxic-ischemic brain injury. In this 
thesis the neuroprotective potential of cell-based therapy in the hypoxic-ischemic pre-
term brain was explored. For this purpose we established and validated a translational 
ovine model, which adequately mimicks the biology of the human preterm brain and 
the etiology of global hypoxia-ischemia.  
Impaired immature cerebrovascular regulatory system 
In chapter 2 we validated the translational model by assessing longitudinal function of 
the baroreceptor reflex in fetal sheep after 25 minutes of umbilical cord occlusion. The 
baroreflex is a vital part of the cerebrovascular autoregulatory system, which maintains 
adequate cerebral perfusion by adapting heart rate, myocardial contraction and vascu-
lar resistance when circulatory homeostasis is disturbed [1]. We hypothesized that 
adequate baroreflex function would be persistently disturbed by transient umbilical 
cord occlusion in fetal sheep. Our results confirmed our hypothesis. We showed that 
global hypoxia-ischemia disturbed optimal baroreflex function (i.e. heart rate mediated 
blood pressure control) as evidenced by an almost immediate and persistent decrease 
in heart rate variability following umbilical cord occlusion [2]. Disturbance of baroreflex 
sensitivity (ms/mm Hg) and increased delay between variations in heart rate and systol-
ic blood pressure became evident 72 hours after transient umbilical cord occlusion and 
persisted until the end of the experiment (one week), suggesting that global hypoxia–
ischemia caused long term deregulation of the baroreceptor reflex arc [2]. Remarkably, 
impaired baroreflex function did not cause apparent changes in systolic blood pressure 
in our experiments. This observation may be explained by the fact that circulatory ho-
meostasis was still maintained by adequate placental perfusion in the intra-uterine 
environment. It is conceivable that the damaged baroreflex function does not become 
clinically evident until after birth when circulatory homeostasis can no longer be sus-
tained by maternal support and solely depends on endogenous regulatory systems.  
 The baroreflex arc consists of baroreceptors in the aortic arch and carotid arteries, 
afferent signaling pathways, the nucleus of the solitary tract in the brain stem and sym-
pathetic and parasympathetic efferent signaling pathways. The observed functional 
disturbances in the baroreflex may thus be situated in various regions, since global 
hypoxia-ischemia may have affected all components of the baroreflex arc. We did nei-
ther assess histological injury of peripheral baroreceptors or nuclei in the brain stem, 
nor did we study function of signaling pathways. Nevertheless, based on previous stud-
ies showing brain stem injury after umbilical cord occlusion in association with short 
term disturbance of the baroreflex [3, 4], it seems plausible that central injury to the 
baroreflex arc plays a predominant role in the pathophysiology of impaired baroreflex 
function after global hypoxia-ischemia. 
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Figure 1: Global hypoxia-ischemia affected central and peripheral components involved in the baroreceptor 
reflex. CNS = central nervous system, la = left atrium, lv = left ventricle, ra = right atrium, rv = right ventricle, 
SA node = sinuatrial node. Adapted from McNeil, Neural Development 2010 [5].  
 
Interestingly, our data showed that baroreflex sensitivity increased during the study 
period, indicating that baroreflex function matures during gestation [2]. This observa-
tion is of high clinical relevance since it demonstrates that preterm infants are born 
with an immature cerebrovascular autoregulatory system, making them highly vulnera-
ble to blood pressure fluctuation and subsequent inadequate cerebral perfusion. 
 In conclusion, in chapter 2 we validated the translational ovine model of HIE by 
demonstrating that global hypoxia-ischemia disturbed normal development of the 
baroreflex causing long term impairment of the heart rate mediated blood pressure 
control. As a consequence, the preterm brain may be prone to blood pressure fluctua-
tions impairing optimal cerebral perfusion which aggravates hypoxic-ischemic injury 
already caused by global hypoxia-ischemia. 
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Cerebral inflammation and the peripheral immune system 
In chapter 3, we hypothesized that global hypoxia-ischemia by transient umbilical cord 
occlusion would induce a cerebral and peripheral inflammatory response similar to the 
one seen after local cerebral ischemia. In addition, we hypothesized that cerebral in-
flammation would be associated with white matter injury and suppression of brain 
function. These hypotheses were confirmed by our study. We demonstrated that global 
hypoxia-ischemia induced profound cerebral inflammation as shown by marked activa-
tion and proliferation of microglia, which play a key role in the initiation of the cerebral 
inflammatory response after injury [6]. The microglial response typically arises within 
24 hours after an ischemic insult [7-9]. Therefore, our data indicated that the first in-
flammatory hit to the preterm brain occurred early after global hypoxia-ischemia.  
 We showed for the first time that the peripheral immune system plays a pivotal 
role in the pathophysiology of HIE following global hypoxia-ischemia. Our findings 
demonstrated marked mobilization of white blood cells into the blood stream, which 
peaked within 24 hours after transient umbilical cord occlusion. Furthermore we ob-
served an influx of neutrophils into the ischemic brain, facilitated by disruption of the 
blood-brain barrier, which is known to occur after hypoxia-ischemia [10-15]. Neutrophil 
invasion has previously been shown to typically occur within 48-72 hours after cerebral 
ischemia [7-9]. Therefore, we postulated that the influx of these immune effector cells 
was a second inflammatory hit to the ischemic preterm brain. Based on our observation 
of splenic involution after global hypoxia-ischemia, which could not be explained by 
increased apoptosis of splenocytes, we postulated that the neutrophils invading the 
ischemic brain originated from the spleen. This concept is in line with previous findings 
showing that the spleen was the predominant source of brain invading neutrophils 
after local cerebral ischemia [16-18] and that splenectomy reduced neutrophil influx 
and microglial activation in the ischemic hemisphere [19]. The ischemic brain may sig-
nal to the spleen directly by the release of DAMPs (intracellular proteins, DNA, RNA, 
nucleotides, heat shock proteins and extracellular matrix protein such as hyaluronic 
acid) and pro-inflammatory cytokines or indirectly by efferent neural signaling or in-
creased activity of the hypothalamic–pituitary–adrenal (HPA) axis [20]. In utero splenic 
involution by depletion of immune cells may have important clinical consequences as 
this has been associated with an increased risk of postnatal infectious complications 
such as early onset sepsis [21, 22]. Furthermore, experimental evidence shows that 
antenatal inflammation leads to hyporesponsiveness of immune cells [23-28] which 
may also predispose to postnatal infection.  
 The cerebral and systemic inflammatory changes observed in our study were ac-
companied by marked white matter injury as evidenced by pre-oligodendrocyte injury 
and demyelination of the preterm brain. The pattern of white matter injury after tran-
sient umbilical cord occlusion was very similar to the pattern observed in clinical studies 
[1, 29], confirming the translational character of the animal model. Cerebral inflamma-
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tion and hypomyelination were associated with suppression of electrophysiological 
brain activity, a strong indicator of impaired brain function and poor clinical neurode-
velopmental outcome [30, 31].  
 
 
Figure 2. Hypoxia-ischemia and chorioamnionitis, two major upstream events causing brain 
injury, converge into a common inflammatory pathway. Global hypoxia-ischemia and 
chorioamnionitis are associated with release of brain-derived danger-associated molecular 
patterns (DAMPs) and pathogen-associated molecular patters (PAMPs), respectively. Upon 
detecting DAMPs and/or PAMPs microglia become activated causing a first inflammatory hit 
to the preterm brain. In addition, systemic DAMPs and PAMPs cause activation and 
mobilization of the peripheral immune system again converging into a common peripheral 
inflammatory response or fetal inflammatory response syndrome (FIRS) which forms a second 
hit to the preterm brain. 
In conclusion, in chapter 3 we provided evidence for a two-stepped inflammatory re-
sponse damaging the preterm brain after global hypoxia-ischemia; with an early in-
flammatory hit mediated by microglia and a second inflammatory hit mediated by 
spleen-derived immune effector cells invading the ischemic preterm brain. The cross-
chorioamnionitishypoxia-ischemia
PAMPs
DAMPs
FIRS
microglia
CEREBRAL INFLAMMATION
brain
immune system
activation and mobilization of
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talk between the preterm brain and the peripheral immune system adds a new concept 
to the understanding of the pathophysiology of hypoxic-ischemic encephalopathy in 
prematurity and is in accordance with the current understanding that the immature 
immune system is capable of mounting an immune response in the face of high levels 
of danger, as is the case following profound global hypoxia-ischemia.  
 We postulate that the pathophysiology of global hypoxia-ischemia shares a com-
mon etiology with chorioamnionitis when considering the cerebral and peripheral in-
flammatory response (Figure 2). Chorioamnionitis similarly induces a cerebral inflam-
matory response [32, 33]. However, in chorioamnionitis (or fetal sepsis) microglia are 
not activated by local release of DAMPs, but instead microglia may become activated 
after sensing pathogen-associated molecular patterns (PAMPs) associated with chori-
oamnionitis or sepsis [29, 34]. Moreover, PAMPs have been shown to activate and 
mobilize the fetal immune system [24, 25, 28, 35, 36] resulting in a peripheral immune 
response, referred to as the fetal inflammatory response syndrome (FIRS). As in the 
pathophysiology of global hypoxia-ischemia the peripheral immune response forms a 
second inflammatory hit to the preterm brain [33].  
Exogenous stem cells 
In chapter 4, we further elaborated on our findings that inflammation and cellular de-
generation play a key role in the pathophysiology of hypoxic-ischemic encephalopathy 
(Figure 2) by addressing these pathogenic processes in an intervention study. We stud-
ied the neuroprotective potential of exogenous administration of MSCs to repair the 
ischemic preterm brain. We hypothesized that intravenously administered human 
bone-marrow derived MSCs would be neuroprotective by inhibiting the cerebral and 
peripheral inflammatory response and stimulate regeneration of injured cells after 
global hypoxia-ischemia (Figure 3). We tested this hypothesis in our translational ani-
mal model of hypoxic-ischemic preterm brain injury. MSCs were infused intravenously, 
to test effectiveness of MSC therapy using a clinically feasible administration route.  
 We found that MSCs reduced cerebral inflammation as evidenced by decreased 
activation and proliferation of microglia, which are typically activated early after global 
HI [7, 37]. Besides inhibition of microglial activation, we postulate that MSCs reduced 
cerebral inflammation by inducing a microglial type switch from a pro-inflammatory M1 
phenotype to a M2 phenotype which has been shown to reduce cerebral inflammation 
[38, 39] and promote oligodendrocyte differentiation towards mature myelin-
producing oligodendrocytes [40]. This concept is in line with previous work that showed 
increased M2/M1 microglia ratio in the brain after transplantation of multipotent adult 
progenitor cells (MAPCs) [38], which can be considered as a subpopulation of MSCs 
with potent anti-inflammatory and regenerative capacities [38, 41-47].  
 In line with our previous findings in chapter 3, we showed that global hypoxia-
ischemia induced a marked loss of preOLs, which was paralleled by hypomyelination of 
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the preterm brain. In chapter 4 we extended these findings using diffusion tensor imag-
ing (DTI), a commonly used clinical diagnostic tool to assess white matter injury in the 
preterm brain [48-50]. DTI confirmed breakdown of white matter organization as evi-
denced by decreased fractional anisotropy (FA) values after global hypoxia-ischemia, 
which is in accordance with clinical evidence [50]. Remarkably, intravenous MSCs re-
duced histological white matter injury, which was confirmed with DTI.  
 
 
Figure 3. Hypothesis of MSC intervention study. MSCs dampen the microglia-mediated cerebral 
inflammation, which reduces signaling to the peripheral immune system. Secondly, MSCs inhibit activation of 
peripheral immune effector cells which prevents mobilization and invasion of these cells into the ischemic 
brain. Reducing the cerebral and peripheral inflammatory response will diminish brain injury. In addition, 
MSCs promote regeneration of oligodendrocytes and neurons, which improves myelination and functional 
outcome, respectively.  
 
We postulate that the protective effects of MSCs on white matter were attributed to 
various mechanisms. First, MSCs reduced cerebral inflammation mediated by microglia, 
which have been shown to directly cause injury to preOLs [51]. Although we did not 
study these direct effects, preOL density and myelination in the subcortical white mat-
ter were inversely related to proliferation of microglia in our study. These results sug-
gest that a reduction in microglial proliferation mediated by MSCs was associated with 
less injury to preOLs. Secondly, replenishment of preOLs by MSCs was considered to be 
attributed to regeneration of lost preOLs and re-activation of arrested oligodendrocyte 
maturation. This concept is supported by in vitro data showing that MSCs stimulate 
neural progenitor cells to differentiate towards the oligodendrocyte lineage [52, 53] 
and in vivo data demonstrating MSC-mediated remyelination of the ischemic brain [54]. 
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Thirdly, MSCs may have induced remyelination indirectly by increasing the M2/M1 
microglia ratio which has been shown to promote oligodendrocyte regeneration and 
differentiation [40].  
 
 
Figure 4. Dual effect of MSCs in two-stepped pathophysiology in hypoxic-ischemic encephalopathy of 
prematurity. I. Initial cerebral inflammatory response after global hypoxia-ischemia mediated by microglia. II. 
Second peripheral inflammatory response mediated by mobilized immune effector cells, which aggravate 
cerebral inflammation and concomitant brain injury after global hypoxia-ischemia. 1a. MSCs dampen the first 
inflammatory hit by reducing microglial activation, 1b. MSCs dampen the second hit by inducing tolerance of 
immune effector cells, thereby reducing mobilization and invasion of these cells into the preterm brain. 2. 
MSCs promote regeneration of pre-oligodendrocytes 
 
We hypothesized that the anti-inflammatory effect of MSCs would not only consist of 
reducing the first inflammatory hit mediated by microglia, but that additionally MSCs 
would prevent the second inflammatory hit mediated by invasion of mobilized immune 
effector cells from the peripheral immune system. Therefore, we studied modulation of 
the peripheral T-cell response and subsequent invasion of these cells into the ischemic 
preterm brain. Our findings showed that proliferation capacity of splenic T-cells was 
inhibited in animals that had received MSCs, suggesting that MSCs induced persistent 
tolerance of T-cells in vivo. Furthermore invasion of T-cells into the ischemic brain was 
markedly reduced my MSCs. Based on these findings, we hypothesize that sequestered 
MSCs induced splenic helper T-cell tolerance. Unresponsive splenic T-cells were consid-
ered to be less receptive to danger signals (DAMPs, pro-inflammatory cytokines, neural 
signaling) from the ischemic preterm brain. As a consequence, tolerant T-cells are not 
mobilized, which prevents a second inflammatory hit mediated by invasion of these 
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immune effector cells in the ischemic brain. Moreover, MSCs are considered to have an 
additional immunomodulating effect by inducing differentiation of naïve T-cells into 
regulatory T-cells (Tregs) [55, 56], which have been shown to play a key role in neuro-
protective immunomodulation following cerebral ischemia [17, 57, 58]. 
 Our findings in chapter 3 suggested a central role for the spleen in the patho-
physiology of preterm brain injury after global hypoxia-ischemia by providing immune 
cells that aggravate cerebral inflammation. Consistently, in chapter 4 we provided evi-
dence that modulation of the splenic inflammatory response plays a pivotal role in the 
neuroprotective effect of MSCs after global hypoxia-ischemia. The concept of the 
spleen as a key mediator of neuroprotection by stem cell therapy is supported by pre-
vious findings indicating that MAPC-splenocyte contact was needed to modulate micro-
glia activation [38]. Moreover, MAPC increased the number of splenic and systemic 
Tregs and concordantly induced a type switch of microglia towards an anti-
inflammatory phenotype [38]. 
 To study engraftment of MSCs in the preterm brain after transplantation, we used 
a human specific Y-chromosome fluorescent in-situ hybridization (FISH) probe to detect 
male human MSCs in the ovine preterm brain. In line with findings from literature [59, 
60], we detected very few MSCs in the brain one week after intravenous administra-
tion. At the end of the study period we observed marked neuroprotective effects of 
MSCs, while only a minor proportion of MSCs was detectable, indicated that the thera-
peutic effect of MSCs lasted longer than their presence. This phenomenon could be 
explained by several mechanisms. First of all, intravenously administered MSCs have 
been shown to engraft in the ischemic brain [61, 62]. MSCs are considered to transmi-
grate across the BBB either through the paracellular or transcellular pathways as in 
leukocyte diapedesis [61-64]. Although paracellular transmigration by MSCs in the pre-
term brain may be facilitated by immature tight junctions between endothelial cells of 
the cerebral vasculature, the efficiency of MSC transmigration across the BBB is still a 
matter of debate and therefore mandates further research [61, 62]. Considering that 
MSCs are capable of reaching the ischemic brain, it is conceivable that in our study 
intravenously administered MSCs invaded the ischemic preterm brain but perished 
within a few days after they established sustained immunomodulation and regenera-
tion. The second explanation for the observation that the therapeutic effect of MSCs 
lasted longer than their presence could be that MSC invasion into the ischemic preterm 
brain is actually marginal in the first place and MSCs rather exert their therapeutic ef-
fect in a long-distance fashion by secreting neuroprotective soluble factors while they 
are circulating, trapped in the lung or sequestrated in the spleen. This concept is sup-
ported by findings demonstrating that intravenously administered MSCs got trapped in 
the lung, but still mediated cardiac protection after myocardial infarction by secreting 
anti-inflammatory proteins [59]. In line, we detected the transplanted MSCs in lung and 
spleen tissue by PCR for human-specific β-2 microglobulin. 
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In conclusion, in chapter 4 we demonstrated that intravenous administration of MSCs 
are neuroprotective for the preterm brain after severe global hypoxia-ischemia. Our 
findings indicated that the therapeutic effect was established (1) by dampening the 
cerebral and peripheral inflammatory response and (2) by establishing regeneration of 
oligodendrocytes. Importantly, we showed that the anti-inflammatory and proliferative 
effects of MSCs were associated with functional improvement in the preterm brain. 
 In summary of chapter 3 and 4, we provided evidence that MSCs established a dual 
effect (anti-inflammatory and regenerative) in the two-stepped (first hit, second hit) 
pathophysiology of global hypoxia-ischemia (Figure 4). The first hit after global hypoxia 
ischemia is attributed to microglial activation. The second hit is caused by the peripher-
al immune response. MSCs modulate inflammation by dampening the hit to the pre-
term brain by reducing microglial activation and by reducing mobilization of the im-
mune effector cells that form the second inflammatory hit to the preterm brain. In 
addition MSCs induce regeneration of vulnerable pre-oligodendrocytes leading to res-
toration of white matter after injury. 
Endogenous stem cells 
In chapter 4, we showed that exogenous administration of MSCs established functional 
neuroprotection and dampened the cerebral and systemic inflammatory response. In 
chapter 5, we explored whether mobilization of endogenous stem cells by G-CSF would 
establish similar neuroprotection in the preterm brain after global hypoxia-ischemia. 
The growth-directed environment in preterm infants makes them excellent candidates 
for such an approach aimed at stimulating the endogenous regenerative potential, 
since in preterm infants the brain and other organs possess high numbers of stem cells 
[65-67]. A pharmacological intervention able to promote proliferation and mobilization 
of these stem cells after injury would have high therapeutic potential. Moreover, such a 
pharmacological therapy would circumvent biological risks, logistics and costs, which 
remain potential obstacles for exogenous stem cell therapy [68].  
 In chapter 4, we found that MSCs were neuroprotective when administered early 
after global hypoxia-ischemia [69]. These results indicated that the therapeutic window 
of opportunity for neuroprotection after global hypoxia-ischemia corresponded with 
the first hours after the insult. In the current study, we aimed at mobilizing endogenous 
stem cells by G-CSF within the same timeframe after global hypoxia-ischemia. There-
fore, we started G-CSF treatment one day before global hypoxia-ischemia to ascertain 
that mobilized endogenous stem cells were readily available within the therapeutic 
window of opportunity. This study design was deliberately chosen as a proof-of-
principle approach; we first wanted to proof the therapeutic effect of G-CSF with opti-
mal timing of stem cell mobilization and future studies would need to assess effective-
ness in a clinically more relevant post-injury treatment approach. G-CSF was chosen in 
this study for several reasons. G-CSF is a registered drug for the use in neonatal and 
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pediatric patients with neutropenia [70-72], which has been shown to mobilize neuro-
protective hematopoietic stem cells (HSCs) and stimulate proliferation of endogenous 
neural progenitor cells (NPCs) [73]. In addition, previous studies have shown that G-CSF 
also has direct neuroprotective effects [74-79].  
 
 
Figure 5. The postulated neuroprotective effects of G-CSF. (1) The direct neuroprotective effect of G-CSF 
involves reduction of neural apoptosis and stimulation of angiogenesis in the ischemic brain. The indirect 
neuroprotective effects of G-CSF consist of (2) mobilization of bone-marrow derived HSCs and other stem cells 
with regenerative, angiogenic and anti-inflammatory properties and (3) modulation of the peripheral 
immune response by inducing T-cell and DC tolerance and increasing the number of regulatory T-cells and 
myeloid suppressor cells (MDSC). G-CSF = granulocyte-colony stimulating factor, HSCs = hematopoietic stem 
cells, MSCs = mesenchymal stem cells, NPCs = neural progenitor cells, EPCs = endothelial progenitor cells 
 
We hypothesized that systemic G-CSF treatment would reduce white matter injury and 
improve electrophysiological brain function in our translational sheep model of hypox-
ic-ischemic preterm brain injury. Our results showed that human recombinant G-CSF 
effectively mobilized ovine HSCs within the therapeutic window of opportunity, which 
coincides with the first 24 hours after global hypoxia-ischemia [69]. We had anticipated 
that G-CSF would be able to cross the placenta, which would have created an eligible 
chance to protect the preterm brain by a reversed administration route (mother to 
fetus) in the case of suspected intrauterine asphyxia. However, administration of G-CSF 
G-CSF
brain
immune system
T-cell tolerance
↑Treg, MDSC, tolerogenic DCsHSCs (MSCs, NPCs, EPCs)
bone-marrow
↑ neuroregeneration
↑ angiogenesis
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to the fetus did not mobilize HSCs in maternal blood, indicating that G-CSF did not pass 
the placenta at sufficient levels to induce mobilization [80].  
 Our findings showed that G-CSF attenuated white matter injury in the preterm 
brain following global hypoxia-ischemia as demonstrated by reduced loss of pre-
oligodendrocytes and reduced hypomyelination [80]. We postulated that this neuro-
protective effect could be attributed to the direct pharmacological effect of G-CSF in 
the ischemic brain and indirect effects via G-CSF mediated mobilization of stem cells 
from the bone-marrow and modulation of the peripheral immune system (Figure 5).  
 G-CSF can exert direct pharmacological effects in the brain since it is able to pene-
trate the blood-brain barrier (BBB) [75]. G-CSF directly activates the anti-apoptotic 
pathway through activation of various intracellular signaling cascades, including the 
activation of bcl-2 [74-76]. The anti-apoptotic effect of G-CSF may account for the re-
duced loss of pre-oligodendrocytes, which have been shown to become apoptotic after 
global hypoxia-ischemia [6]. G-CSF preferentially mobilizes HSCs from the bone-marrow 
[81-83]. Interestingly, previous reports have shown concomitant mobilization of MSCs 
[84, 85] and neural progenitor cells (NPCs) [73, 86], which could potentiate the neuro-
protective effects of G-CSF. In addition, G-CSF has been shown to stimulate prolifera-
tion of intrinsic neural stem cells, which can replenish pre-oligodendrocytes [73, 75]. 
Mobilized HSCs have been shown to migrate to the ischemic brain [87], where these 
stem cells support neuronal repair by secreting neurotrophic factors in the ischemic 
brain [88] and adapt a neuronal phenotype [73, 86]. However, differentiation of HSCs 
into neurons is most likely a rare event [89] and therefore neuronal differentiation from 
mobilized HSCs is considered to reflect simultaneous mobilization of NPCs [73, 77, 86] 
or transdifferentiation of concomitantly mobilized MSCs into a neural phenotype [90-
92]. Furthermore, G-CSF may additionally increase the availability of endothelial pro-
genitor cells (EPCs), either by mobilization from the bone-marrow [77] or by differentia-
tion of HSCs into EPCs [93]. EPCs could play an important role after cerebral hypoxia-
ischemia by contributing to neovascularization [93-97]. Remarkably, the neuroprotec-
tive effect of G-CSF has been shown to be potentiated by additional treatment with 
stem cell factor (SCF) [73, 98], which synergistically increased mobilization and prolifer-
ation of bone marrow-derived HSCs and NPCs [99-101]. 
 We showed that G-CSF treatment attenuated the cerebral inflammatory response 
after global hypoxia-ischemia. We postulated that the anti-inflammatory effect of G-
CSF was attributed to direct inhibition of microglial activation (first hit) and indirect 
modulation of the peripheral immune response (second hit) after global hypoxia-
ischemia. Activated microglia are injurious to pre-oligodendrocytes [51] and therefore 
G-CSF mediated inhibition of microglial activation may contribute to reduction of hy-
pomyelination. G-CSF has been shown to modulate T-cell immunity by polarizing pro-
inflammatory Th1 cells to anti-inflammatory Th2 cells and induce tolerance of T-cells 
[102-105]. Furthermore, G-CSF has been shown to increase the number of regulatory T 
cells [103, 106, 107], myeloid suppressor cells [106] and tolerogenic dendritic cells [105, 
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108]. These processes may modulate the peripheral immune system towards a tolerant 
state preventing recruitment of peripheral immune effector cells, which constitutes the 
second inflammatory hit when these cells invade the preterm brain [6, 7, 69, 109, 110]. 
In line with this concept, we found that invasion of immune effector cells into the is-
chemic brain was attenuated by G-CSF [80]. In experimental neonatal hypoxia-ischemia, 
G-CSF decreased the activity of the hypothalamic–pituitary–adrenal (HPA) axis [111], 
which is known to modulate peripheral immune responses [20]. 
 Despite marked reduction of cerebral inflammation and decreased hypomye-
lination, G-CSF did not improve brain function as studied by seizure burden after global 
hypoxia-ischemia [80]. Since seizures predominantly occur in the acute phase following 
cerebral hypoxia-ischemia, increased seizure burden mainly indicated initial dysfunction 
of the brain. Seizure burden, however, is not a reliable measure for long-term function-
al performance, although seizures in neonatal HIE are associated with adverse neuro-
developmental outcome [112-114]. Therefore, follow-up studies need to assess wheth-
er the structural improvements that we observed in our study will actually result in 
improved function on the long term [80].  
 Since G-CSF showed such promising neuroprotection in rodent models of stroke 
[75, 79, 115-120], several clinical studies have been initiated in stroke patients [87, 121-
124]. The first results of those randomized placebo-controlled clinical trials disappoint-
ingly showed that G-CSF failed to improve the degree of disability or dependence in 
the daily activities of stroke patients [125]. However, there was a trend for reduced 
infarct growth and a significant decrease of interleukin-1 in the G-CSF group [125]. 
These results should not discourage future clinical trials investigating the neuroprotec-
tive effect of G-CSF in the preterm neonate with HIE, since our findings have indicated 
in a translational animal model that the endogenous regenerative capacity in the pre-
term environment could be enhanced by G-CSF. 
 In conclusion, we reported in chapter 5 that G-CSF-mediated mobilization of en-
dogenous stem cells attenuated cerebral inflammation and white matter injury in the 
preterm brain following global hypoxia-ischemia. However, seizure burden within the 
acute phase following ischemia was not reduced by G-CSF. Before clinical translation in 
preterm infants with HIE, future experimental studies should assess the effect of G-CSF 
on neurodevelopmental outcome in our translational model, which closely mimics the 
physiology of preterm infants and the etiology of HIE. 
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Future directions 
In this translational project, we transferred the clinical problem of preterm infants with 
HIE from bedside to bench. We developed an animal model, which mimicked the hu-
man situation as closely as possible and demonstrated that cell-based therapy has great 
potential to protect the preterm ischemic brain. Many questions, however, remain to 
be answered before cell-based therapy becomes an established treatment modality in 
neonatal medicine. 
 We have demonstrated that the peripheral immune system plays a pivotal role in 
the etiology of cerebral inflammation and white matter injury in the preterm brain after 
global hypoxia-ischemia. Future studies should further explore the temporal and spatial 
dynamics of the peripheral immune response. Our data indicated that the spleen may 
be the predominant source of mobilized immune effector cells that invade the brain 
and aggravate inflammation and injury. Splenectomy in our model could confirm this 
important cross-talk between the spleen and the preterm brain following global hypox-
ia-ischemia. Furthermore future experimental studies should further assess the cellular 
response in the peripheral immune system after global hypoxia-ischemia. In particular 
the role of T-cell immunity in global hypoxia-ischemia needs to be further explored. 
 We have shown neuroprotection by exogenous administration of MSCs within the 
acute phase after global hypoxia-ischemia. The regenerative effects of MSCs may be 
enhanced when a repetitive dose of MSCs is administered outside the acute window in 
which inflammation is initiated. This hypothesis needs to be tested in future studies. 
Dose-effect studies should be performed to optimize treatment effects of cell-based 
therapy for the ischemic preterm brain. Furthermore, we provided evidence that induc-
tion of T-cell tolerance by MSC might play an important role in the neuroprotective 
effects of MSCs in HIE. The exact mechanisms underlying the immunosuppressive ef-
fects of MSCs remain thus far largely unknown and therefore needs further exploration. 
Administration of labeled stem cells will give more insight in the distribution and migra-
tion of MSCs and will provide more detailed information on whether the anti-
inflammatory and regenerative effects of MSCs result from cell-cell contact, paracrine 
effects or a combination of both.  
 We have developed a translational model of ischemic preterm brain injury, which 
is a strong tool to test new therapies for preterm infants suffering from HIE. One im-
portant limitation of the current set-up of the model is the lack of long-term neurode-
velopmental outcome assessment. For this purpose, instrumented lambs would need 
to be delivered at a viable age and receive supportive care until they can sustain them-
selves independently. Cognitive and motoric evaluation tools would need to be devel-
oped to consequently follow up neurodevelopmental outcome in these animals. An-
other important drawback of the sheep model is that the possibility of genetic manipu-
lation and availability of sheep reactive antibodies is limited.  
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Ahead of us lies the challenge to translate our findings of neuroprotective cell-based 
therapy for the ischemic preterm brain from bench to bedside. Efficacy, safety and 
feasibility of cell-based therapy needs to be demonstrated before such an innovative 
intervention strategy becomes standard of care in preterm infants suffering from HIE. 
Our findings confirmed the efficacy of cell-based therapy in a preclinical animal model 
of preterm HIE, which needs to be confirmed in clinical trials in preterm infants with 
HIE. A recent meta-analysis confirmed the safety of MSC therapy for the treatment of 
cardiovascular, neurological and oncological/ hematological disease in a mixed popula-
tion of adult and pediatric patients and healthy volunteers [126]. Although these results 
are reaffirming concerning the safety of MSC therapy, more clinical data is required to 
confirm the safety of cell-based therapy in preterm infants. We consider allogeneic 
stem cell therapy as the most feasible cell-based therapy in perinatal medicine, since 
allogeneic cells can be used “off the shelf” in the acute setting of perinatal ischemic 
brain injury.  
 In conclusion, we showed in a translational animal model of HIE that cell-based 
therapy is partially effective in protecting the preterm brain against the detrimental 
cerebral and peripheral inflammatory response underlying white matter injury follow-
ing global hypoxia-ischemia. Our findings form the basis of future preclinical work and 
followed by clinical trials testing the neuroprotective potential of cell-based therapy in 
preterm infants with HIE. These endeavors create an eligible chance to improve the life 
of many preterm infants that suffer from hypoxic-ischemic brain injury. 
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Cell-based therapy for hypoxic-ischemic injury in the preterm brain 
Introduction 
Preterm infants are prone to hypoxic-ischemic encephalopathy. Unfortunately, no 
therapy exists to treat this brain injury. The objective of this translational research pro-
ject was (1) to study the role of the cerebral and peripheral inflammatory response in 
the etiology of preterm brain injury following global hypoxia-ischemia, and (2) to assess 
the neuroprotective effect of exogenous administration of stem cells and the mobiliza-
tion of endogenous stem cells in the preterm brain after global hypoxia-ischemia. 
Methods 
Instrumented preterm sheep were subjected to global hypoxia-ischemia by 25 minutes 
of umbilical cord occlusion at a gestational age of 104 (term is 150) days (± 32 weeks of 
human gestation). One hour after global hypoxia-ischemia animals were either treated 
with (1) exogenous mesenchymal stem cells (MSCs) or (2) mobilization of endogenous 
stem cells using granulocyte-colony stimulating factor (G-CSF). The study consisted of 
the treatmentgroups with appropriate controle groups. During a 7 day reperfusion 
period, all vital parameters, including (amplitude-integrated) electroencephalogram, 
were recorded. At the end of the experiment, the preterm brain was assessed using 
histology and diffusion tensor imaging (DTI). The effect of MSCs on the peripheral im-
mune system was assessed in a splenocyte proliferation assay. 
Results 
Our findings showed that global hypoxia-ischemia induced marked activation and pro-
liferation of microglia in the preterm brain. Furthermore, we observed mobilization of 
immune effector cells (T-cells and neutrophils), most likely originating from the spleen, 
that invaded the preterm brain. These pro-inflammatory changes were associated with 
loss of pre-oligodendrocytes and hypomyelination. Moreover, global hypoxia-ischemia 
caused persistent suppression of brain activity and a pronounced increase in the num-
ber of seizures. 
 Administration of exogenous mesenchymal stem cells (MSCs) reduced cerebral 
inflammation and white matter injury. MSCs induced T-cell tolerance, which was paral-
leled with diminished mobilization and invasion of these cells in the preterm brain. In 
addition, MSCs established functional improvement, as shown by decreased number of 
seizures after global hypoxia-ischemia. 
 Similarly, mobilization of endogenous stem cells using systemic granulocyte-colony 
stimulating factor (G-CSF) reduced cerebral inflammation and white matter injury. 
However, G-CSF did not reduce the number of seizures after global hypoxia-ischemia. 
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Conclusion 
We have shown in a translational animal model that cell-based therapy is effective in 
protecting the preterm brain against the cerebral and peripheral inflammatory re-
sponses that are involved in the etiology of white matter injury in the preterm brain 
after global hypoxia-ischemia. Our findings indicated that the administration of exoge-
nous MSCs in particular is an effective method to reduce hypoxic-ischemic injury in the 
preterm brain. Our studies form the basis for future clinical trials, which will study fea-
sibility of cell-based therapy in preterm infants with hypoxic-ischemic encephalopathy, 
creating an eligible chance to improve the life of many preterm infants that suffer from 
hypoxic-ischemic brain injury. 
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Celtherapie voor schade door zuurstofgebrek in het premature brein 
Introductie 
Hersenschade door zuurstofgebrek komt vaak voor bij premature pasgeborenen . He-
laas bestaat er vooralsnog geen therapie om deze schade te behandelen. Het doel van 
dit translationele project was (1) het onderzoeken van de rol van de cerebrale en peri-
fere ontstekingsresponse in het ontstaan van schade aan het premature brein na zuur-
stofgebrek en (2) het bestuderen van het beschermende effect van buitenaf toege-
diende stamcellen, dan wel mobilisatie van eigen stamcellen, op het premature brein 
na zuurstofgebrek. 
Methode 
Geinstrumenteerde premature schapen werden bij een draagtijd van 104 (à terme is 
150) dagen (± 32 weken humane zwangerschapsduur) in de baarmoeder blootgesteld 
aan zuurstofgebrek middels 25 minuten navelstrengcompressie. Kort na het zuurstof-
gebrek werden de dieren behandeld met (1) toediening van mesenchymale stamcellen 
(MSCs) of (2) met mobilisatie van lichaamseigen stamcellen middels granolocyte-colony 
stimulating factor (G-CSF). De studies bestonden uit de behandelgroepen en de ge-
schikte controle groepen. Gedurende een reperfusieperiode van 7 dagen werden ver-
volgens alle vitale parameters, inclusief hersenfilmpje (EEG), opgenomen. Het prematu-
re brein werd aan het einde van de studie beoordeeld middels histologie en diffusion 
tensor imaging (DTI), een geavanceerde MRI techniek. Het effect van MSCs op het peri-
fere immuunsysteem werd beoordeeld middels een kweek experiment waarin miltcel-
len uit alle studiegroepen werden gestimuleerd om te proliferen. 
Resultaten 
Onze resultaten lieten zien dat zuurstofgebrek uitgesproken activatie van microglia, de 
immuuncellen van het brein, teweeg bracht. Daarnaast zagen we mobilisatie van ont-
stekingscellen (T-cellen en neutrofiele granulocyten), waarschijnlijk afkomstig uit de 
milt, die het premature brein binnendrongen. Deze veranderingen gingen gepaard met 
verlies van pre-oligodendrocyten (witte stof producerende cellen) en verlies van witte 
stof in het premature brein. Bovendien veroorzaakte zuurstofgebrek blijvende onder-
drukking van de hersenactiviteit en een evidente toename van het aantal epileptische 
insulten (convulsies).  
 Toediening van MSCs van buitenaf verminderde ontsteking in de hersenen en witte 
stofschade. MSCs zorgden er voor dat ontstekingscellen niet meer reageerden op prik-
kels, hetgeen gepaard ging met verminderde mobilisatie en invasie van deze cellen in 
het premature brein. Tevens brachten MSCs functioneel herstel teweeg, hetgeen werd 
aangetoond door verminderde convulsies na zuurstofgebrek. 
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Mobilisatie van lichaamseigen stamcellen middels intraveneuze toediening van G-CSF 
reduceerde eveneens ontsteking in de hersenen en witte stofschade. Echter, G-CSF 
verminderde niet het aantal convulsies na zuurstofgebrek. 
Conclusie 
Wij hebben in een translationeel diermodel aangetoond dat celtherapie (toediening 
van MSCs en mobilisatie van lichaamseigen stamcellen middels G-CSF) in staat is het 
premature brein te beschermen tegen de ontstekingsrespons in het brein en de ontste-
kingsrespons van het perifere immuunsystem die beide ten grondslag liggen aan witte 
stof schade in het premature brein na zuurstofgebrek. Onze resultaten laten zien dat 
met name het toedienen van MSCs een effectieve methode is om hersenschade door 
zuurstofgebrek in het premature brein te verminderen. Onze studies vormen het fun-
dament voor toekomstige klinische studies waarin de toepasbaarheid van celtherapie 
voor hersenschade bij premature pasgeborenen onderzocht gaat worden. Met deze 
inspanningen kunnen we in de toekomst mogelijk het leven van vele premature kin-
deren met hersenschade verbeteren. 
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Relevance 
This thesis addresses a huge health care problem. The project is aimed at developing a 
therapy for preterm babies with brain injury. Brain injury is the biggest contributor to 
perinatal mortality and long-term morbidity in preterm infants [1, 2]. The magnitude of 
the problem of prematurity and brain injury on a societal scale is illustrated by the large 
impact on the health care budget. Health care costs for preterm birth are inversely 
related with gestational age [3]. In Finland for example, health care costs of preterm 
birth in the first two years of life have been estimated to be around 100.000,- EUR for 
each surviving preterm infants (< 1000 g) compared to 3.000,- EUR for normal birth 
weight children [4]. Two thirds of these costs consist of initial hospitalization costs [4]. 
Initial hospitalization costs can increase up to 250.000, - EUR in extremely preterm 
infants born around 25 weeks of gestation [3, 5]. These extremely preterm infants are 
usually in hospital for a mean of one hundred days with an average of 45 days on 
intensive care or high care, which costs around 2.500,- EUR per infant per day [6]. 
Furthermore, initial hospitalization costs are related to the degree of surgical 
intervention and the intensity of assisted ventilation [3]. Inevitably, neonatal costs of 
surviving children are higher than for those infants who die [3]. Longer term economic 
costs of preterm birth after the neonatal period are associated with re-hospitalization, 
medical aids, outpatient visits, medical and non-medical therapy, special education and 
day care and have a great impact on the health care budget [3, 5]. Brain injury and 
consecutive developmental disabilities are the most important contributors to 
economic life time costs of prematurity. A study by the Centers for Disease Control and 
Prevention in the United States calculated life time economic costs per infant of 
1.000.000 USD for mental retardation, 920.000 USD for cerebral palsy, 420.000 USD for 
hearing loss and 570.000 USD for vision impairment [7]. A Danish study estimated the 
life time economic costs of cerebral palsy to be around 800.000 EUR per patient [8] 
 Besides a huge financial burden for society, preterm birth and brain injury pose an 
enormous financial burden on families of patients [3, 5]. Parents of preterm infants are 
confronted with increasing out of pocket expenses which are not covered by their 
insurance. These expenses are predominantly caused by transportation, child care for 
siblings and accommodation during hospitalization [3]. In addition, parents of preterm 
infants often have to reduce their number of working hours which leaves them with 
significant wage losses [3-5]. 
 It is evident that preterm birth is not merely a financial burden to society and 
families, it has a huge impact on the emotional well-being of patients, siblings and 
parents [3, 5, 9]. Mothers of preterm infants are at high risk to develop postpartum 
depression caused by stress and disappointment of the early birth, self-reproaches, the 
separation from their fragile child with only limited opportunities to interact, the 
ongoing medical crisis and the possibility of death or continued health and 
developmental problems of their child [9]. On the longer term parents of preterm 
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infants are at higher risk to get divorced and loose friends and social activities, this risk 
significantly increases when the child is handicapped [10]. The enormous familial 
burden of preterm birth stresses the need for family centered care in perinatal 
medicine. 
 Fortunately, health care in perinatology has made huge steps in the last decades, 
which has improved outcome in preterm infants. As a consequence of enhanced 
perinatal care, the boundary of survival has shifted to earlier age. This shift comes at a 
cost, since chances of event-free survival are low in extreme prematurity. The most 
important disabling sequelae of prematurity are related to injury to the vulnerable 
immature brain. It can be expected that neurological outcome will be improved with 
ongoing reduction of risk factors for brain injury, such as prevention of preterm birth in 
the first place, growth retardation, infection, circulatory and ventilator disturbances by 
mechanical ventilation. Nevertheless a certain degree of brain injury reversely related 
to gestational age will always be associated with prematurity. The preceding 
emphasizes the strong need for neuroprotective therapy for preterm infants with brain 
injury. 
Therapeutic strategy 
Given the large impact on a societal and familial scale and the high incidence of 
neurodevelopmental complications, it is of utmost importance to accelerate the 
development of brain protective strategies for preterm infants. Therefore, the general 
objective of this thesis is to develop a therapy for preterm babies with brain injury, for 
whom currently there is no cure. In this thesis, we have studied the neuroprotective 
effects of cell-based therapy in the preterm brain. An innovative therapeutic strategy 
such as cell-based therapy for brain injury in the preterm brain must be first tested for 
efficacy and safety in an animal model before clinical application. We have established 
a reproducible translational animal model for white matter disease induced by global 
hypoxia-ischemia in fetal sheep. This animal model has important advantages over 
other potential species, since the developmental biology and the physiology of the fetal 
lamb closely resemble humans and the model allows complex fetal surgery. In this 
model we established clinical read-out parameters such as diffusion tensor imaging and 
amplitude integrated EEG. These elements provide a reliable clinical platform for the 
investigation of drugs for potential use in humans.  
 Our findings showed the reproducibility of our model and that global hypoxia-
ischemia induced marked activation and proliferation of microglia in the preterm brain 
[11, 12]. Furthermore, we observed mobilization of immune effector cells (T-cells and 
neutrophils), most likely originating from the spleen, that invaded the preterm brain 
[11, 13]. These pro-inflammatory changes, which are initiated within hours after the 
ischemic insult, were associated with loss of pre-oligodendrocytes and hypomyelination 
[11]. Moreover, global hypoxia-ischemia caused persistent suppression of brain activity 
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and a pronounced increase in the number of seizures [11, 13, 14]. Administration of 
exogenous mesenchymal stem cells (MSCs) reduced cerebral inflammation and white 
matter injury. MSCs prevented severness of the inflammation and induced T-cell 
tolerance, which was paralleled with diminished mobilization and invasion of these cells 
in the preterm brain [13]. In addition, MSCs established functional improvement, as 
shown by decreased number of seizures after global hypoxia-ischemia [13]. Similarly, 
mobilization of endogenous stem cells using systemic granulocyte-colony stimulating 
factor (G-CSF) administration reduced cerebral inflammation and white matter injury 
[14]. However, G-CSF did not reduce the number of seizures after global hypoxia-
ischemia [14]. 
 In conclusion, we have shown that cell-based therapy can be effective in protecting 
the preterm brain against the cerebral and peripheral inflammatory responses that are 
involved in the etiology of white matter injury. Our findings indicated that cell-based 
therapy may become an effective method to reduce white matter injury in the preterm 
brain.  
Target groups 
The patient group that we intend to target with this research primarily consists of 
preterm babies that suffer from brain injury caused by antepartum, peripartum or 
postpartum perinatal hypoxia-ischemia. In addition, term babies that suffer from brain 
injury may also benefit from the findings of this project. Although cooling therapy has 
been shown to improve neurodevelopmental outcome in mild to moderate cases of 
brain injury in term infants, cell-based therapy may enhance neuroprotection in these 
cases. In addition, severe cases of hypoxic-ischemic brain injury in term infants have 
been shown not to benefit from cooling. Cell-based therapy may provide 
neuroprotective potential in these term infants with severe brain damage.  
 The outcome of this innovative project is of high interest for a broad spectrum of 
clinicians, such as obstetricians, perinatologists, neonatologists, pediatric intensive care 
specialists, child neurologists and rehabilitation physicians, who focus on the 
neuroprotection of the developing brain and improving neurodevelopmental outcome 
for preterm infants suffering from white matter disease. 
 Basic scientists will benefit from the knowledge on the basic mechanisms of white 
matter disease in the preterm brain that has been acquired in our clinically relevant 
animal model. Neuroscientists can adopt the findings of our study and investigate the 
therapeutic effect of cell-based therapy into more detail. Additionally, in vitro or ex-
vivo (co-)culture studies will further unravel the neuroprotective properties of MSCs 
and G-CSF. Furthermore, in our model, we have established an array of outcome 
parameters including brain histology, functional immunological cell-culture assays, 
diffusion tensor imaging techniques and brain activity monitoring by (amplitude-
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integrated) electroencephalogram. These outcome parameters can be adopted by 
other research groups for experimental purposes and to improve clinical practice. 
 Due to the close similarity with the human situation, the sheep model has a track 
record of translation of experimental findings into neonatal medicine, for example in 
neonatal neurology (e.g. cooling therapy in term infants) and neonatal respiratory care 
(e.g. ventilation strategies and surfactant administration). Therefore, translational 
neuroscientists and clinical trial scientists can use the preclinical data gained in our 
study as a template for the design of future clinical trials.  
Spin-off activities and products 
The potential spin-off of this innovative research project is considerable. Understanding 
the basic mechanisms of disease and the therapeutic mechanisms of cell based therapy 
creates new insights in disease processes and provides exciting opportunities for the 
development of therapies. The concept of cell-based therapy for hypoxic-ischemic 
injury in the preterm brain presented in this thesis can be further developed and 
commercialized by (spin-off) companies that provide the tools (i.e. the cells) and 
support the logistics of clinical implementation (i.e. initiating clinical trials). 
 Before clinical translation, a number of activities and products need to be 
developed. Stem cell products need to be manufactured in closed systems under Good 
Manufacturing Practice (GMP). Quality control and assurance need to be firmly 
embedded in the process of developing GMP stem cell products. This demands the set-
up of an infra-structure with clean rooms, closed culturing systems and GMP laboratory 
facilities. Standard operating procedures (SOP) have to be developed. The 
Investigational Medicinal Product Dossier (IMPD), which is the basis for approval of 
clinical trials in Europe, has to be written. Permission for a clinical trial needs to be 
obtained from the Central Committee on Research Involving Human Subjects (Centrale 
Commissie Mensgebonden Onderzoek; CCMO). Intellectual property or first to market 
principle may be claimed to protect the developed stem cell product. The 
commercialization of the stem cell product requires the writing of a business plan, 
market research and estimation of production costs and target earnings. Fund raising 
activities can be organized to raise awareness for prematurity and neurodevelopmental 
disability and to obtain sponsorship for further research. 
 The road to clinical translation of cell-based therapy for brain injury in preterm 
infants involves many steps for which our group has the adequate infrastructure in our 
institute supported by our cross-disciplinary network of international collaborators. As 
such, Maastricht University Medical Center could play a leading role as a center of 
excellence for neonatal cell-based therapy in the Benelux and the Euregion. 
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Innovation 
This thesis presents an innovative approach to develop a state-of-the-art therapy for 
preterm babies with brain injury. We adopted a translational strategy by first taking the 
clinical problem of brain injury in preterm infants from bedside to bench. First, we 
developed a translational animal model of brain injury induced by global hypoxia-
ischemia in preterm sheep, which closely mimics the human situation and used read-
out parameters which are common practice in daily clinical care. [11, 12]. Second, we 
studied the potential underlying mechanisms of brain injury in the preterm brain to 
identify targets for therapy. We identified the reduction of neuroinflammation and 
support of regeneration as two principal targets to prevent brain injury in the preterm 
brain [11]. Consistently, we explored the neuroprotective potential of different types of 
cell-based therapies in our ovine model and assessed whether their anti-inflammatory 
and regenerative properties improved the structural and functional outcome of the 
preterm brain [13, 14]. Our findings indicated that cell-based therapy may become an 
effective method to reduce white matter injury in the preterm brain [13].  
 Now that we have shown the effectiveness of cell-based therapy in a highly 
relevant animal model of preterm brain injury, it is time to make the translational step 
from bench to bed and assess the neuroprotective potential of stem cell therapy in 
clinical trials. We aim to prevent the progression of brain injury as early as possible by 
reducing inflammation and stimulating regeneration early after the ischemic insult. This 
creates the opportunity to treat white matter disease in the earliest possible window of 
therapeutic opportunity. These endeavors create an eligible chance to improve the life 
of many preterm infants that suffer from brain injury thereby increasing disability-free 
lives. 
Scope 
The first steps towards clinical implementation of cell-based therapy for hypoxic-
ischemic injury in the preterm brain have been taken. If clinical application reaffirms 
the experimental promises of regenerative medicine, it may still take a decade before 
this innovative therapy becomes standard of clinical care. 
 Translation from bench to bedside mandates proof of effect and safety in a clinical 
setting. We have shown in our translational animal model that stem cell therapy 
induces short-term improvement in structure and function of the preterm brain. The 
long-term therapeutic effects of cell-based therapy for hypoxic-ischemic injury in the 
preterm brain remain to be determined. Can we improve the motor skills of affected 
preterm infants? Can their school and social performance be improved? All these 
questions remain to be answered. Concerning the safety of stem cell therapy, several 
studies have shown the genetic stability of therapeutic stem cell products and the low 
risk of graft-induced malignancies [15]. Clinical trials in adult stroke patients show no 
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side effects of allogeneic stem cell infusion [16]. However, the life-time risk of 
developing complications related to the cell-based therapy can be expected to be 
higher in preterm infants, whom may have a longer post-treatment life expectancy in 
comparison to older stroke patients.  
 In order to develop an optimal cell-based therapy for hypoxic-ischemic injury in the 
preterm brain timing is essential. In this thesis the optimal therapeutic window of 
opportunity was identified within the acute phase after the insult. The short time span 
between the insult and the optimal timing of therapy complicates the application of 
autologous stem cells (i.e. cord blood stem cells or induced pluripotent stem cells 
derived from fibroblasts), which take time to harvest and culture. Therefore, off-the-
shelf allogeneic stem cell products seem to be most feasible for cell-based therapy for 
hypoxic-ischemic injury in the preterm brain. 
 Further research is needed to determine whether the actual stem cells are needed 
for the therapeutic effect. There is evidence that the secretome of MSCs mediates 
similar anti-inflammatory and regenerative effects than the cells that secreted them 
[15, 17-19]. This strategy avoids the potential risks involved with living allogeneic cell 
transplantation, i.e. graft versus host disease or tumour formation [15]. Thinking one 
step further, intensive stem cell research may lead to the identification of a single 
immunomodulatory or neurotrophic factor, which is primarily responsible for the 
therapeutic effect. The discovery of such a therapeutic agent may pave the way for its 
(recombinant) pharmaceutical manufacturing and clinical application as a drug. 
 In conclusion, this thesis presents the potential of cell-based therapy for hypoxic-
ischemic injury in the preterm brain. Our studies may form the basis for future clinical 
trials, which will study feasibility of neuroprotective therapy in preterm infants with 
hypoxic-ischemic brain injury, creating an eligible chance to improve the life of many 
preterm infants by increasing disability-free lives. 
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